SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions December patent applications/inventions, industry category 12/09

20090324489 - Wortmannin conjugates and uses thereof: The invention features conjugates of wortmannin, and wortmannin derivatives, and their use as inhibitors of PI3-kinase activity in treating cancer, inflammatory diseases, and C. albicans infections.... Agent: Clark & Elbing LLP

20090324490 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090324491 - Diagnosis and treatment of cancer using anti-ereg antibody: Methods that entail detection of an epiregulin (EREG) protein for cancer diagnosis are disclosed. In colon cancer, lung adenocarcinoma, pancreatic cancer, stomach cancer, and kidney cancer, the gene and protein expressions of EREG were frequently found to be elevated. Antibodies that recognize an EREG protein are used for diagnosing or... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090324492 - Treatment for central nervous system disorders: Compositions that include an Aβ polypeptide linked to a non-Aβ polypeptide are described, as well as methods of using such compositions.... Agent: Quarles & Brady LLP

20090324493 - Method for preparing a saline solution comprising [13n] nh4 + and use of a device: The invention relates to a method for preparing a saline solution comprising [13N]NH4+. The method comprises following steps: preparing [13N]NH3 gas, transporting [13N]NH3 gas to a diffusion chamber, to a first side of a semipermeable membrane, transporting sterile saline solution to the diffusion chamber, to a second side of a... Agent: James C. Lydon

20090324495 - Compounds and methods for enzyme-mediated tumor imaging and therapy: The invention provides methods and compositions, e.g., for tumor imaging and therapy.... Agent: Edwards Angell Palmer & Dodge LLP

20090324494 - Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance: The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific... Agent: Sheridan Ross PC

20090324496 - Radioactive material for inhibiting cancer and preparation method thereof: A radioactive material for inhibiting cancer and a preparation method thereof are disclosed. The radioactive material for inhibiting cancer is M-SOCTA-Z and M is a radioactive nuclide such as 188Re or 99mT while Z is protein or peptides having amino acid with NH or NH2 group. The preparation method of... Agent: Sinorica, LLC

20090324497 - Tc and re labeled radioactive glycosylated octreotide derivatives: Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or... Agent: Mallinckrodt Inc.

20090324498 - Method of measuring quantity of in-vivo substance by use of coherent anti-stokes raman scattered light: A method of measuring the quantity of an in-vivo substance includes the steps of: irradiating an in-vivo substance with two near infrared femtosecond laser beams of different frequencies; detecting coherent anti-Stokes Raman scattered light emitted from the in-vivo substance due to coincidence of the frequency difference between the two near... Agent: Wolf Greenfield & Sacks, P.C.

20090324499 - Vitamin-targeted imaging agents: for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M... Agent: Barnes & Thornburg LLP

20090324502 - Nasal formulations of insulin: The present invention provides a method for achieving a therapeutically effective plasma levels of insulin by administering at least two doses of pharmaceutical formulation of insulin sequentially into the same nostril. The administration of the second dose in the same nostril gives substantially higher plasma levels of insulin when compared... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090324500 - Screen for inflammatory response modulators: The present invention relates to transgenic aquatic vertebrate organisms and methods of their use in screening for, or identifying agents that are useful in modulating the inflammatory response and particularly for identifying agents useful for treating inflammatory disorders.... Agent: Myers Bigel Sibley & Sajovec

20090324501 - Vaccine carrier: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.... Agent: Chalker Flores, LLP

20090324503 - Methods for detecting a mycobacterium tuberculosis infection: Methods for detecting an infection with Mycobacterium tuberculosis (Mtb) in a subject are disclosed. The methods include detecting the presence of CD8+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+ T cells in a biological sample, and in... Agent: Klarquist Sparkman, LLP

20090324504 - Method for delivering liquid active agents for deodorising and disinfecting an enclosed space, in particular an animal enclosure: A method is described for delivering liquid active agents for deodorising and disinfecting an enclosed space (1), in particular an animal enclosure, wherein the active agents are sprayed with the aid of a compressed gas by means of atomizing nozzles (2) distributed in the enclosed space (1). In order to... Agent: Collard & Roe, P.C.

20090324505 - Surfactant gas pressurized liquid composition and method and package for delivering: A self gassing composition comprising at least one surfactant and a fermentation base including a gas producing organism and at least one sugar is disclosed. Use of a nonionic surfactant in the self gassing composition allows the fermentation base to continue reacting and producing gas. Additionally, a personal care cleansing... Agent: Kimberly-clark Worldwide, Inc. Tara Pohlkotte

20090324508 - Broad spectrum and skin friendly disinfecting composition: The present invention discloses a composition for use in a foam dispenser comprising: 0.1-5% (w/w) hydrogen peroxide, 21-55% (w/w) of a C2-C6 alcohol, and 0.01-2% (w/w) of a foam booster. The foam booster is capable of providing a stable foam when dispensing a composition consisting of 36% (w/w) ethanol and... Agent: Oliff & Berridge, PLC

20090324511 - Compounds, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090324510 - Drug combinations for the treatment of respiratory tract diseases: The present invention relates to novel drug combinations which, besides one or more, preferably on compound of the general formula (1), wherein remainder n, A, R1, R2, and R3 can have the meanings given in the claims and in the description comprise at least one further active ingredient 2 and... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090324509 - Insecticidal composition: A pesticidal composition which comprises cymene and either a pyrethrin insecticide or an insect growth regulator. In particular the composition is formulated as an aerosol for killing or controlling pests and in particular flying pests.... Agent: Intellectual Property / Technology Law

20090324507 - Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.... Agent: Alcon

20090324506 - Sprayable skin protectant formulation and method of use: The present disclosure is directed to a skin protectant formulation that is designed to be sprayed onto human skin for the purpose of protecting the skin. In particular, an exemplary formulation of the present disclosure contains at least a carrier, a structurant and a skin protectant agent. An exemplary formulation... Agent: Kimberly-clark Worldwide, Inc. Tara Pohlkotte

20090324512 - Polypeptide constructs for nasal administration: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method... Agent: Wolf Greenfield & Sacks, P.C.

20090324515 - Antimicrobial flavouring composition: A flavouring composition for use in an oral care product, confectionary product or beverage. The composition includes an antimicrobial key and optionally at least one flavouring ingredient of current use, wherein the antimicrobial key comprises 3,4-dimethylphenol together with one or more antimicrobial flavour ingredients each having a minimum inhibitory concentration... Agent: Winston & Strawn LLP Patent Department

20090324514 - Methods and composition for treating a material: A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. The composition generally includes an aqueous composition mixture that includes:... Agent: Ian C. Mcleod Ian C. Mcleod, P.C.

20090324513 - Process for producing chlorinated sucrose: Present invention relates to disclosure of application of some innovative techniques useful for substantially improving process efficiency of production of chlorinated sucrose including their intermediates and derivatives. Application of mild methods of drying has been made for recovery of chlorinated sucrose or their intermediates and derivatives, in substantially pure form... Agent: The Nath Law Group

20090324516 - Composition and method for enhancing flouride uptake using bioactive glass: e

20090324517 - Halitosis treatment: A method of oral treatment to eliminate odors, particularly halitosis, using two or more oral treatment compositions. A four step method in a sequential order may be followed using compositions including hydrogen peroxide, metal ions, bactericidal agents and essential oils. Gargling increases the effectiveness of the treatment. Good breath is... Agent: Schmeiser Olsen & Watts

20090324523 - Compositions comprising an ultraviolet radiation-absorbing polymer: Ultraviolet radiation-absorbing polymers having a first pendant group that comprises an ultraviolet radiation-absorbing moiety and a second pendant group that comprises at least one siloxane linkage and/or an intermediate length carbon chain are disclosed. Personal care compositions including the ultraviolet radiation-absorbing polymer are provided.... Agent: Philip S. Johnson Johnson & Johnson

20090324519 - Esterification reaction product, gelling agent containing the product, and cosmetic preparation containing them: Disclosed is an esterification reaction product which is capable of gelling both an oil agent and a cyclic silicone or a volatile dimethylpolysiloxane, or both an oil agent and a nonvolatile dimethylpolysiloxane. Also disclosed are a gelling agent contacting the esterification reaction product, and a cosmetic preparation containing the esterification... Agent: Mcginn Intellectual Property Law Group, PLLC

20090324518 - Novel compositions against alkyl-acyul-gpc the derivatitves and products thereof: The compositions of the invention are used for the manufacture of compounds to protect against alkylacyl-like destabilized cells by preference under the conditions of critical lifestyle. Persons are clinically treated who have problems concerning body weight, critical morning urine samples, tendency to diabetes and hypersensitivity syndromes and/or desequilibration of mentality... Agent: Kenyon & Kenyon LLP

20090324521 - Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials: The personal care article comprises a single chamber package and a personal care product. The package comprises a dispensing orifice, a first zone, a second zone and a third zone that are located proximal, medial and distal to the dispensing orifice. The personal care product comprises a first, a second... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324520 - Personal-care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents: The present invention relates to a personal-care article comprising a package and a personal-care product. The package comprises at least one chamber, a dispensing orifice, a first zone proximate to the dispensing orifice, and a second zone distal to the dispensing orifice. The first zone and second zone are both... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324522 - Skin protectant compositions: A topical composition for the protection of skin from damage caused by ultraviolet radiation. The composition includes a direct antioxidant and a phase 2 enzyme inducer (indirect antioxidant) in cosmetic and dermopharmaceutical compositions that protects and prevents skin damage and aging caused by UV radiation. In a particular embodiment, the... Agent: Traskbritt, P.C.

20090324524 - Compositions comprising an ultraviolet radiation-absorbing polymer: Ultraviolet radiation-absorbing polymers having a first pendant group that comprises an ultraviolet radiation-absorbing moiety and a second pendant group that comprises at least one siloxane linkage and/or an intermediate length carbon chain are disclosed. Personal care compositions including the ultraviolet radiation-absorbing polymer are provided.... Agent: Philip S. Johnson Johnson & Johnson

20090324525 - Foundation with high chromatic stability and method to obtain such foundation: Preparation of a foundation is described. The foundation is obtainable by mixing specific precursor emulsions, each of them having the complete composition of a foundation and containing a single pigment. The mixing directly provides the final foundation in the desired colour tone. Also described is a kit to obtain a... Agent: Steinfl & Bruno

20090324526 - Compositions comprising madecassoside and/or terminoloside and an arginine and/or a salt and/or a derivative thereof for inducing and/or stimulating the growth of human keratin fibers and/or preventing loss thereof: R1═H or —CH3; R2═H or —CH3; R3═—CH3, with the proviso that R1 and R2 are not simultaneously H, or an extract of Centella asiatica containing the compound or the mixture of compounds of formula (I); such compositions are useful for treating human keratin fibers and/or the scalp, for inducing and/or... Agent: Buchanan, Ingersoll & Rooney PC

20090324529 - Hair conditioning composition containing a salt of behenyl amidopropyl dimethylamine, and having higher yield point: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being a salt of behenylamidopropyldimethylamine and l-glutamic acid; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 5 Pa, and the yield point meeting the following... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324528 - Hair conditioning composition containing a salt of stearyl amidopropyl dimethylamine, and having higher yield point: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being a salt of stearylamidopropyldimethylamine and 1-glutamic acid; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 5 Pa, and the yield point meeting the following... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324527 - Hair conditioning composition containing behenyl trimethyl ammonium chloride, and having higher yield point: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being behenyltrimethylammonium chloride; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 5 Pa, and the yield point meeting the following mathematical expression: Y≧4.47X−5.10, wherein Y... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324532 - Hair conditioning composition containing a salt of cetyl trimethyl ammonium chloride, and having higher yield point: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being cetyltrimethylammonium chloride; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 9 Pa, and the yield point meeting the following mathematical expression: Y≧3.50X−7.80, wherein Y... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324531 - Hair conditioning composition containing behenyl trimethyl ammonium methosulfate, and having higher yield point: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant being behenyltrimethylammonium methosulfate; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the composition has a yield point of at least 15 Pa, and the yield point meeting the following mathematical expression: Y≧3.57 X2−44.4 X+151,... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324530 - Hair conditioning composition having higher yield point and higher conversion rate of fatty compound to gel matrix: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the cationic surfactant, the high melting point fatty compound, and the aqueous carrier form a gel matrix; wherein the composition has from about 90% to about... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324533 - Bacillus amyloliquefaciens strain: The composition of the invention comprises an aqueous mixture of an odor neutralizer component, an enhancer component for microbial activity, and a microbial component. This composition is designed to provide short- and long-term odor control effects and is environmentally friendly and economical for use.... Agent: Novozymes North America, Inc.

20090324534 - Solid emulsion containing a liquid fatty phase structured with a polymer: The invention relates to a physiologically acceptable solid emulsion, especially a cosmetic emulsion, containing an aqueous phase and a liquid fatty phase, one dispersed in the other, said liquid fatty phase being structured with at least one polymer having a weight-average molecular mass ranging from 1000 to 30 000, comprising... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090324535 - Modified macromolecule: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor;... Agent: Knobbe Martens Olson & Bear LLP

20090324536 - Antimicrobial polymers and coatings: Biocidal compounds have been synthesized and tested. These biocidal compounds have broad-spectrum efficacy and their biocidal properties are easily renewable. Illustrative examples of these biocidal compounds include N-halamine monomers and polymers and silver sulfadiazine polymers. These compounds can be used to add biocidal function to various materials and articles.... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090324537 - Polymeric materials as stomach filler and their preparation: The present invention relates to swellable polymeric materials comprising a synthetic polymer, or copolymer, comprising a carboxylic group and a biopolymer that are suitable for bioapplications. Because of their ability to swell, the polymeric materials are suitable for use as stomach fillers for the treatment of being over weight or... Agent: Elmore Patent Law Group, PC

20090324539 - Cancer treatment combining lymphodepleting agent with ctls and cytokines: In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in... Agent: Philip S. Johnson Johnson & Johnson

20090324540 - Compounds and compositions for delivering active agents: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20090324538 - Fusion molecules and il-15 variants: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.... Agent: Peter F. Corless Edwards Angell Palmer & Dodge LLP

20090324541 - Prophylactic or therapeutic agent for viral disease: A prophylactic or therapeutic agent for a viral disease, characterized by combining 22β-methoxyolean-12-ene-3β,24(4β)-diol with an interferon as active ingredients is disclosed. The prophylactic or therapeutic agent of the present invention exhibits a high therapeutic effect by administering 22β-methoxyolean-12-ene-3β,24(4β)-diol and interferon as a combination thereof.... Agent: Sughrue Mion, PLLC

20090324543 - Pyrido(3,2-d)pyrimidines useful for treating viral infections: 2-amino-pyrido(3,2-d)pyrimidine derivatives with a specific substitution pattern on positions 4 and 6 of the core structure are useful in the treatment or prevention of an infection due to a virus from the Flaviviridae family, especially HCV, when administered to a patient in a therapeutically effective amount.... Agent: Gilead Sciences Inc

20090324542 - Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders: Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b)... Agent: Novartis Corporate Intellectual Property

20090324544 - Substituted cyclic pyrrolidine derivatives: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC

20090324545 - Polymorphic forms of (s)-1-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzyl carbamate: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate, processes therein, pharmaceutical compositions thereof, and uses therewith.... Agent: Vertex Pharmaceuticals Inc.

20090324546 - Method for modulating gene expression by modifying the cpg content: The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.... Agent: Fulbright & Jaworski, LLP

20090324547 - Probiotic oral health promoting product: The present invention discloses an oral composition comprising a combination of probiotic bacteria selected from the group comprising Streptococcus, Eubacterium, Neisseria, Veillonella and pH-rising and/or buffering components, which re-establishes an oral microflora associated with good oral health in subjects with a disturbed oral microflora. The invention also discloses the use... Agent: Harness, Dickey & Pierce, P.L.C

20090324549 - Proteins and/or peptides for the prevention and/or treatment of neurodegenerative diseases: Proteins and/or peptides originate from the gene which results from the retention of the intron 3 of the gene SMN identified in the gene bank with the access number AY876898 with use for the diagnosis and/or prevention and/or treatment of neurodegenerative diseases.... Agent: Amster, Rothstein & Ebenstein LLP

20090324548 - Vaccinia virus strains: The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.... Agent: Clark & Elbing LLP

20090324562 - Defensin proteins: This invention relates to the novel proteins, termed INSP108 and INSP109, herein identified as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090324550 - Composition and method for inhibition of microorganisms: A composition and method for the inhibition of microorganisms.... Agent: Barnes & Thornburg LLP

20090324552 - Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20090324551 - Tlr agonists: The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help... Agent: Schwegman, Lundberg & Woessner, P.A.

20090324563 - Moisturizer: The present invention provides a moisturizer comprising heat-killed cells of Lactobacillus plantarum as an active ingredient. The moisturizer of the present invention improves the water retention capacity of the stratum corneum, and is useful for prevention and improvement of rough skin.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090324564 - Microorganism capable of controlling plant diseases and plant disease-controlling agent using the microorganism: The object of the present invention is to provide a microorganism which places little burden on the environment, shows an extremely low possibility of a resistant pathogenic bacterium to emerge, and has a superior controlling ability against various plant diseases (in particular, soft rot and canker of leaf and root... Agent: Oliff & Berridge, PLC

20090324565 - A colicinogenic strain of e. coli: Described herein is the isolation of colicin-producing strains of E. coli for use as probiotic treatments for the prevention of E. coli K88+diarrhea. These strains of E. coli, designated as UM-17, and UM-19, express a filament and produce colicin but produce no compounds toxic to the host animal and as... Agent: Ade & Company Inc.

20090324553 - Chimeric viral envelopes: The invention relates to chimeric polytropic viral envelope polypeptides and uses thereof, as well as to polynucleotides encoding said chimeric polypeptides and constructs comprising said polypeptides and/or polynucleotides. The invention also relates to chimeric retroviral envelope polypeptides, polynucleotides and vectors encoding said chimeric retroviral envelope polypeptides, virus particles and cells... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090324554 - Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates: A therapeutic agent which carries a peptide sequence containing a mammalian cell adhesion sequence can be used to inhibit or treat diseases associated with intracellular formation of protein fibrillar inclusions or aggregates, to inhibit the intracellular formation of protein fibrillar inclusions or aggregates, and to disaggregate pre-formed intracellular protein fibrillar... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090324561 - Cells exhibiting neuronal progenitor cell characteristics and methods of making them: Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells.... Agent: Robins & Pasternak

20090324560 - Method for preparation of cartilage cell: The present invention provides a cell derived from a perichondrial tissue, the cell being capable of differentiating into a chondrocyte. The present invention also provides a method of preparing the above-described cell and a composition comprising the same. A method of preparing a chondrocyte and a medium for use in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090324557 - Method to induce and expand therapeutic alloantigen-specific human regulatory t cells in large-scale: Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4+CD25−T cells by using CD40− activated B cells. The regulatory T cells can be human T cells. In one embodiment, the alloantigen-specific human regulatory T cells can be... Agent: Turocy & Watson, LLP

20090324559 - Methods and platforms for drug discovery: The present invention involves methods for identifying an agent that corrects a phenotype associated with a health condition or a predisposition for a health condition. The invention also involves methods for identifying a diagnostic cellular phenotype, determining the risk of a health condition in a subject, methods for reducing the... Agent: Wilson, Sonsini, Goodrich & Rosati

20090324556 - Mutated immunogenic peptides derived from r9m, polynucleotides coding for same and therapeutic uses thereof: The invention concerns the optimization of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukaemia in humans. More particularly, the invention concerns mutated immunogenic peptides derived from the human TEL/AML1 fusion protein comprising the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. The... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090324555 - Neural stem cells: Subject of the invention is a method for generating neural stem cells in vitro, wherein dental progenitor cells are isolated from soft tissue of tooth or wisdom tooth and cultivated until they form primary spheres which are then dissociated into single cells. These single cells are cultivated until they form... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090324558 - Transdiscal administration of cycline compounds: The present invention relates to administering a doxycycline compound into a diseased intervertebral disc.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090324567 - Leukocyte cell banks: The invention relates to a novel form of leukapheresis (isolated leukapheresis), to processes and apparatus for carrying out isolated leukapheresis, to leukocyte cell banks created thereby and to various forms of therapy based thereon.... Agent: K&l Gates LLP

20090324566 - T-cell receptor and nucliec acid encoding the receptor: A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of... Agent: Birch Stewart Kolasch & Birch

20090324569 - Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders: p

20090324568 - Colonic delivery of adsorbents: Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the delivery systems, and methods of preparing the delivery systems, are also disclosed. The particulate delivery... Agent: Intellectual Property / Technology Law

20090324570 - Photostabilization of retinoids with alkoxycrylene compounds: wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase... Agent: Marshall, Gerstein & Borun LLP

20090324572 - Methods and compositions for the treatment of symptoms of williams syndrome: A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies.... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. PLLC

20090324571 - Use of bacterial amylases in feed for bovine animals: The invention relates to the use of at least one bacterial amylase in feed for ruminant animals of the subfamily Bovinae in particular for improving milk yield, apparent digestibility of the diet fed, feedstuff dry matter disappearance, weight gain, and/or Feed Conversion Ratio (FCR). Examples of bovine animals are dairy... Agent: Novozymes North America, Inc.

20090324573 - Pharmaceutical composition comprising p43 protein for the treatment of gastric adenocarcinoma: A pharmaceutical composition for the treatment of gastric adenocarcinoma is provided, wherein the pharmaceutical composition comprises p43 protein and pharmaceutically acceptable carriers, and does not comprise paclitaxel. A use of p43 protein for the treatment of gastric adenocarcinoma is also provided.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090324574 - Esterases and related nucleic acids and methods: The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phosphplipase A, B, C and D activity, patatin activity, lipid acyl... Agent: Verenium Corporation Intellectual Property Department

20090324575 - Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus... Agent: Marshall, Gerstein & Borun LLP

20090324576 - Phage derived antimicrobial activities: The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.... Agent: Townsend And Townsend And Crew, LLP

20090324577 - 6-11 bicyclic ketolide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20090324578 - Composition and method to treat wounds: A composition to treat wounds comprising non-geniculate marine coral algae in combination with one or more sugars.... Agent: Dale F. Regelman

20090324579 - Anti-apoptotic protein antibodies: Single-domain anti-bodies that bind pro-apoptotic proteins Bax and caspase-3 are identified and isolated. These single-domain antibodies may be used to modulate the active of Bax and caspase-3, thereby modulating the symptoms and steps of oxidative stress and/or cell apoptosis, including Bax dimerization, mitochondrial permeabilization and the release of apoptotic proteins.... Agent: Cassan Maclean

20090324585 - Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis: The present disclosure is directed to methods and compositions for treating osteoarthritis and preventing osteoarthritis, by administering a compound that modulates one or more components in the complement system. In one embodiment, a compound that inhibits a component in the complement system is administered to prevent, delay the progression of,... Agent: King & Spalding LLP

20090324581 - Heteroarylamide lower carboxylic acid derivative: The invention provides a compound represented by general formula (I) (wherein A is a single bond, —O—, or —CH2—; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3): (1) -G1-, (2) -G2-N(R2)-G3-, and (3)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090324586 - Lyophilization cycle robustness strategy: The present invention provides methods for assessing and optimizing lyophilization cycle robustness. In particular, the present invention provides rapid assessment of cycle robustness with respect to a variety of lyophilization process deviations by varying a relatively small number of parameters.... Agent: Wyeth Patent Law Group

20090324583 - Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation: The present invention relates to a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets, more particularly, a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets comprising the steps of coculturing CD34+ hematopoietic stem cells with stromal cells and... Agent: Seed Intellectual Property Law Group PLLC

20090324584 - Nucleic acid of formula (i): gixmgn, or (ii): cixmcn, in particular as an immune-stimulating agent/adjuvant: The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a... Agent: Connolly Bove Lodge & Hutz, LLP

20090324582 - Process for identification of molecular mimicry and the uses thereof: The present invention discloses a process for simple and rapid detection and identification of molecular mimicry or mimic antigens or molecules existing in/on humans, animals and plants. The molecular mimicry can be related to infections, autoimmune diseases, cancers, obesity and other disorders. Therefore, novel methods for the diagnosis, prevention, and... Agent: Mccracken & Frank LLP

20090324580 - Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090324594 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific... Agent: Woodcock Washburn LLP

20090324587 - Cancer therapies and pharmaceutical compositions used therein: The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides co-therapies comprising oligonucleotides plus other therapies to treat cancer.... Agent: Honigman Miller Schwartz & Cohn LLP

20090324592 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090324593 - Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof: The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said... Agent: Drinker Biddle & Reath (dc)

20090324589 - Methods for controlling blood pharmacokinetics of antibodies: The present inventors discovered that the half-life in blood of an IgG antibody which is a polypeptide comprising an FcRn-binding domain can be controlled by controlling the surface charge through modification of residues exposed on the surface among residues in the variable regions of the IgG antibody. Antibodies whose half-life... Agent: Fish & Richardson PC

20090324590 - Myostatin antagonists: An isolated recombinant polypeptide having myostatin antagonist activity, comprising a C-terminally truncated mature myostatin peptide, wherein the C-terminal truncation is at a position at or between amino acids 281 and 329, or a fragment, variant or derivative thereof.... Agent: Knobbe Martens Olson & Bear LLP

20090324588 - Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors: An antibody or an antigen binding fragment thereof which binds to mammalian α7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090324591 - Treatment of pulmonary disease conditions: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or... Agent: Knobbe Martens Olson & Bear LLP

20090324595 - Cancer prognostic diagnostic and treatment methods: The invention disclosed herein provides methods comprising detection of EphB2 polypeptide and/or polynucleotide in a biological sample from a subject, wherein the detection of EphB2 is predictive or indicative of cancer prognosis for the subject. The invention also provides methods for selecting cancer treatment, methods comprising detection of EphB2 polypeptide... Agent: Genentech, Inc.

20090324596 - Methods of identifying and treating poor-prognosis cancers: The present invention relates generally to methods for identifying cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. Embodiments of the present invention provide an objective means of prognostication regarding the long-term outcome of an incident of... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090324602 - Anti-fn14 antibodies and uses thereof: Antibodies and antibody fragments that bind to the receptor Fn14 and induce or enhance cell killing of Fn14-expressing cancer cells are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a tumor cell and treat disorders and in a subject.... Agent: Fish & Richardson PC

20090324599 - Fibroblast growth factor-like polypeptides: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090324598 - Method for the treatment of inflammatory disorders: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.... Agent: Lando & Anastasi, LLP B2047

20090324601 - Targeted binding agents directed to pdgfr-alpha and uses thereof: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such... Agent: Astrazeneca R&d Boston

20090324597 - Ulbp antibodies: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the... Agent: Immunex Corporation Law Department

20090324600 - Use of an anti-cd151 antibody in the treatment of cancer: The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity,... Agent: The Firm Of Hueschen And Sage

20090324603 - Met fab and scfv fragments and methods of use: Antibody fragments (Fabs and scFvs) specific to the Met receptor are disclosed. Compositions and kits including these Fabs and scFvs, and drug and imaging conjugates of these Fabs and scFvs also are disclosed. The novel Fabs and scFvs can be internalized into the interior of a cell. Methods include using... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20090324605 - Interferon alpha antibodies and their uses: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules... Agent: Baker Botts L.L.P.

20090324604 - M-csf specific monoclonal antibody and uses thereof: M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.... Agent: Marshall, Gerstein & Borun LLP

20090324606 - Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also... Agent: Bozicevic, Field & Francis LLP

20090324610 - Gene associated with arteriosclerotic disease, and use thereof: Two genes implicated in arteriosclerotic diseases such as cerebral infarction were successfully identified by performing genome-wide correlation studies using SNPs by targeting the entire genome. Polymorphic mutations that can be used to examine the presence or absence of risk factors for arteriosclerotic diseases were successfully found on the genes. Subjects... Agent: Townsend And Townsend And Crew, LLP

20090324609 - Method of treating autoimmune disease with mesenchymal stem cells: Methods and compositions for treating an autoimmune disease, such as new onset type 1 diabetes (T1D) in a subject using autologous or allogeneic mesenchymal stem cells administered to the subject prior to autoimmune-induced complete depletion of insulin-producing pancreatic beta cells, e.g., within six months of new onset type 1 diabetes... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090324612 - Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule: Compositions and methods for modulating neural outgrowth, including treating neural damage, via the major histocompatibility complex I (“MHC I”) molecule. Methods for identifying agents that reduce MHC I-induced inhibition of neurite outgrowth. Methods for promoting neural outgrowth comprising administering MHC I molecules (native, recombinant, or those encoded by gene fusion)... Agent: Bingham Mccutchen LLP

20090324608 - Novel human protein kinase, phosphatase, and protease family members and uses thereof: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin... Agent: Millennium Pharmaceuticals, Inc.

20090324611 - Targeting vegf-b regulation of fatty acid transporters to modulate human diseases: The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity.... Agent: Crowell & Moring LLP Intellectual Property Group

20090324607 - Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts: A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090324613 - Compositions and methods for the therapy and diagnosis of cytomegalovirus: The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090324614 - Fc receptor binding proteins: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.... Agent: Dyax Corp. C/o Wolf, Greenfield & Sacks, P.C.

20090324615 - Methods and compositions for modulating t cell and/or b cell activation: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.... Agent: Myers Bigel Sibley & Sajovec

20090324617 - Cancer specific glycans and use thereof: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of... Agent: Birch Stewart Kolasch & Birch

20090324616 - Differential cytokine expression in human cancer: The invention concerns a method for diagnosing a cancer type, whereby the expression of anti-apoptotic cytokines is determined in the tumour cells. The differential diagnosis of the present invention is used to classify tumour disorders and to recommend the required treatment and to monitor the progress and response to the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090324620 - Conjugates of therapeutic or cytotoxic agents and biologically active peptides: The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof.... Agent: Clark & Elbing LLP

20090324619 - Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain: A protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain. Also described herein is an immunoconjugate containing the protein carrier with an antigen conjugated to multiple cysteine residues in the cysteine-rich domain, and an immune composition containing the immunoconjugate and an adjuvant, as well as their... Agent: Occhiuti Rohlicek & Tsao, LLP

20090324618 - Novel signature self renewal gene expression programs: The present invention relates to compounds and methods which are useful in molecular investigations of target genes, as well as their encoded RNAs and protein, belonging to signature self renewal programs in leukemia and/or cancer stem cells. Data herein shows that leukemia stem cells can be generated from committed progenitors... Agent: Polsinelli Shughart PC

20090324621 - Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions... Agent: Townsend And Townsend And Crew LLP

20090324622 - Antibody vaccine conjugates and uses therefor: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (βhCG) antigen linked to an anti-mannose receptor (MR) antibody.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090324624 - Chitin micro-particles as an adjuvant: A composition and method for the preparation of micro-particles of chitin (a naturally occurring polymer of N-acetyl-D-glucosamine), the characterization of chitin micro-particles as an immune adjuvant and the use of chitin micro-particles to enhance protective immunity against intracellular infectious agents and diseases as well as to inhibit allergic responses and... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20090324625 - Heterocyclic aromatic compounds useful as growth hormone secretagogues: c

20090324627 - Isolated dna directed 50kd regulatory subunit (pold2) genomic polynucleotide fragments from chomosome 7 and their uses: The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments.... Agent: Cheryl H Agris Phd

20090324626 - Isolated snare ykt6 genomic polynucleotide fragments from chomosome 7 and their uses: The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The... Agent: Cheryl H Agris Phd

20090324623 - Two-component genome flavivirus and uses thereof: The present invention discloses a two-component genome flavivirus and a method for propagating such virus. Since the genetic material of this flavivirus is distributed between two genomes, the flavivirus is deficient in replication, incapable of causing disease but capable of inducing an immune response. Nevertheless, the design of the replication... Agent: Benjamin Aaron Adler Adler & Associates

20090324629 - Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof: Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm... Agent: Swanson & Bratschun, L.L.C.

20090324628 - Compounds useful in the diagnosis and treatment of malaria: The present invention relates to nucleic acid molecules related to the PFD1235w/MAL7P1.1, PF11_0008, and PF13_0003 gene families as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to endothelial cells, which is characteristic for the... Agent: Seattle Biomedical Research Institute Attn: Karen Blochlinger

20090324630 - Fusion multiviral chimeric antigen: Novel recombinant vectors encoding viral antigens within a single vector or construct are disclosed. The vectors may be used to initiate immunological responses to antigens and to combat opportunistic and other infections. Viral antigens include those derived from CMV, EBV, adenovirus (Ad), Influenza A, herpes simplex, varicella, polyoma virus and... Agent: Perkins Coie LLP

20090324632 - Methods and reagents for vaccination which generate a cd8 t cell immune response: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090324631 - Polyvalent vaccine: The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens... Agent: Nixon & Vanderhye, PC

20090324633 - Immunogens from uropathogenic escherichia coli: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.... Agent: Novartis Vaccines And Diagnostics Inc.

20090324634 - Trypanosoma antigens, vaccine compositions, and related methods: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.... Agent: Fish & Richardson P.C.

20090324635 - Caspofungin free of caspofungin impurity a: Provided is caspofungin free of caspofungin impurity A, methods for preparation thereof and isolation of caspofungin impurity A.... Agent: Kenyon & Kenyon LLP

20090324636 - Fish oil in stabilized form: A method of production and composition of a extremely stable fish oil blend and method of use of said blend. The instant invention provides phospholipid additives to fish oil or other long-chain polyunsaturated fatty acid in an admixture that enhances the stability of the final product. Most preferably said composition... Agent: Moore & Van Allen PLLC

20090324637 - Process for producing a stable concentrated dietary supplement and supplement produced thereby: A process for producing a stable concentrated dietary supplement containing fucoxanthin as the main active component. The method entails grinding crude freeze-dried flakes of wakame seaweed (Undaria pinnatifida) with desirable characteristics into a powder, extracting the active fucoxanthin from the powder with use of an aliphatic or aromatic organic solvent,... Agent: Ostrolenk Faber Gerb & Soffen

20090324638 - Live bacterial vaccine: The present invention relates, e.g., to a Lactobacillus bacterium, which (1) expresses a recombinant polypeptide containing a lipoprotein signal sequence from the OspA protein of Borrelia burgdorferi, or an active variant of the leader sequence, operably linked to one or more heterologous polypeptide(s) of interest and/or (2) which comprises an... Agent: Venable LLP

20090324639 - Compositions and methods for activating innate and allergic immunity: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic... Agent: Seed Intellectual Property Law Group PLLC

20090324640 - Neuraminidase-deficient live influenza vaccines: Attenuated, neuraminidase deficient influenza virus, and compositions and methods to prepare that virus, are provided.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090324641 - Novel adjuvant compositions: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the... Agent: Pharmacia & Upjohn

20090324643 - Compositions and methods for treating and preventing infection: This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to treat or prevent infection. The compositions of the invention can be used in vitro or in vivo to decrease the load of a microorganism in a biological sample. Methods of generating an immune response against a microorganism... Agent: Dla Piper LLP (us)

20090324642 - Method of elicting or inducing an immune response: A method for eliciting or inducing an immune response in a human or animal subject, comprises administering to said subject a composition comprising an antigen and an adjuvant, wherein the composition is administered to the subject by the intra-lung route.... Agent: Foley And Lardner LLP Suite 500

20090324644 - Chimeric vaccine antigens against the avian influenza virus: The present invention describes chimeric vaccine antigens against the avian influenza virus (AIV). Said vaccine antigens are based on viral subunits that are coupled to protein molecules that stimulate not only the cellular but also the humoral immune system. The chimeric antigens may be produced in expression systems that guarantee... Agent: Hoffmann & Baron, LLP

20090324645 - Production of vaccines: Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The... Agent: Traskbritt, P.C.

20090324646 - Targeting the histone code as a bacterial strategy for selectively modulating gene expression: The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090324647 - Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use: The present invention provides compositions that contain botulinum toxin and a hyaluronidase, and that lack human or recombinant serum albumin. The present invention also provides methods of administering the pharmaceutical composition to a subject in need thereof.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090324648 - Vaccine for edwardsiella disease and streptococcal disease in fish: Disclosed is a vaccine for edwardsiellosis and streptococcosis in a fish. Specifically, disclosed is a vaccine for edwardsiellosis in a fish, which comprises inactivated cells of (A) an Edwardsiella tarda strain derived from the target fish, and inactivated cells of (B) an Edwardsiella tarda strain derived from a fish other... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090324649 - Leishmania vaccine using sand fly salivary immunogen: The present invention provides vectors that contain and express in vivo or in vitro sand fly Lu. longipalpis salivary antigens that elicit an immune response in animal or human against Leishmania, vaccine compositions comprising said vectors and/or Lu. longipalpis salivary polypeptides, methods of vaccination against Leishmania, and kits for use... Agent: Judy Jarecki-black Ph.d., J.d.

20090324650 - Method for the production of hydrolyzed allergen: e

20090324651 - Methods for stimulating an immune response using bacterial antigen delivery system: The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells... Agent: Wolf Greenfield & Sacks, P.C.

20090324658 - Cosmetic and method for production thereof: A cosmetic exhibiting improved thermal stability and storage stability, which is prepared by using a three-phase emulsification-dispersing method in an aqueous phase. In the cosmetic containing an oily base material and/or a pigment as a component to be emulsification-dispersed, an emulsification-dispersing agent and water, the thermal stability and storage stability... Agent: Mcginn Intellectual Property Law Group, PLLC

20090324656 - Cosmetic preparations with an additive from the baobab tree: The present invention relates to cosmetic and dermatological preparations, in particular skincare, cosmetic and dermatological emulsions containing an additive from the baobab plant (monkey bread tree).... Agent: Knobbe Martens Olson & Bear LLP

20090324662 - Dental appliance, oral care product and method of preventing dental disease: A method for reducing dental disease in a patient comprises a patient wearing in the patient's mouth an appliance containing an oral care product comprising a carrier and an anti-dental disease agent with a pH above 7.0. The appliance brings the patient's teeth in direct and sustained contact with the... Agent: Connors Associates

20090324663 - Kit for formulating a cosmetic product: The present invention relates to kits for formulating a cosmetic product, containing an aqueous composition and at least one water-soluble anhydrous film, the aqueous composition and the film(s) being mixed together extemporaneously to form the cosmetic product.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090324661 - Niacinamide containing cosmetic compositions with improved skinfeel properties: A cosmetic composition is provided which includes niacinamide, a carboxylic acid bearing structurant, and particles of a condensation polymerized polyamide, the polyamide having an amine value no lower than 0.3 and an HLB value of at least 16. The polyamide particles prevent interaction between niacinamide and the carboxylic acid/salt structurant... Agent: Unilever Patent Group

20090324660 - Personal-care article for sequentially dispensing compositions with different fragrances: The present invention relates to a personal-care article for dispensing and or applying a personal-care product that comprises a package and a personal-care product. The package comprises at least one chamber, a dispensing orifice, a first zone proximate to the dispensing orifice and a second zone distal to the dispensing... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090324659 - Sunscreen composite particles: Composite particles for providing UV photo protection in cosmetic compositions are reported which include an organic sunscreen agent dispersed within a condensation polymerized resin having carboxylic acid groups and a dielectric constant ranging from 6.5 to 18.... Agent: Unilever Patent Group

20090324654 - Sunscreen composite particles and porous particles in cosmetic compositions: A cosmetic composition is provided which includes composite particles of a sunscreen agent and a condensation polymerized polyamide binder, a water-insoluble powdered polymer of porous particles having an Oil Absorbance (castor oil) Value ranging from about 90 to about 500 ml/100 gm, and a cosmetically acceptable carrier. The composition exhibits... Agent: Unilever Patent Group

20090324653 - Sunscreen composite particles dispersed in water-in-oil cosmetic compositions: A cosmetic water-in-oil emulsion composition is provided which includes composite particles of a sunscreen agent and a condensation polymerized polyamide binder, an emulsifying silicone surfactant sufficient to form the water-in-oil emulsion, an oil phase, and a water phase. The composition exhibits relatively high SPF photoprotection while maintaining excellent soft focus... Agent: Unilever Patent Group

20090324652 - Sunscreen composite particles in cosmetic compositions: A cosmetic composition is provided which includes hydrophilic composite particles of an organic sunscreen agent, particles of a crosslinked silicone elastomer, and a cosmetically acceptable carrier. The hydrophilic composite particles are formed as a composite of sunscreen agent and binder in a relative weight ratio of about 5:1 to about... Agent: Unilever Patent Group

20090324655 - Sunscreen formula vanishing cream: A cosmetic composition is provided which is a vanishing cream structured with 0.5 to 50% by weight of C12-C20 fafty acid, 0.1 to 20% by weight of C12-C20 fatty acid salt and hydrophilic composite particles with organic sunscreen agent. The hydrophilic composite particles are formed as a composite of sunscreen... Agent: Unilever Patent Group

20090324657 - Zinc oxide power blends, their production and use: This disclosure provides sunscreen products that contain metal oxide powders having discrete size distributions. Metal oxide powders include, for example, zinc oxide and titanium dioxide. Sunscreen products made in accordance with the principles of this disclosure contain metal oxide powders having primary particle sizes of about 10-30 ran and about... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090324664 - Spray-on, non-woven fabric system and multilayer topical covering: The invention is directed to a spray-on, multilayer, non-woven fabric system and multilayer topical coverings suitable for reducing or alleviating a discomforting condition of the skin and/or an area underlying the skin when applied thereto, where the fabric system includes a first spray-on composition containing a material suitable for reducing... Agent: Philip S. Johnson Johnson & Johnson

20090324665 - Antibacterial, anti-absorbent and antimicrobial breast supports, bras and related apparel: A breast support system, bra and related apparel are disclosed that comprise a support member having an outer surface and an inner surface, wherein the support member comprises at least one antibacterial material, at least one anti-absorbent material, at least one antimicrobial material or a combination thereof.... Agent: Buchalter Nemer

20090324666 - Methods for making antimicrobial resins: Methods for making antimicrobial resins and for forming coatings comprising antimicrobial resins on substrate surfaces are disclosed. The methods involve providing a mixture comprising about 15 weight % to about 80 weight % of a hydrophilic acrylic oligomer, about 10 weight % to about 80 weight % of a multifunctional... Agent: Marshall, Gerstein & Borun (baxter)

20090324667 - Use of fungal inocula for the improvement of market gardening production: The present invention relates to a novel use of termites' nest powder, as an agent for controlling phytoparasitic nematodes for improving crops, in particular cereal, fodder, market garden, fruit or horticultural crops, and to the method for obtaining same.... Agent: Young & Thompson

20090324668 - Implant, its uses and methods for making it: An implant containing a source of oxygen capable of releasing oxygen in the form of molecular oxygen or reactive oxygen species, and a material selected from the group consisting of biodegradable and/or bioactive glass, sol-gel produced silica and mixtures thereof. Also disclosed are uses of the implant and methods of... Agent: James C. Lydon

20090324669 - Osteogenic enhancer composition: An osteogenic enhancer composition for bone and cartilage repair and methods of using the same are described.... Agent: Squire, Sanders & Dempsey L.L.P.

20090324675 - Bioocompatible polymer compositions: The present invention provides a biocompatible prepolymer comprising hydrophilic and hydrophobic segments, wherein the hydrophobic segments have at least one ethylenically unsaturated functional group and at least 5% of the segments have two or more ethylenically unsaturated functional groups and water. The invention further provides a biocompatible prepolymer composition comprising... Agent: Ballard Spahr LLP

20090324674 - Genetically modified heart valve xenografts: A method for producing a heart valve xenograft from bovine tissue expressing reduced or undetectable levels of I1-3 galactosyl transferase are provided.... Agent: Fish & Richardson P.C.

20090324679 - Medical copolymers: According to an aspect of the present invention, medical copolymers are provided which comprise (a) a polymer backbone comprising (i) a plurality of —C═C— groups within the polymer backbone, (ii) a plurality of -R9- groups within the polymer backbone, wherein R9 comprises a radical-substituted C2-C10 cyclic or heterocyclic group, or... Agent: Mayer & Williams PC

20090324673 - Method for producing bioactive composites: An object of the present invention is to provide a method for producing bioactive composites having imparted thereto bioactivity, to thereby form and grow in vivo or in vitro a coating layer containing a calcium phosphate compound as the major component with a high adhesion strength on the surface of... Agent: Kratz, Quintos & Hanson, LLP

20090324678 - Methods and kits for treating joints and soft tissues: Methods to treat and provide pain relief for damaged and degenerated tissues of a musculoskeletal joint are disclosed. These methods include introducing into, around and/or on the musculoskeletal joint an effective amount of a pharmaceutical composition containing a biocompatible matrix or biocompatible polymeric compound, a pain reliever, and a corticosteroid... Agent: Andrews Kurth LLP

20090324680 - Nanofiber-reinforced composition for application to surgical wounds: A nanofiber-reinforced composition suited to applying to a wound site in a human body includes a carrier liquid and nanofibers dispersed therein. The viscosity of the composition is such that it is able to be applied through a tube yet adhere proximate the wound site to provide a barrier layer... Agent: Fay Sharpe LLP

20090324671 - Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same: The current invention relates to poly(amide) and poly(ester-amide) polymers, coatings including the polymers, and narrow polydispersity drug delivery particles including the polymers.... Agent: Squire, Sanders & Dempsey LLP

20090324672 - Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug: This invention is generally related to coatings for implantable medical devices, such as drug delivery vascular stents. The coating includes a drug reservoir layer above the outer surface of the device body, the drug reservoir layer with a peptide or protein, a hydrophobic drug, and a polymer with a weight... Agent: Squire, Sanders & Dempsey LLP

20090324670 - Polyester implantable medical device with controlled in vivo biodegradability: This invention relates to blends of high, optionally medium, and low molecular weight polyesters where at least the low molecular weight polyester is substituted with an acidic moiety, the biodegradation of the blends being controllable by selection of the mean molecular weigh of each fraction, the quantity of each fraction... Agent: Squire, Sanders & Dempsey LLP

20090324677 - Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090324676 - Porous coating incorporating fluid reservoirs: Porous coating for the controlled release of fluids such as drugs comprising a porous structure with internal reservoirs and passages, said reservoirs communicating with the external environment through said passages, in such a way that a fluid can move between the reservoirs and the external environment, characterized by the fact... Agent: Nixon & Vanderhye, PC

20090324681 - Vascularization enhanced graft constructs: A tissue graft construct for use in repairing diseased or damaged tissues is provided. The tissue graft construct comprises a matrix composition selected from the group consisting of liver basement membrane and extracts and hydrolysates thereof, and processed collagen from vertebrate non-submucosal sources, added endothelial cells, and at least one... Agent: Barnes & Thornburg LLP

20090324683 - Controlled release tissue graft combination biomaterials: In one aspect, the invention relates to tissue graft combination biomaterials capable of controlled release of bioactive agents or pharmaceutically active agents through a rate-controlling polymer coating encapsulating the graft material, methods for preparing same, methods of controlled release using same, and methods for treating tissue defects. This abstract is... Agent: Ballard Spahr LLP

20090324685 - Medical device coatings containing charged materials: In accordance with certain aspects of the present invention, medical devices are provided which are configured for implantation or insertion into a subject. The medical devices include at least one coating region that comprises (a) a charged polyamino-acid-containing polymer having a first net charge and (b) an additional charged polymer... Agent: Mayer & Williams PC

20090324684 - Medical devices having surface coatings: According to an aspect of the present invention, medical devices are provided which comprise a metallic region and a coating on all or part of the metallic region that comprises a multivalent acid.... Agent: Mayer & Williams PC

20090324682 - Medical stent provided with inhibitors of atp synthesis: A stent provided with a composition having at least one type of inhibitor of ATP synthesis, optionally together with at least one inhibitor of the pentose phosphate pathway is disclosed. The medical stent is useful for treating stenosis and preventing restenosis in vascular ducts and for treating cancerous tumors present... Agent: Knobbe Martens Olson & Bear LLP

20090324686 - Transscleral delivery: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or... Agent: Morrison & Foerster LLP

20090324687 - Transscleral delivery: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or... Agent: Morrison & Foerster LLP

20090324688 - Transscleral delivery: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or... Agent: Morrison & Foerster LLP

20090324689 - Transscleral delivery: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or... Agent: Morrison & Foerster LLP

20090324690 - Transscleral delivery: Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or... Agent: Morrison & Foerster LLP

20090324691 - Methods and ophthalmic devices used in the treatment of ocular allergies: Ophthalmic devices containing anti-allergic agents and methods of preparing the same are disclosed herein.... Agent: Philip S. Johnson Johnson & Johnson

20090324692 - Polyurethane elastomers: A linear polymer is obtained by reacting together a polyethylene glycol or polypropylene glycol; a PEG-PPG-PEG or PPG-PEG-PPG block copolymer; a difunctional amine or diol; and a diisocyanate. A controlled release composition comprises the polymer together with an active agent. Active agents of molecular weight 200 to 20,000 may be... Agent: Law Office Of John K. Pike, PLLC

20090324693 - Delivery product for topical compositions: A delivery product is used to deliver a skin composition to the skin of a user. The delivery product includes a thermo-responsive polymer film. The polymer film is solid at room temperature but, once contacted with the skin, increases in temperature and degrades. A skin composition is associated with the... Agent: Dority & Manning, P.A.

20090324694 - Gastroretentive drug delivery system comprising an extruded hydratable polymer: According to the present invention there is provided a pharmaceutical product for retention in the stomach. The product is produced by extrusion. The use of extrusion enables the product to take many useful forms. The product may comprise a sheet of hydratable polymer, the hydrated sheet being of a size... Agent: Davidson, Davidson & Kappel, LLC

20090324695 - Biocompatible polymer ceramic composite matrices: Biocompatible composites of flexible polymers/copolymers films and dispersed solid silica-based ceramic microparticles are provided. The composites uniquely combine material and drug delivery properties that are essential for wound dressings and drug delivery applications. The flexible copolymer films are preferably tyrosine-based polycarbonates, and the ceramic microparticles are biodegradable silica-based glass particles... Agent: Woodcock Washburn LLP

20090324696 - Nail patch: The present subject matter provides a nail patch comprising a backing layer and a pressure-sensitive adhesive layer disposed on at least one side of the backing layer, wherein the pressure-sensitive adhesive layer comprises a pressure-sensitive adhesive base, terbinafine and/or a pharmacologically acceptable salt thereof, and sodium acetate and/or sorbitan monolaurate... Agent: The Nath Law Group

20090324697 - Transdermal hormone delivery system: compositions and methods: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20090324699 - Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders: There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and/or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.... Agent: Morgan Lewis & Bockius LLP

20090324703 - Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders: Curcuminoid formulations having enhanced bioavailability are provided and comprise a curcuminoid, antioxidant, glucuronidation inhibitor, and water-soluble, pharmaceutically acceptable inhibitor. A method of treating Alzheimer's and other age-related diseases by administering such a composition is also provided.... Agent: Christie, Parker & Hale, LLP

20090324701 - Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders: The present invention provides pharmaceutical compositions comprising (S)-bethanechol or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier and optionally at least one diabetes drug. The use of said composition in the treatment of insulin resistance, type 2 diabetes, impaired glucose tolerance and related disorders is also provided. The invention... Agent: Merchant & Gould PC

20090324708 - Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprising thereof and a method for the treatment of rho-gtpase cell protein-mediated condition: The present invention relates to a compound having inhibitory activity on a Rho-GTPase cell protein, the compound having the formula I (Formula I) wherein A is selected from N and N—H, R1 is selected from H and NHR3, R2 is selected from NHR4, OR4, O and halogen, R3 is selected... Agent: Sughrue Mion, PLLC

20090324698 - Liposomal composition comprising an active ingredient for relaxing smooth muscle, the production of this composition and the therapeutic use thereof: The invention relates to a pharmaceutical composition made from an active ingredient included in liposomes for topical application, whereby the liposomes have an aqueous medium in the interior thereof and contain at least one active ingredient therein which exerts a direct or indirect relaxing effect on smooth musculature and is... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090324709 - Liposomal formulations: The invention relates to formulations of hydrophilic substances encapsulated in liposomes, to the method of encapsulation of the hydrophilic substances in the liposomes and the use of said formulations in the prevention and/or treatment of diseases and/or disorders in humans and animals.... Agent: Sheridan Ross PC

20090324707 - Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines: The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further... Agent: Proskauer Rose LLP

20090324700 - Methods and compositions for the inhibition of cathepsins: Methods and compositions for modulating cell death by contacting a cell with an Spi2A polypeptide or an Spi2A polypeptide equivalent are disclosed. In addition, methods of treating a subject by providing the subject a composition that includes an Spi2A polypeptide or an Spi2A polypeptide equivalent are disclosed. The Spi2A polypeptide... Agent: Fulbright & Jaworski L.L.P.

20090324706 - Nanostructures suitable for sequestering cholesterol and other molecules: Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that... Agent: Wolf Greenfield & Sacks, P.C.

20090324702 - Novel viral vector: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases... Agent: Sughrue Mion, PLLC

20090324704 - Phosphate diester amides: The present invention relates to lipid-analogous phosphoric acid compounds and in particular phosphoric triesters, phosphoric diester amides and phosphoric diesters. These are preferably cationic phospholipids preferably having at least one free hydroxyl group.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090324705 - Phytonutrient compositions for topical use: Topical anti-oxidant liposomal phytonutrient formulations and methods for their use such as the treatment of skin inflammation and skin-lightening applications.... Agent: Stemedica Cell Technologies, Inc

20090324710 - Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor: Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are... Agent: K&l Gates LLP

20090324711 - Oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof: An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition including an anilinopyrimidine derivative of Formula (I) and a pharmaceutically acceptable excipient selected from the group consisting of polyethylene glycol, a glyceryl ester of capric acid or a mixture thereof. The liquid fill composition is formulated... Agent: Marshall, Gerstein & Borun LLP

20090324712 - Methods and compositions related to production of coenzyme q10: Disclosed are methods, compounds, and compositions related to the production of coenzyme Q.... Agent: Ballard Spahr LLP

20090324713 - Spray-on, non-woven fabric system and multilayer wound coverings: The invention is directed to a spray-on, non-woven fabric system and multilayer wound coverings for promoting wound healing, where the fabric system includes a first spray-on composition including a non-volatile carrier for keeping the wound moist and a second spray-on composition for covering the first composition and protecting the wound... Agent: Philip S. Johnson Johnson & Johnson

20090324714 - Dual adhesive technology: A dual adhesive layer dosage form for delivery of active agent to and across, the mucosa is disclosed. Particularly, bioadhesive tablets for administration at the vaginal mucosa are disclosed as having a central active layer sandwiched between two bioadhesive layers.... Agent: Pepper Hamilton LLP/wyeth

20090324715 - High dose oral pharmaceutical compositions of artemether and lumefantrine: The present invention relates to high dose oral pharmaceutical compositions of artemether and lumefantrine, and process for preparation thereof. The compositions comprise of artemether and lumefantrine comprising artemether in an amount of from about 40 mg to about 80 mg, lumefantrine in an amount of from about 240 mg to... Agent: Ranbaxy Inc.

20090324716 - Coated particles containing pharmaceutically active agents: The present invention features a tablet including particles containing a pharmaceutically active agent, wherein the particles are coated with (a) a first film layer containing a modified release polymer; and (b) a second film layer containing (i) a first polymer, wherein the first polymer is a polymer of ethyl acrylate... Agent: Philip S. Johnson Johnson & Johnson

20090324717 - Extended release pharmaceutical formulation of metoprolol and process for its preparation: The invention provides an extended release coated granule comprising a granule having a particle size ranging from 0.2 to 2 mm, a friability lower than or equal to 1% and comprising metoprolol succinate as active ingredient in an amount ranging from 10 to 75% by weight of the granule and... Agent: Berenbaum Weinshienk PC

20090324718 - Imatinib compositions: Provided are compositions of imatinib, methods for their preparation, and methods for treatment using the same.... Agent: Kenyon & Kenyon LLP

20090324720 - Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same: Disclosed are hydrogel compositions formed by the mixture of a tetramethylmethane substituted with one or more polyethylene glycols, and wherein each polyethylene glycol substituent is independently further substituted with one or more electrophilic groups, and a tetramethylmethane substituted with one or more polyethylene glycols, and wherein each polyethylene glycol substituent... Agent: Seed Intellectual Property Law Group PLLC

20090324719 - Extracellular matrix composition: The invention relates to a process for preparing an extracellular matrix composition comprising cross-linked fibrinogen or a derivative thereof, to an extracellular matrix composition obtained by said process and to the use of said composition in wound healing, tissue regeneration or as a tissue engineering scaffold.... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20090324721 - Hydrogels suitable for use in polyp removal: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable, or not, are provided,... Agent: Mark Farber, Esq. Tyco Healthcare Group Lp

20090324722 - Cartilage filling device: Compositions and methods for treating a tissue defect.... Agent: Peter F. Corless Edwards Angell Palmer & Dodge LLP

20090324723 - Method of prophylaxis of infection: A method for prophylaxis of infection of the respiratory tract of a subject by pathogenic airborne bacteria the method comprising administering to the subject by inhalation binding proteins directed against the bacteria. the pathogenic bacteria is a bacteria which survives inside phagocytes and the binding proteins are directed against said... Agent: Gerstenzang, William C .

20090324727 - Nanoemulsion: The present invention relates to a nanoemulsion comprising at least one aqueous component and a carrier, wherein the carrier comprises at least one lipophilic component, at least one surfactant and at least one alcohol, characterised in that at least one alcohol has at least three carbon atoms. The present invention... Agent: Sutherland Asbill & Brennan LLP

20090324726 - Non-viral gene therapy using chitosan-containing nanoparticles: The present invention concerns a new drug delivery system and more particularly, a non-viral drug delivery system comprising a polymer according to the following formula and useful for treating a disease characterized by over-expression of folic acid receptors on the cell surface.... Agent: Gowling, Lafleur And Henderson LLP

20090324725 - Peg-modified hydroxyapatite, pharmaceutical using the same as base material and production process thereof: The present invention provides a PEG-modified HAP having a high degree of safety and novel functions by modifying the surface of hydroxyapatite particles with a polyethylene glycol derivative, applications thereof, and a production process of the same. The PEG-modified HAP of the present invention is a substance in which hydroxyapatite... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090324728 - Pharmaceutical compositions comprising amorphous benzimidazole compounds: Compositions comprising amorphous substituted benzimidazole compounds.... Agent: Dr. Reddy''s Laboratories, Inc.

20090324724 - Soluble amide & ester pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090324730 - Methods and compositions for the treatment of symptoms of complex regional pain syndrome: A therapeutic composition for the treatment of the symptoms of complex regional pain syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. PLLC

20090324729 - Use of solid carrier particles to improve the processability of a pharmaceutical agent: t

20090324731 - Method for making biodegradable superabsorbent particles: A method for making particles containing carboxyalkyl cellulose, comprising blending a carboxyalkyl cellulose and a starch in water to provide an aqueous gel; treating the aqueous gel with a crosslinking agent to provide a crosslinked gel; drying the crosslinked gel to provide a solid; comminuting the solid to provide a... Agent: Weyerhaeuser Company Intellectual Property Dept., Ch 1j27

20090324733 - Composition of whey growth factor extract for reducing muscle inflammation: The invention relates to the production of compositions containing milk products for use as a nutritional supplement. More specifically, it relates to compositions containing whey growth factor extract, as well as their use in methods for reducing muscle inflammation in individuals undertaking resistance exercise training. According to one aspect of... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090324732 - Method for the production of milk or milk products with a high proportion of melatonin: A method for the production of milk with increased melatonin content or a milk product made therefrom. The method comprises dividing the daily cycle of a female mammal into a daytime phase under a first light regime with a proportion of blue light and a night-time phase under a second... Agent: Greenblum & Bernstein, P.L.C

20090324734 - Throat care composition: A throat care composition including water, honey, vegetable glycerine, natural lemon flavor, at least one of liquefied slippery elm and liquefied marshmallow root, grape seed extract and malic acid. In at least one embodiment, the throat care composition is applied via a spray applicator.... Agent: Amster, Rothstein & Ebenstein LLP

20090324735 - Means and method for enhancing a human sexual activity: The invention relates to enhancing a human sexual activity. The inventive means for enhancing a human sexual activity is embodied in the form of a light water containing at least 99.739 molecular % or at least 99.760 molecular % or at least 99.774 molecular % of the lighter 1H216O molecules... Agent: Notaro & Michalos P.C.

20090324736 - Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic: The present invention relates to formulations and kits for the treatment of bowel disease, to their use in medicinal preparations and to therapeutic methods thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20090324737 - Antimicrobial and sporicidal composition: Germicidal compositions with enhanced activity towards killing microbiological spores and vegetative cells comprising certain quaternary ammonium compounds (QACs), phenolic compounds, monohydric alcohols, hydrogen peroxide, iodine, triclocarban, triclosan or combinations thereof with one or more spore coat opening agents. The invention also provides for the application of the germicidal compositions to... Agent: Thorpe North & Western, LLP.

20090324739 - Antibacterial composition containing organic silver complexes, antibacterial treatment methods using the same and antibacterial formed article: The present invention relates to antibacterial composition containing silver complexes, antibacterial treatment methods using the same and antibacterial formed article, in which the antibacterial composition containing silver complexes is economical, not wearing off due to washing, cleaning, rubbing, etc., firmly combined to improve durability and antibacterial effect, and applicable to... Agent: The Webb Law Firm, P.C.

20090324738 - Methods for making antimicrobial coatings: Methods for forming antimicrobial coatings on substrate surfaces are disclosed. The methods involve providing a mixture comprising a metal salt, a biguanide compound, and a reducing agent, wherein the mixture is free of polymeric binders; and depositing the mixture onto a substrate surface, thereby forming a coated substrate surface.... Agent: Marshall, Gerstein & Borun (baxter)

20090324740 - Novel nasal spray: Systems and methods are disclosed for treating a plurality of sinsousal conditions to be treated. These systems and methods include selecting a combination of at least two compounds that are capable of addressing a plurality of sinsousal conditions. At least one of the at least two compounds is selected from... Agent: Docket Clerk

20090324744 - Effective antitumor treatments: ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug.... Agent: King & Spalding

20090324741 - Injectable polymer-lipid blend: An injectable polymer-lipid blend is provided. The blend may provide a localized drug delivery system for a pharmaceutically active agent. The blend may be prepared from a chitosan-based material, fatty acid and phospholipid. The chitosan-based material may be a water soluble chitosan derivative. The fatty acid may be a fatty... Agent: Stephen R. Burri

20090324742 - Peham dendrimers as excipients: The present invention concerns poly(etherhydroxylamine) PEHAM dendritic polymers wherein they function as excipients for the enhancement of water solubility of poorly water soluble (hydrophobic) Active Materials or enhancement of oil solubility of poorly oil soluble (hydrophilic) Active Materials. These dendritic polymers can have Active Materials associated with them by one... Agent: Technology Law, PLLC

20090324743 - Pulmonary drug delivery: The present invention relates to formulations for delivery of drugs to the respiratory tract, especially the lungs, as well as improved methods of treating subjects suffering or predisposed to suffering from lung conditions/diseases. The invention is particularly directed to lung cancer treatment using, for example, cytotoxic platinum-based drugs.... Agent: Intellectual Property / Technology Law

20090324745 - Compositions and methods for nutrition supplementation: The present invention relates to compositions, that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment, comprise vitamin B6, vitamin B9, vitamin B12, calcium, vitamin D3, magnesium, and boron, and methods for using these compositions for nutritional supplementation in order to prevent, treat... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090324746 - System for producing and dispensing chlorine dioxide: The invention relates to a multi-component chlorine dioxide producing system. The invention produces effective amounts of chlorine dioxide in five minutes or less without instantaneous production or loss of chlorine dioxide. The invention further includes a dispensing apparatus to allow for the dispensing of the multi component system to allow... Agent: Johnsondiversey, Inc.

20090324747 - Apparatus and method for mixing a concentrated water treatment solution: An apparatus includes a reservoir for holding a chemical solution, a pump and a discharge nozzle. The pump has an inlet and an outlet connected to the reservoir by inlet and discharge lines. The nozzle is disposed in a lower portion of the reservoir and discharges the solution toward the... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090324748 - Trauma therapy: The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) a local anaesthetic. Also provided is a composition... Agent: Venable LLP

20090324749 - Ethanolic and/or aqueous composition of an ammoniacal solution of alkaline metal salts of azide, mainly sodium and potassium: The present invention consists of the discovery about an ammoniacal solution of sodium azide (NaN3) or other azide salts that in low concentrations induces the budding of grapevine buds and potentially other deciduous fruit trees with the same efficiency as H2CN2 makes.... Agent: Wolf Greenfield & Sacks, P.C.

20090324751 - Chinese herb extract for treating dementia and preparation method thereof: The present invention relates to a Polygonum multiflorum extract and the preparation process thereof. The Polygonum multiflorum extract of the present invention mainly comprises 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside and catechin. The present invention also relates to the use of the Polygonum multiflorum extract of the present invention for the treatment or prevention of... Agent: Husch Blackwell Sanders LLP

20090324752 - Cosmetic use of active ingredients increasing the production of growth factors: The invention relates to a cosmetic skin care method, intended to prevent and/or treat at least one cutaneous sign of ageing, including topical application to the skin of a composition containing at least one botanical active ingredient which increases the production by keratinocytes of at least one growth factor chosen... Agent: Young & Thompson

20090324750 - Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity: The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, antiallergic and anti-asthmatic activity. The extract of Pseudolysimachion genus plant and the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL-13 levels and... Agent: Lucas & Mercanti, LLP

20090324753 - Product and composition for alleviating post-menstrual symptoms: The current invention relates to a natural composition for topical application to skin to alleviate post-menstrual symptoms of cramping, backache, and breast tenderness; and for other aches and pains including Rheumatic, muscular and articular pains; and local treatment such as tendinitises, tennis elbow, benign distorsions, arthritis, osteoarthritis, neuralgia, sciatic nerve,... Agent: Rick B. Yeager, Attorney

20090324754 - Eucalyptus extract, method of preparation and therapeutic uses thereof: The present invention relates to the use of a Eucalyptus for preparation of a drug or a dietary supplement intended for treatment and/or prevention of affections or pathologies caused by neuromediator recapture disorder. The present invention also relates to a new enriched extract of Eucalyptus characterized in that it contains... Agent: The Firm Of Hueschen And Sage

20090324755 - Method for the production of a plant-based medicament: A method for the production of a plant-based medicament which contains Iberis amara, Menthae piperitae folium, Matricariae flos, Carvi fructus, Melissae folium, Angelicae radix, Liquiritiae radix, Cardui mariae fructus and Chelidonii herba in the form of alcoholic extracts and a medicament produced according to this method, and its use.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090324756 - Topical preparations comprising flower wax and candelilla: The invention pertains to topical, wax-based compositions comprising one or more flower waxes and candelilla wax, in the ratio of about 20:1 to about 1:20. Such compositions may have improved shear resistance or be substantially plasticizer free. Stick-type and stay-in-place topical preparations are contemplated.... Agent: The Estee Lauder Cos, Inc

20090324757 - Compositions and methods for modulating visceral sensation and/or gastrointestinal reflex activity: The invention relates to compositions capable of modulating visceral sensation and/or gastrointestinal activity obtained from botanical sources. More specifically, the invention relates to compositions comprising an extract product of an Asclepias plant, and methods of modulating visceral sensation and/or gastrointestinal activity in an individual using same.... Agent: Marshall, Gerstein & Borun LLP

20090324758 - Plant extract mixtures and their uses: A composition comprising an effective amount of Cissus quadrangularis to reduce fat and cause weight loss in a mammal. Such compositions have beneficial activity principally in controlling weight gain and obesity.... Agent: Greenberg Traurig LLP (la)

20090324759 - Immune enhancement by seed oil and/or seed flour: A method of treating a subject requiring immune mediation includes administering to the subject an immunostimulatory composition which contains black raspberry seed oil. Administering this composition stimulates the production of certain immune cells, including NK cells and CD8(+) lymphocytes. Administering the composition by this method also provides a method of... Agent: Briggs And Morgan P.A.

20090324760 - Hair tonic: m

20090324761 - Methods and compositions for improving gastrointestinal health: Methods for maintaining or improving the gastrointestinal health of an animal by administering a gastrointestinal health maintaining or improving amount of at least one banana musa fruit to the animal susceptible to or suffering from poor gastrointestinal health. In one embodiment, banana is administered to the animal to prevent or... Agent: Colgate-palmolive Company

20090317324 - Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain: The present invention relates to a phage display vehicle composed of a filamentous bacteriophage displaying on its surface, as a non-filamentous bacteriophage molecule, protein A or a fragment or variant thereof capable of binding the Fc portion of antibodies, and an antibody or an antigen-antibody immunocomplex bound to protein A... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090317325 - Diagnostic substance and method for the analysis of metabolism processes in the brain: The present invention relates to a diagnostic substance, containing at least one complex of lipophilic anions and metal ions, wherein the lipophilic anions are selected from the group comprising: triethylene tetramine dihydrochloride (TETA), ethyl cysteinate dimer (ECD), methoxyisobutylisonitrile (MIBI), HMPAO (d,l-hexamethylpropylene aminoxime), ethylenediamine N,N,N′,N′-tetraacetanilide (EDTAN), dimethyldithiocarbamate (DMC) and diethyldithiocarbamate (DDC)... Agent: Kriegsman & Kriegsman

20090317326 - Radiofluorination methods: The present invention relates to radiolabelled substitute benzene compounds for diagnostic imaging. The present invention provides methods for preparation of such compounds, in particular, preparation of novel compounds which serve as precursors for 18F-labeling, and the use of thus 18F-labeled compounds for diagnostic imaging.... Agent: Millen, White, Zelano & Branigan, P.C.

20090317327 - Aqueous dispersion of superparamagnetic single-domain particles, production and use thereof in diagnosis and therapy: The invention relates to an aqueous dispersion of superparamagnetic iron-containing particles bearing α-hydroxycarboxylic acids as stabilizer substances on their surface, said dispersion comprising N-methyl-D-glucamine (meglumine) and/or 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol) and the content of free iron ions being lower than 1 mg of iron per liter. In a preferred embodiment the dispersion... Agent: Norris, Mclaughlin & Marcus, P.A.

20090317328 - Tricyclic oxazepines as in vivo imaging compounds: Novel compounds of formula (I): suitable for use as in vivo imaging agents are provided as well as precursors suitable for the preparation of said compounds. The present invention also provides pharmaceuticals comprising the compounds and kits for the preparation of the pharmaceuticals. Furthermore, use of the compounds for imaging... Agent: Ge Healthcare, Inc.

20090317331 - Method of identifying partial agonists of the a2a receptor: The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090317332 - Human g protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto: The present invention relates to methods of using a G protein-coupled receptor (GPCR) to screen one or more candidate compounds as a modulator of body mass or of adiposity or of percentage body fat in a subject or as a pharmaceutical agent for obesity and conditions related thereto. Inverse agonists... Agent: Arena Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20090317335 - Hybrid nanomaterials as multimodal imaging contrast agents: The presently disclosed subject matter provides hybrid nanomaterials for use as magnetic resonance imaging (MRI), optical and/or multimodal contrast imaging agents. The hybrid nanomaterials comprise a polymeric matrix material and a plurality of coordination complexes, each coordination complex comprising a functionalized chelating group and a paramagnetic metal ion. The nanoparticle... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090317334 - Optical detection method or imaging method of implanted cells: There is provided a method of an animal model experiment to observe cells implanted to an experimental small animal in which the position or spatial spread only of the implanted cells can be detected and observed with time progress and with sufficient accuracy while a plurality of kinds of the... Agent: Scully Scott Murphy & Presser, PC

20090317333 - Protein kinase a reporters useful in high throughput assays: Protein kinase A reporters useful for obtaining measurements of protein kinase A activity with high spatial and temporal resolution can be used in high throughput assays to identify potentially therapeutic compounds.... Agent: Banner & Witcoff, Ltd.

20090317336 - Method and apparatus for high mass concentration nano particle generation: A method and apparatus for generating nano particles, including but not limited to nano particles of Ceo, at high concentration. The invention uses a solid aerosol disperser in communication with a furnace tube having a vaporization chamber and a dilution chamber. A heating element surrounds the furnace tube. Heat from... Agent: Battelle Memorial Institute

20090317337 - Aerosol formulation for inhalation containing an anticholinergic agent: The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X represents an anion, and containing at least one pharmacologically compatible organic acid and optionally additional pharmacologically compatible adjuvants and/or complexing agents. The cation of formula... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090317338 - Foamable iodine compositions: The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective... Agent: Wilmerhale/boston

20090317339 - Teeth bleaching compositions and devices: The present invention is directed to an oral care device configured to contact teeth, where the device includes disposed therein a bioactive glass in an amount effective to mineralize teeth when contacted with the teeth under conditions effective to mineralize the teeth; and a tooth-bleaching agent in an amount effective... Agent: Philip S. Johnson Johnson & Johnson

20090317340 - Concentrated beverage composition for cleaning oral cavity, method of manufacturing the concentrated beverage composition and natural tea comprising the same: Disclosed are a concentrated beverage composition for cleaning an oral cavity, a method of manufacturing the concentrated beverage composition, and a natural tea comprising the same. The concentrated beverage composition may comprise 100 parts by weight of water, 0.1 to 3 parts by weight of a flavoring agent, 1 to... Agent: Marshall, Gerstein & Borun LLP

20090317341 - Compositions for lightening skin color: Skin lightening additives and skin lightening compositions having at least one of a heterosubstituted, saturated or unsaturated aliphatic acid are described. The compositions are suitable for topical application and may comprise 12-hydroxystearic acid, ricinoleic acid or both.... Agent: Unilever Patent Group

20090317343 - Personal care compositions containing silicone elastomer gels: Personal care compositions are disclosed containing a silicone elastomer from the reaction of an organohydrogen-siloxane having at least two SiH containing cyclosiloxane rings in its molecule, a compound having at least two aliphatic unsaturated groups in its molecule, and a hydrosilylation catalyst.... Agent: Dow Corning Corporation Co1232

20090317342 - Use of flavonoids: The present invention relates to the use of at least one flavonoid for odour improvement and/or odour stabilisation, and to corresponding compositions and the preparation thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20090317344 - High-water content lipstick and its preparation: This invention describes a high water content lipstick and its preparation. This formula includes 1-10 wt % emulsifiers, 1-30 wt % water phase and 69-98 wt % oil components phase. Pigments, pearl agents, water soluble active ingredients can be introduced when required. Polyglyceryl fatty ester, fatty ester and silicone derivative... Agent: Scully Scott Murphy & Presser, PC

20090317345 - Antiperspirant/deodorant gel composition with low pouring temperature: Solid stick antiperspirant and deodorant compositions containing both branched and linear N-acyl gelling agents along with dipropylene glycol are provided. Such compositions exhibit advantageous pouring temperatures below about 80° C.... Agent: Joy S. Goudie Revlon Consumer Products Corporation

20090317346 - Deodorant agent: l

20090317347 - Antiperspirant/deodorant compositions: A composition comprising a structuring agent for the composition comprising a partially hydrogenated soybean oil with a melting point of about 26 to about 38° C. in an amount of about 5% or less by weight: and at least one active chosen from antiperspirant actives and deodorant actives in an... Agent: Colgate-palmolive Company

20090317348 - Production of structured hairstyles using a composition comprising reactive silicone compounds: The present invention relates to the treatment of human keratin fibres to obtain structured hairstyles, for example with structured locks, which consists in applying a composition comprising at least one compound X and Y, at least one of which is a silicone compound, these compounds furthermore being capable of reacting... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090317349 - Stabilized hydrogen peroxide compositions and methods: A hydrogen peroxide-containing composition comprising at least one antioxidant and at least one free radical scavenger operable to neutralize reactive oxygen species generated by the hydrogen peroxide and a method for stabilizing hydrogen peroxide containing compositions.... Agent: Julie M. Blackburn

20090317350 - Keratin fibre coating composition comprising an aqueous phase and a tackifying resin: The present invention relates to a keratin fibre coating composition comprising an aqueous phase and at least one resin chosen from rosins, rosin derivatives and hydrocarbon-based resins, and mixtures thereof, the said resin having a number-average molecular weight of less than or equal to 10 000, the said composition being... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090317351 - Concentrated beverage compositon for hair health care, method of manufacturing the concentrated beverage composition and natural tea comprising the same: Disclosed are a concentrated beverage composition for hair health care, a method of manufacturing the concentrated beverage composition, and a natural tea comprising the same. The concentrated beverage composition for hair health care comprises 100 parts by weight of water, 10 to 20 parts by weight of Pleuropterus multiflorus extract,... Agent: Marshall, Gerstein & Borun LLP

20090317352 - Hyperphosphatemia in domestic animals: compositions and methods of treatment: The present invention is generally related to the treatment of hyperphosphatemia in domestic animals. It is specifically directed to compositions containing phosphate binders that are palatable to domestic animals and methods using such compositions. In a composition aspect, the present invention provides a composition that includes: a rare earth compound... Agent: Dillon & Yudell LLP

20090317354 - Composition for restoring damaged skin comprising a saccaride and povidone-iodine: The present invention relates to a composition for repairing injured skin containing a saccharide and povidone-iodine. The present invention has the following characteristics: suppresses time-dependent increase of consistency, it is easy to use, it is a soft preparation, and has superior applicability to a deep wounded lesion and a granulation... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090317353 - Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator: The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field.... Agent: Stradley Ronon Stevens & Young, LLP

20090317355 - Abuse resistant melt extruded formulation having reduced alcohol interaction: The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the... Agent: Paul D. Yasger Abbott Laboratories

20090317356 - Composition and method for repelling mammals: A composition that first attracts then repels mammals, which is delivered via an easy-to-use open container, or on a transportable flat surface. The open container or transportable flat surface holding the composition may be placed near, in or on an object or area to be protected. The composition maintains its... Agent: Michael A. Casey

20090317359 - 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of raf kinase: New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase... Agent: Chiron Corporation Intellectual Property - R440

20090317358 - Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities: The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by a recombinant chimeric protein between human interleukin-2 (IL2) and Bax. The chimeric protein specifically targets IL2 receptor (IL2R)-expressing cells and induces cell-specific apoptosis.... Agent: Volpe And Koenig, P.C.

20090317357 - Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents: Methods for treating or preventing an autoimmune disease using agents that block the histamine H1 receptor are disclosed. H1 receptor-blocking agents useful in accordance with the methods provided herein include, for example, H1 antihistamines, particularly H1 antihistamines that do not substantially block the serotonin receptor.... Agent: Townsend And Townsend And Crew, LLP

20090317360 - Anti-viral inhibitors and methods of use: Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.... Agent: Glaxosmithkline C/o Foley & Lardner LLP

20090317361 - Carba-nucleoside analogs for antiviral treatment: Provided are imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.... Agent: Gilead Sciences Inc

20090317362 - Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection: The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.... Agent: Wellstat Management Company. LLC

20090317368 - B7-h1, a novel immunoregulatory molecule: The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.... Agent: Millen, White, Zelano & Branigan, P.C.

20090317369 - Compositions comprising cardiac stem cells overexpressing specific micrornas and methods of their use in repairing damaged myocardium: The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090317363 - Cytokine derivatives: The invention relates to polypeptides comprising an N-terminal portion and a C-terminal portion, wherein said N-terminal portion comprises the signature sequence QGP[P or L] and the amino acid sequence of said C-terminal portion is at least 70% identical to SEQ ID NO: 1, and uses thereof.... Agent: Klauber & Jackson

20090317364 - Novel compositions for prevention and treatment of mastitis and metritis: A novel stable synergistic compositions used for the prevention and/or treatment of mastitis and metritis in mammals comprising a combination of therapeutically effective amount of Serratiopeptidase, Lysozyme, Oscimum sanctum and Azadirechta indica are disclosed in the present invention. The present invention further discloses a method of treatment and/or prevention of... Agent: Ladas & Parry LLP

20090317370 - Methods and means for protecting the skin against pathogenic microorganisms: Described are microorganisms which are, in a first aspect, able to to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit... Agent: Connolly Bove Lodge & Hutz, LLP

20090317366 - Method for treating progressive neurodegenerative disorders: A method for treating a progressive neurodegenerative disorder with bone marrow stem cells and a G-CSF receptor agonist.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090317367 - Methods of producing preadipocytes and increasing the proliferation of adult adipose stem/progenitor cells: The present invention describes preadipocytes and methods of differentiating macrophages into preadipocytes by co-culturing adipocytes and resident adipose tissue macrophages. Also described are methods of increasing the proliferative rate of adipose adult stem/progenitor cells.... Agent: Davis Wright Tremaine LLP/los Angeles

20090317365 - Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof: A method for making hepatocytes from extrahepatic somatic stem cells comprises: a) culturing somatic stem cells in a medium comprising hepatic growth factor to cause the stem cells to differentiate toward hepatocytes; b) culturing cells from a) in a medium comprising HGF and oncostatin M to facilitate the cell differentiation... Agent: Ipc Intellectual Property Connections, Inc.

20090317371 - Method, composition, and device, for the treatment of amylase malfunctions / inactivity in association with saccharides (mainly polysaccharides) based diseases: Physiological protein and enzyme complex having active Trimethylglycine, active amylases, active lipases, and active proteases, of human (saliva enzymes), yeast, plant, fungi, and or microbial origin, preferably digestive enzyme complex such as, Trimethylglycine, 4-α-D-glucan glucanohydrolase; Exo-1,4-α-glucosidase; Beta-fructofuranosidase; Protease (3.0); Pectinase; Lipase; Cellulase; Lactase; Malt Diastase, or digestive enzyme complex containing... Agent: Tarig Sayed Mustafa Arbab

20090317372 - Small molecules for the reduction of high blood glucose level: Embodiments of the present invention include the in vivo use of a family of heterocyclic compounds containing a quaternary ammonium group as exemplified by the thioxanthone and thioxanthene compounds [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, or CCcompound1, N,N,-diethyl-N-methyl-2-[9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide, or CCcompound3, and N,N,N-trimethyl-3-(9H-thioxanthen-9-ylidene)-propane-1-aminium iodide, or CCcompound19 to reduce higher than normal blood glucose level... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090317374 - Composition containing arazyme for the prevention and treatment of cancer: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and... Agent: Lucas & Mercanti, LLP

20090317373 - Inhibition of the anti-fviii immune response: The invention relates to a compound capable of inhibiting the endocytosis of FVIII (factor VIII) by immune system cells capable of endocytosing the antigen and to the therapeutic use of such a compound for the manufacture of a medicament for use in the treatment of hemophiliacs in order to reduce... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090317375 - Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction: This invention relates to methods for treating or preventing an infarction by administering to a patient in need thereof a compound capable of suppressing the expression or activity of the von Willebrand Factor (VWF). Thus, the invention relates to the use of a pharmaceutically effective amount of a VWF inhibitor,... Agent: Baxter Healthcare Corporation

20090317329 - Anticoagulation agent and uses thereof: The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe... Agent: Clark & Elbing LLP

20090317330 - Diagnosis and treatment of diseases involving platelet activation: Disclosed herein are compositions, methods, and kits for diagnosing or predicting a disease in a subject, for detecting activated platelets in a subject, and for treating a disease in a subject, wherein the diseases are mediated by platelet activation.... Agent: Clark & Elbing LLP

20090317378 - Antimicrobial composition and uses thereof: A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof,... Agent: Oliff & Berridge, PLC

20090317379 - Autophilic antibodies and method of making the same: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090317376 - Compositions and methods for lipo modeling: Methods for lipomodeling by peripherally administering a modulator of a Y receptor are provided. Methods may comprise reduction of a fat depot by administering a Y receptor antagonist proximally and/or directly to the site of the fat depot. Other methods comprise increasing or stabilizing a fat depot or fat graft... Agent: Wolf Greenfield & Sacks, P.C.

20090317377 - Therapy procedure for drug delivery for trigeminal pain: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.... Agent: Morrison & Foerster LLP

20090317380 - Use of prion conversion modulating agents: The use of Apolipoprotein B, Apoliporpotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications in prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090317381 - Clearance of abnormal iga1 in iga1 deposition diseases: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention.... Agent: Choate, Hall & Stewart LLP

20090317382 - Use of effector-function-deficient antibodies for treatment of auto-immune diseases: The invention relates to the treatment of autoimmune diseases and disorders, in particular myasthenia gravis, by administration of effector-function-deficient antibodies, wherein said effector-function-deficient antibodies are capable of competing with one or more of the auto-antibodies involved in mediating the antibody-mediated auto-immune disease or disorder for binding to a target auto-antigen.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090317383 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090317384 - Methods of using death receptor ligands and cd20 antibodies: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies... Agent: Genentech, Inc.

20090317385 - Methods using immunomodulatory compounds for modulating level of cd59: Provided herein are methods of treating, preventing or managing disorders associated with low CD59 levels. The methods encompass the administration of an immunomodulatory compound provided herein, such as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline. Further described are methods of treatment using the immunomodulatory compounds in combination with other therapeutic agents or therapies. Pharmaceutical... Agent: Jones Day

20090317386 - Transcription infidelity, detection and uses thereof: The present invention relates to the identification of a novel mechanism of transcription infidelity in cells. The invention provides compositions and methods to detect the level of transcript ion infidelity in a sample, as well as the use thereof, e.g., for therapeutic, diagnostic, pharmacogenomic or drug design. As will be... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090317387 - Treatment of metastatic breast cancer: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or... Agent: Goodwin Procter LLP

20090317389 - Fusion molecules and methods for treatment of immune diseases: The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090317388 - Tl1a in treatment of disease: Methods of modulating TL1A for the treatment of disease are disclosed.... Agent: Miller, Canfield, Paddock And Stone, PLC

20090317390 - Novel tissue factor targeted antibodies as anticoagulants: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, and inhibit FX activation. The antibodies bind at the site of injury and prevent the... Agent: Banner & Witcoff, Ltd.

20090317396 - Antibody specifically binding to dr5 and composition for preventing or treating cancers comprising the same: The present invention provides an antibody specifically binding to death receptor 5 (DR5), which is selected from the group consisting of: an antibody comprising a heavy chain variable region (VH) having the amino acid sequences of SEQ ID NOs: 1 to 3 at complementary determining regions (CDRs) and a light... Agent: Sughrue Mion, PLLC

20090317395 - Antimicrobial peptide derived from galanin message associated peptide (gmap): The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090317391 - Cancer related genes (ptpe): This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the tm-PTPε gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating... Agent: Marshall, Gerstein & Borun LLP

20090317398 - Mammalian cx3c chemokine antibodies: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090317392 - Method of diagnosing small cell lung cancer: Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an... Agent: Townsend And Townsend And Crew, LLP

20090317393 - Method of modifying glucose activity using polypeptides selectively expressed in fat tissue: Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other... Agent: Merchant & Gould PC

20090317397 - Soluble ctla4 mutant molecules and uses thereof: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments... Agent: Louis J. Wille Bristol-myers Squibb Company

20090317394 - Vascular endothelial growth factor-2: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090317399 - Uses and compositions for treatment of crohn's disease: The invention provides methods, uses and compositions for the treatment of Crohn's disease. The invention describes methods and uses for treating Crohn's disease, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to induce and maintain remission of Crohn's disease in a subject.... Agent: Mccarter & English, LLP / Abbott Laboratories Ltd.

20090317400 - Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090317401 - Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2: The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD 160 compounds in the fields of EC angiogenesis, and NK and T cytokine production... Agent: Marshall, Gerstein & Borun LLP

20090317402 - Antibodies to il-6 and their uses: Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.... Agent: Dickstein Shapiro LLP

20090317403 - Use of csf-1 inhibitors: Disclosed is the use of inhibitors of CSF-1 activity for preparing a medicament for the treatment of tumor diseases.... Agent: Buchanan, Ingersoll & Rooney PC

20090317404 - Reduction and prevention of cell-associated hiv transepithelial migration, microbides and other formulations and methods: A vaginal microbicide including scFv-type antibodies reduces or prevents transepithelial HIV transmission. As the antibodies, anti-CD 18 and/or anti-CD 11 antibodies (of the scFv type) are used. Preferably, anti-ICAM antibody also is used. The antibodies may be delivered to the to-be-protected epithelium using a bacterial delivery system such as a... Agent: Edwards Angell Palmer & Dodge LLP

20090317406 - Phosphorylation of tau by abl: Methods of diagnosing a tauopathy and predicting whether a subject will develop a tauopathy are provided. Also provided are antibody preparations that specifically bind to tau phosphorylated at tyr394 and/or tyr310. Methods of inhibiting tau phosphorylation in a cell and methods of treating a subject having a tauopathy are additionally... Agent: Amster, Rothstein & Ebenstein LLP

20090317405 - Antibody and uses thereof: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative... Agent: Ip Group Of Dla Piper LLP (us)

20090317407 - Augmentation of immune response to cancer vaccine: Methods are disclosed for stimulating an immune response against a target antigen, such as one or more tumor associated antigens. In particular examples the method includes reducing the number of CD4+ T cells in a subject after the subject receives a first dose of an immunogenic composition that includes the... Agent: Klarquist Sparkman, LLP

20090317408 - Ligand conjugated thermotherapy susceptors and methods for preparing same: Magnetic nanoparticles exhibiting enhanced heating ability in thermotherapeutic applications are described, as are several strategies to conjugate such nanoparticles. Methods for using conjugated nanoparticles are also provided.... Agent: Pepper Hamilton LLP

20090317409 - Antibodies for ubiquitinated proteins: The invention relates to particular ubiquitination epitopes, antibodies that specifically recognize and bind to ubiquitinated proteins and peptides (particularly after the ubiquitin is removed by proteolytic cleavage) and to methods of using these epitopes and antibodies.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090317411 - Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment: An immune composition containing Globo H or its fragment (e.g., SSEA3) and an adjuvant, e.g., α-GalCer, for eliciting immune responses against Globo H or its fragment and uses thereof in cancer treatment. Also disclosed is a method of treating cancer by inhibiting the activity of one of FUT1 and FUT2,... Agent: Occhiuti Rohlicek & Tsao, LLP

20090317410 - Use of zwitterionic polysaccharides for the specific modulation of immune processes: The invention relates to three-dimensional molecular structure determination of polymers, three-dimensional computer molecular modeling, rational drug design, and immunomodulatory polymers. In particular the invention is directed to immunomodulatory polymers, as well as to methods for designing, selecting, and screening therapeutic agents having immunomodulatory activity.... Agent: Wolf Greenfield & Sacks, P.C.

20090317414 - Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide: A cancer vaccine, and a composition for the ex vivo priming of dendritic cells, is disclosed which comprises a MUC1 T cell epitope-derived peptide or peptide analogue capable of provoking a cytotoxic T cell immune response. Particular MUC1 T cell epitope-derived peptides disclosed include TTAPPVHGL, STAPPVHGL, STAPPAHGL, TTAPPAHGV and SAPDTYPAL.... Agent: Sheridan Ross PC

20090317413 - Detection of human platelet antigen (hpa) antibodies: This invention relates to recombinant GPIIIa molecules that lack the ligand binding βA domain and bind to HPA-1 antibodies in monomeric form. These GPIIIa molecules can be recombinantly expressed at high levels and may be useful, for example, in the detection of HPA-1 antibodies. Such detection may be useful, for... Agent: Banner & Witcoff, Ltd.

20090317415 - Hpv vaccine comprising peptides from host cell proteins: The present invention relates to an immunogenic composition for a human papillomavirus (HPV) vaccine that comprises BAX peptides from BAX host cell proteins and more particularly, a vaccine including those peptides that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer... Agent: King & Schickli, PLLC

20090317412 - Induction of an immune response against streptococcus pneumoniae polyaccharides: The present invention provides conjugates of pan DR binding peptides with Streptococcus pneumoniae polysaccharides, and methods of preventing and treating diseases associated with Streptococcus pneumoniae infection with such conjugates.... Agent: Townsend And Townsend And Crew, LLP

20090317416 - Induction of immune responses to isoaspartyl-modified antigens: The present invention is directed to a method of enhancing the immune response of a patient relative to the normal immune response, by administering isoaspartyl-modified proteins, peptides, or cells, to a patient. The present invention is also directed to vaccines containing the isoaspartyl-modified proteins, peptides, or cells, as well as... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090317417 - Modified aav vectors having reduced capsid immunogenicity and use thereof: A method of reducing the cellular immune response and/or toxicity of AAV-mediated delivery is described. The method provides for masking or ablating a RxxR motif which induces T-cells, and which is located on select AAV capsids. The method further provides for reducing or eliminating heparin binding to an AAV. Also... Agent: Howson & Howson LLP

20090317419 - Tetramers: The present invention relates, in general to human immunodeficiency virus (HIV), and, in particular, to B cell tetramers and to methods of using same for diagnosis, disease monitoring and vaccine development.... Agent: Nixon & Vanderhye, PC

20090317418 - Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus: The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the... Agent: Townsend And Townsend And Crew, LLP

20090317421 - Compositions and methods related to staphylococcal bacterium proteins: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacteria. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a secreted virulence factor, which may be EsxA... Agent: Fulbright & Jaworski L.L.P.

20090317420 - Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may... Agent: Novartis Vaccines And Diagnostics Inc.

20090317422 - Use of ppd for the adjuvantation of a nucleic acid vaccine: The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines.... Agent: Buchanan, Ingersoll & Rooney PC

20090317423 - Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions: Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090317424 - Oral vaccines: This invention features a composition that includes a multiple-cell organism for use as food for an aquatic animal (e.g., a fish or a shrimp), and a single-cell organism fed to, and as a result, bioencapsulated by, the multiple-cell organism. The single-cell organism has been transformed to express a recombinant antigen... Agent: Occhiuti Rohlicek & Tsao, LLP

20090317425 - Refrigerator-temperature stable influenza vaccine compositions: Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided.... Agent: Medimmune, LLC Patrick Scott Alban

20090317426 - Method for treating knee joint pain caused by saphenous nerve entrapment: A method using a pharmaceutical composition comprising botulinum toxin and a pharmacologically acceptable carrier to treat pain in the knee joint caused by saphenous nerve entrapment. The composition of the present invention is for subcutaneous injection above the medial side of the knee.... Agent: Volpe And Koenig, P.C.

20090317427 - Zwitterionic polysaccharides for promotion of immune system maturation and health: Certain zwitterionic polysaccharides, including those naturally expressed by commensal B. fragilis in the gut, interact with cells of the immune system and affect the TH1/TH2 balance so as to promote health. Nutritional formulas and nutritional supplements containing isolated preparations of such zwitterionic polysaccharides, and methods for preparing the nutritional formulas... Agent: Wolf Greenfield & Sacks, P.C.

20090317428 - Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090317429 - Aloe vera cotton swab tips: This paper describes how implementing an aloe vera on a Q Tip will enhance the cleaning of the ear. It is a very simple product that the average consumer uses on a daily basis. The only difference is that it will have the available medicinal quality improvement in the product.... Agent: Michael V. Parris

20090317430 - Cosmetic composition for lightening or unifying the complexion: Cosmetic composition for lightening or unifying the complexion The present invention relates to a composition comprising, in a physiologically acceptable medium, concave or annular particles, especially in the form of hollow sphere portions, the said particles comprising a matrix that is coloured in the bulk.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090317432 - Felt-tip pen for making up or caring for nails, skin, lips eyelashes or teeth: a nail varnish composition, or a composition for making up and/or caring for keratin materials, with a continuous aqueous phase comprising a particulate phase having an average particle size of less than or equal to 0.5 μm, at least one film-forming polymer and a dispersing agent.... Agent: Oliff & Berridge, PLC

20090317431 - Peeling capsules: A cosmetic peeling preparation which comprises a plurality of capsules. A capsule comprises a casing and a filling. The casing material is solid at 25° C. and selected from cosmetically conventional lipids, waxes, emulsifiers, natural polymers, synthetic polymers, and mixtures thereof. The filling comprises an oil or lipid mixture having... Agent: Greenblum & Bernstein, P.L.C

20090317433 - Liquid pesticide composition containing n-phenylsemicarbazone pesticide compounds: wherein R1 and R2 are each independently hydrogen, halogen, CN, C1-C4alkyl, C1-C4 alkoxy, C1-C4 haloalkyl or C1-C4 haloalkoxy and R3 is C1-C4 alkoxy, C1-C4 haloalyl or C1-C4 haloalkoxy. The invention also relates to a process for preparing the liquid pesticide compositions and to spray liquors of the invention, respectively, and... Agent: Brinks, Hofer, Gilson & Lione

20090317434 - Preparation method for antibacterial nanocomposite fiber materials containing organic intermediates or free-radical scavengers: The invention relates to a novel preparation method for antibacterial nano metal composite fiber materials containing organic intermediate or free radical scavengers. The technology for the invention mainly uses γ-ray radiation to a solution mixture containing PAA (polyacrylic acid intermediate) or IPA (Isopropyl alcohol free radical scavenger) and silver nitrate... Agent: Michael Lin

20090317436 - Computer devices and accessories: Computer devices (10) that are resistant to contamination by microbes are provided. The device (such as a keyboard (10), mouse or other computer device) is treated or manufactured with a photosensitizer compound that is activated by electromagnetic radiation (16) to provide an antimicrobial effect. One or more light sources (14;... Agent: Nixon & Vanderhye, PC

20090317435 - Methods for processing substrates having an antimicrobial coating: Methods for processing substrate surfaces carrying coatings comprising a metal are disclosed. The methods involve providing a substrate surface having a coating comprising a metal, and exposing the substrate surface to a mixture including an oxidizing agent and an anion.... Agent: Marshall, Gerstein & Borun (baxter)

20090317439 - Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090317437 - Cellulose gel formulations: The invention relates to dispersible cellulose powder compositions comprising non-seed cellulose powder derived from algae, fungi or tunicates, which compositions are useful in a variety of products such as food products, pharmaceuticals, cosmetics, paints, biocompatible materials for artificial tissue engineering and implantable biomaterials and relates to methods for preparing non-seed... Agent: Porter Wright Morris & Arthur, LLP Intellectual Property Group

20090317438 - Whole blood-derived coagulum device for treating bone defects: Whole blood-derived coagulum devices are described for use in treating bone defects.... Agent: Leon R Yankwich Yankwich & Associates

20090317440 - Anti-mitotic anti-proliferative compounds: Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.... Agent: Fox Rothschild LLP

20090317441 - Bioengineered tissue constructs and cardiac uses thereof: Cultured tissue constructs comprising cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090317446 - Calcium phosphate nanofibers: Calcium-phosphate nanofiber matrices comprising randomly dispersed crystalline calcium-phosphate nanofibers are provided. The nanofibers are synthesized using sol-gel methods combined with electrospinning. The nanofibers may be hollow, solid or may comprise a calcium-phosphate shell surrounding a polymer containing inner core to which biologically functional additives may be added. The nanofiber matrices... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090317443 - Coated implant: A method forming a coated implant is described. The implant comprises a surface which is first coated with a primer and subsequently with a biocompatible polymer capable of forming a covalent bond to the primer. The polymer coating is then crosslinked. The invention also relates to implants, in particular, stents,... Agent: Sughrue Mion, PLLC

20090317445 - Drug delivery system with thermoswitchable membranes: The present invention provides a device for controlled release of molecules. The device is particularly suitable for controlled release of therapeutic drugs to a patient. The device includes a housing with an opening for release of the molecules from the housing. The housing also comprises a reservoir for containing the... Agent: Philips Intellectual Property & Standards

20090317444 - Process for cell proliferation: In vitro process for the proliferation or culture of conjunctive tissue cells selected from the group consisting of chondrocytes, osteoblasts, chondroprogenitor cells, osteoprogenitor cells, tenocytes and ligament cells comprising the step of contacting said cells with an aminosugar selected from the group consisting of mannosamine, N-acetylmannosamine, mannosamine salts and their... Agent: Sughrue Mion, PLLC

20090317442 - Super elastic epoxy hydrogel: Described is a super elastic epoxy hydrogel that is easy to manufacture and can be engineered for various performance enhancements of the polymer. Also described are methods of enhancing the performance of this hydrogel and other hydrogels. Various polymer hydrogel composites, structures, and their uses are included, such as the... Agent: Hayes Soloway P.C.

20090317447 - Biodegradable bone graft for orthopedic use: In the present invention, a biodegradable bone graft is disclosed, which includes: a scaffold made of a biodegradable material; and a collagen-embedding matrix portion which completely encompasses the scaffold. The above-mentioned bone graft can increase the micro-porosity of the scaffold to enable cells to grow adhesively thereon. Compared with the... Agent: Bacon & Thomas, PLLC

20090317448 - Tympanic membrane patch: The invention features methods of making living tissue constructs that can be used to repair perforations in tympanic membranes, the repair constructs themselves, and methods of repair.... Agent: Fish & Richardson PC

20090317449 - Animal food package with chewable scoop to promote dental health: An edible animal food scoop formulated to promote dental health is provided. The edible animal food scoop is used to dispense animal food from a container and, typically when the container is empty, is provided to the animal for chewing or consumption. Over the time the edible food scoop is... Agent: Holland & Hart, LLP

20090317450 - Pharmacokinetics of iontophoretic sumatriptan administration: Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.... Agent: Mccarter & English, LLP Boston

20090317451 - Pressure-sensitive adhesive for skin surface and/or transdermal substance delivery: A pressure-sensitive adhesive composition is described having a reservoir of medication or other substance and capable of intimate contact with a target area of skin, rapid conveyance of the medication onto and/or into the target area, and ready removal from the area of skin using water. Polyvinylpyrrolidone and glycerol mixtures... Agent: Cochran Freund & Young LLC

20090317454 - Body or plant part dressing: A dressing having a flexible sleeve shaped to accommodate a substantially cylindrical body or plant portion, the sleeve having a lining which is substantially non-adherent to the body or plant part being bandaged and having a peripheral securement means which attaches two peripheral portions to each other without those portions... Agent: Irving M. Fishman C/o Cohen, Tauber, Spievack And Wagner

20090317453 - Transdermal and topical administration of drugs using basic permeation enhancers: Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20090317452 - Transdermal patch: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAE or its pharmacologically acceptable salt. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: 2-amino-1-(2′,5′-dimethoxyphenyl)ethanol or its pharmacologically acceptable salt; 40... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090317457 - Anti-inflammatory and wound healing effects of lymphoid thymosin b-4: The invention relates to a method of treating inflammatory conditions in a subject comprising administering to a subject a composition comprising a lymphoid thymosin-β4 polypeptide or a functional lymphoid thymosin-β4 polypeptide variant. The invention also provides a method of promoting wound healing in a subject comprising administering to the subject... Agent: Wolf Greenfield & Sacks, P.C.

20090317458 - Fluid-jet pens configured for making modulated release bioactive agents: The present invention is drawn to methods of preparing a bioactive agent-containing emulsion for delivery to a biological system. This method can comprise the step of jetting a bioactive agent and a first fluid medium from a fluid-jet pen into a second fluid medium to form a bioactive agent-containing emulsion,... Agent: Hewlett-packard Company Intellectual Property Administration

20090317455 - Reverse targeting lipid vesicle: The present invention provides an immunomodulating agent and a therapeutic agent for a immune disease, which comprise a lipid vesicle encapsulating a drug capable of suppressing or damaging an immunocyte that expresses or binds to an antibody, the lipid vesicle having an antigen for the antibody bound to the outer... Agent: Leydig Voit & Mayer, Ltd

20090317456 - Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer: The present invention relates to a combination of at least one oncolytic virus and at least one antiangiogenic agent and to the use of this combination in tumor therapy.... Agent: Clark & Elbing LLP

20090317459 - Material: There is provided a granular material comprising (i) at least 50% by weight based on the weight of the granular material of solid water-insoluble mixed metal compound capable of binding phosphate of formula (I): MII1−xMIIIx(OH)2Λn−y.ZH2O (I) where MII is at least one of magnesium, calcium, lanthanum and cerium; MIII is... Agent: Mayer Brown LLP

20090317461 - Oral compositions effective for the treatment of oral cavity malodor associated with the consumption of odor-causing compounds: This invention generally relates to oral compositions (e.g., a confection or chewing gum product) effective for the treatment of oral cavity malodor caused by odor-causing compounds (e.g., diallyl disulfide) associated with the consumption of, for example, garlic and/or onion. In particular, this invention relates to oral compositions containing menthone, isomenthone... Agent: Derick E. Allen (28850) Armstrong Teasdale LLP

20090317460 - Solid dosage form: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090317463 - Composition for oral use based on s-adenosylmethionine and a process for their preparation: The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based... Agent: Dykas, Shaver & Nipper, LLP

20090317462 - Peptide pharmaceutical for oral delivery: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise... Agent: Ostrolenk Faber Gerb & Soffen

20090317465 - Composition and method of preparation of release systems for constant (zero-order) release of active agents: The present invention includes methods and compositions for pharmaceutical compositions that exhibit substantially constant release profile. The composition includes at least two layers with different drug to polymer ratios. The layers can be arranged in any order to achieve desirable pharmaceutical effects.... Agent: Chalker Flores, LLP

20090317464 - Methods and compositions for producing anti-androgenic effects: The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a... Agent: Ladas & Parry LLP

20090317466 - Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine: Pharmaceutical composition, containing fixed doses of hydroxyurea and didanosine, a method of manufacturing such composition, and to the use of the composition for the treatment of retroviral infections.... Agent: The Law Offices Of Valerie E. Looper

20090317469 - Composite extracellular matrix materials and medical products formed therefrom: Described in certain aspects are composite extracellular matrix material products including expanded collagenous materials in combination with non-expanded collagenous materials. Methods for their preparation and use are also disclosed. Certain expanded collagenous materials can be prepared by treating a first collagenous material with an alkaline substance under conditions effective to... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090317467 - Hydrocolloid composition: A therapeutic composition is described comprising a particulate dispersion of a hydrocolloid in a low water activity anti-microbial matrix. The composition may also contain any or all of a sequestrant, excipient, carrier and surfactant. The hydrocolloid may be naturally occurring, semisynthetic or synthetic. The invention extends to a method of... Agent: Knobbe Martens Olson & Bear LLP

20090317468 - Multicompartment granulate formulations for active substances: The invention relates to molded article that contains active substances and comprises at least two compartments that have a different material composition. Each compartment is independently provided with at least one active substance that is contained in a matrix. Each matrix encompasses at least one filler at a concentration of... Agent: Norris, Mclaughlin & Marcus, Pa

20090317472 - Controlled releases of actives in skin: Topical compositions are provided in which active compounds for topical delivery through the stratum corneum are complexed with nanospheres of a triblock copolymer having an A-B-A structure wherein each A end block is a water-soluble, hydrophilic and non-toxic polymer or oligomer; and the hydrophobic middle B block is a hydrophobic... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090317471 - Controlled-release formulations, method of manufacture, and use thereof: The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt or solvate thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090317470 - Oramucosal pharmaceutical dosage form: This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use... Agent: Jacobson Holman PLLC

20090317473 - Controlled-release formulations, method of manufacture, and use thereof: The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt, solvate, ester, and/or prodrug thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090317474 - Use of polyethylene glycol in inflammation related topical disorders or diseases and wound healing: The present invention relates to hydrogel compositions or aqueous solutions comprising one or more forms of Poly-ethylene Glycol, for use as medicaments, more particularly for topical application in the treatment of wounds, for the treatment of inflammatory skin disease and in particular for the prevention of scar formation and/or for... Agent: Clark & Elbing LLP

20090317475 - Combination antitumor therapies: Improved methods of treating cancers that are characterized by unwanted angiogenesis employ combinations of therapies designed to inhibit the VEGF mediated angiogenesis pathway with therapies designed to inhibit the bFGF-mediated angiogenesis pathway.... Agent: Morrison & Foerster LLP

20090317477 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a glucocorticosteroid for the treatment of asthma, chronic obstructive pulmonary disease, allergic rhinitis, or any other respiratory disease. The composition is provided in various... Agent: Wilson, Sonsini, Goodrich & Rosati

20090317476 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a leukotriene receptor antagonist for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations... Agent: Wilson, Sonsini, Goodrich & Rosati

20090317478 - Method of preparing covered porous biodegradable polymer microspheres for sustained-release drug delivery and tissue regeneration: The present invention relates to covered porous biodegradable polymer microspheres for sustained-release drug delivery and tissue regeneration which has an interconnected inner open pore structure having a wide surface area and high porosity and an outer closed pore structure in which the surface of the microsphere is covered with a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090317480 - Chimeric immunomodulatory compounds and methods of using the same-ii: The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.... Agent: Morrison & Foerster LLP

20090317481 - Modafinil formulations: The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns.... Agent: Ross J. Oehler Cephalon, Inc.

20090317479 - Nanoparticles containing water-soluble non-peptide low-molecular weight drug: Drug-containing nanoparticles are provided that enable effective targeting and sustained-release of a water-soluble, non-peptide, low-molecular weight drug and cause reduced accumulation of the drug in the liver. The nanoparticles containing a water-soluble, non-peptide, low-molecular weight drug are obtained by hydrophobicizing the water-soluble, non-peptide, low-molecular weight drug by a metal ion,... Agent: Drinker Biddle & Reath (dc)

20090317482 - Methods and compositions for treating congestive heart failure: Compositions and methods for treating congestive heart failure are provided herein.... Agent: Dechert LLP

20090317483 - Bicomponent bioadhesive for biomedical use: The invention relates to new biocomponent bioadhesive formulations, with a synthetic part and an autologous biological part of blood origin comprising plasma rich in platelets and in growth factors, and its use of same in biomedicine, preferably in opththalmic surgery.... Agent: Ratnerprestia

20090317484 - Salivary substitute: A salivary substitute is produced from egg white so as to have chemical, rheological and physiological properties that are analogous to those of natural human saliva. A packaging containing the salivary substitute and uses of the salivary substitute are also disclosed.... Agent: Young & Thompson

20090317485 - Skin protectant spray compositions: A liquid, water-repellent, substantially anhydrous, spray-pumpable skin protectant composition is disclosed. The composition is designed for spraying directly onto skin, has suitable adherence to the skin, and resists running. The composition contains one or more actives, one or more rheology modifiers, and a carrier. The rheological modifiers can be waxes... Agent: Philip S. Johnson Johnson & Johnson

20090317487 - Kits for prevention and treatment of rhinitis: Kits providing a combination of one or more pharmaceutical information comprising one or more agent(s) for the treatment or alleviation of symptoms commonly associated with a cold and an immunonutritional composition comprising immunonutritional agent and methods of using these kits are described. The kits provide both the pharmaceutical agent(s) and... Agent: Sheridan Ross PC

20090317486 - Weekly floater pool sanitizer: A composition for the treatment of a liquid, particularly a body of water, such as a swimming pool, spa, or the like. The composition includes calcium hypochlorite, a water soluble zinc salt for controlling algae, and sodium aluminate as an agglomerating agent that may safely be combined with said calcium... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090317488 - Formulations containing an ionic mineral-ion exchange resin complex and uses thereof: A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride.... Agent: Howson & Howson LLP

20090317489 - Combination comprising an iron chelator and an anti-neoplastic agent and use thereof: The present invention relates to a combination comprising a a substituted 3,5-diphenyl-1,2,4-triazole, e.g. 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and at least one anti-neoplastic agent and to the use of said combination for the preparation of a medicament for the treatment of proliferative diseases.... Agent: Novartis Corporate Intellectual Property

20090317490 - Substituted chroman derivatives, medicaments and use in therapy: Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.... Agent: Sughrue Mion, PLLC

20090317491 - Manufacturing method of medical sterilized isotonic solution having low-concentratedly controlled free chlorine including hypochlorous acid therein: The present invention relates to a manufacturing method of medical sterilized normal saline, more specifically, to such a method for manufacturing sterilized normal saline for medical purpose with effective sterilizing efficacy comprising: a step of disposing at least one electrode set immersed in saline solution of pH 4.0 to pH... Agent: Kusner & Jaffe Highland Place Suite 310

20090317492 - Therapeutic composition and use: The use of liquid formulations in the preparation of a medicament for the prevention and treatment of oral, gastric and digestive infections and in particular for the prevention of ventilator associated pneumonia as well as liquid enteral and parenteral tube feeding compositions. The feeding compositions are suitable for use in... Agent: O'keefe, Egan, Peterman & Enders LLP

20090317495 - Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases: The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising a mixture of herbal extracts of Trachelospermi caulis and Pyrola japonica as active ingredients. More particularly, the pharmaceutical composition of the present invention comprises a mixture of herbal extracts of Trachelospermi caulis and... Agent: Frommer Lawrence & Haug

20090317494 - Herbal composition containing cox-2 and its manufacturing method: A herbal composition, containing natural COX-2, includes a powder of Labiatae plant, wherein the herbal composition is prepared by a method including the steps of dehydrating the Labiatae plant and grinding the dried Labiatae plant into a powdered form. The herbal composition is used for treatment of a disease including... Agent: David And Raymond Patent Firm

20090317493 - Trehalose-containing topical drying composition and method of using same: h

20090317497 - Compositions and methods for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders: Compositions, kits and methods are provided for promoting brain and cardiovascular health, preventing or treating neurological and vascular disorders. In one embodiment, the composition comprises Rhodiola rosea (root), Ginkgo biloba (leaf), Panax notoginseng (root), and Ligusticum chuanxiong (rhizome). The composition can be used as pharmaceuticals or nutraceuticals for promoting general... Agent: Wilson, Sonsini, Goodrich & Rosati

20090317496 - Method for preventing and treating the disease caused by vascular damage and the use thereof: The present invention relates to compositions containing an extract of processed Panax genus plant and saponin compounds isolated therefrom for treat the diseases caused by vascular injury in human or mammal, the method for treating said diseases using thereby and the use thereof. The extract of processed Panax genus plant... Agent: Kirk Hahn

20090317498 - Composition comprising extract of cinnamomum cassia bark for improving normal flora and enhancing immune response: The present invention relates to a composition for improving intestinal flora and enhancing immune response containing Cinnamomum cassia bark extract as an effective ingredient, more precisely, a composition containing Cinnamomum cassia bark extract is an effective ingredient that has the effects of increasing the growth of such intestinal beneficial bacteria... Agent: Lucas & Mercanti, LLP

20090317499 - Artemisinins in the clinical and veterinary management of kinetoplastid infections: The invention relates to the treatment of kintoplastid infections by administering a pharmaceutical composition containing an extract from the plant Artemisia annua. The invention also relates to isolated, semi-synthetic and synthetic artemisinins that show improved efficacy in treating kinetoplastid infections. This invention also relates to a method of treating kintoplastid... Agent: Nash & Titus, LLC

20090317500 - Pesticide and repellant: A pesticide or repellent comprising a liquid concentrate obtained from garlic juice by the removal of water from the juice.... Agent: Renner Otto Boisselle & Sklar, LLP

20090317501 - Pinus pinea plant extracts for treating osteoporosis and the extraction process thereof: The present invention is concerned with nutritional or pharmaceutical compositions comprising extracts or concentrates of plants and the mixtures thereof belonging to Pinus. sp with specific reference to Pinus pinea. The extracts have been screened and characterized for their activity in the treatment of increased bone resorption and bone formation,... Agent: Pearl Cohen Zedek Latzer, LLP

20090317502 - Dandruff treatment compositions with anti-inflammatory agents including botanic seed oils: The botanic seed oils used in the compositions may be prepared using a cold press method, and may include three or more botanic seed oils. The blend of botanic seed oils may include, for example, red raspberry seed oil, black raspberry seed oil, pomegranate seed oil, blueberry seed oil, pumpkin... Agent: Briggs And Morgan P.A.

20090317503 - Eyelid preparation and method of use: Embodiments of the invention comprise an eyelid preparation, a method for producing the eyelid preparation, a method for treating or preventing eyelid conditions and a method for applying an eyelid preparation on human eyelids or eyelashes. The eyelid preparation may be used to treat ocular conditions, such as blepharitis, dry... Agent: D'ambrosio & Associates, P.l.l.c.

20090311172 - Massage cream and massaging method using the same: The present invention relates to a massage cream which contains 5.0 Bq to 300.0 Bq of powders of one or more radioactive materials per 1 g of base materials. Furthermore in the massage cream the radioactive materials include 4.0 Bq to 240.0 Bq of thorium. Moreover in the massage cream... Agent: Squire, Sanders & Dempsey L.L.P.

20090311173 - Method and device for radiotherapy: A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090311174 - Method for treating cancer: The present invention relates to methods, kits, compositions and uses thereof for treating cancer. In particular, the present invention relates to methods, kits, compositions and uses thereof for the treatment of metastatic cancer, the treatment of angiogenesis associated with metastatic cancer, inhibiting formation of vasculature associated with metastatic cancer, killing... Agent: Townsend And Townsend And Crew, LLP

20090311175 - Methods for treating thyroid cancer: The invention provides methods for enhancing iodine absorption in a thyroid in a subject and treating thyroid cancer by administering to the subject a composition which includes a multi-kinase inhibitor. Furthermore, the invention provides methods for improving a medical diagnostic procedure based on radioactive iodine in a subject by administering... Agent: Pearl Cohen Zedek Latzer, LLP

20090311176 - 2-arylpyrazolo[l,5-alpha] pyrimidin-3-yl acetamide derivatives as ligands for translocator protein (18 kda): The invention provides compounds of formula (I) radiolabelled with 18F, 123I, 76Br, 124I or 75Br and salts thereof, and a method of imaging translocator protein (18 kDa) (TSPO) in a subject comprising administering a compound of formula (I) radiolabelled with 18F, 123I, 76Br, 124I or 75Br or a pharmaceutically acceptable... Agent: Wolf Greenfield & Sacks, P.C.

20090311177 - Radiolabelling methods: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-N3 (II) or, a compound of formula... Agent: Ge Healthcare, Inc.

20090311178 - Pyrrolinidium derivatives as m3 muscarinic receptors: Compounds of formula (I) in salt or zwitterionic form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds... Agent: Ge Healthcare, Inc.

20090311179 - Selective targeting of apoptotic cells: The invention relates to a method of selectively targeting an active agent (or agent capable of becoming an active agent) to apoptotic cells in a vertebrate, comprising administering to said vertebrate a system comprising an arsenoxide (or arsenoxide equivalent) compound and said agent, wherein said system selectively targets apoptotic cells.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090311181 - Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting: The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to... Agent: Townsend And Townsend And Crew, LLP

20090311184 - High penetration prodrug compositions of peptides and peptide-related compounds: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of peptides and peptide-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier... Agent: Perkins Coie LLP

20090311182 - Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the... Agent: Dann, Dorfman, Herrell & Skillman

20090311183 - Metalloproteinase 12 binding proteins: Proteins that bind to matrix metalloproteinase 12 and methods of using such proteins are described.... Agent: Lando & Anastasi, LLP

20090311180 - Protein isoforms and uses thereof: A method for screening for or diagnosis or prognosis of a neurological disorder in a subject, for determining the stage or severity of such a neurological disorder in a subject, for identifying a subject at risk of developing such a neurological disorder, or for monitoring the effect of therapy administered... Agent: Klauber & Jackson

20090311188 - In vivo methods of identifying compounds which target suppressed cancer cells: In vitro and in vivo methods for identifying compounds capable of targeting suppressed cancer cells such as micrometastatic cells. The in vitro method includes the steps of comparing the response to a test compound of cancer cells grown on a suppressing cell support matrix which causes suppression of a malignant... Agent: Dunlap Codding, P.C.

20090311186 - Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptides: Disclosed is a method for controlling the therapeutic treatment of a patient suffering from cardiac insufficiency. In said method, it is determined how the concentration of at least one of the vasoactive peptides adrenomedullin (ADM), endothelin-1 (ET-1), and/or vasopressin (AVP) changes in the patient's blood after beginning the therapy, and... Agent: Heslin Rothenberg Farley & Mesiti PC

20090311187 - Methods for predicting patient response to modulation of the co-stimulatory pathway: The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a patient will have favorable response to the administration of a pharmaceutically acceptable amount of an activator of the immune system (e.g, T-cells).... Agent: Louis J. Wille Bristol-myers Squibb Company

20090311185 - Peptide having antianxiety activity and screening method therefor: The objects of the present invention are to provide a polypeptide having an antianxiety activity; a therapeutic agent containing the polypeptide; a method for treating anxiety using the polypeptide; a method of screening for a compound capable of activating or suppressing a receptor for the polypeptide and involved in the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090311191 - Imaging of atherosclerotic plaques using liposomal imaging agents: Compositions and methods are disclosed for imaging atherosclerotic plaques. Example compositions comprise liposomes, the liposomes comprising: at least one first lipid or phospholipid; at least one second lipid or phospholipid which is derivatized with one or more polymers; and at least one sterically bulky excipient capable of stabilizing the liposomes.... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn:IPDepartment Docket Clerk

20090311190 - Self-assembled, micropatterned, and radio frequency (rf) shielded biocontainers and their uses for remote spatially controlled chemical delivery: The present invention relates to a nanoscale or microscale particle for encapsulation and delivery of materials or substances, including, but not limited to, cells, drugs, tissue, gels and polymers contained within the particle, with subsequent release of the therapeutic materials in situ, methods of fabricating the particle by folding a... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090311189 - Temperature-jump dynamic nuclear polarization: In one aspect, the present invention provides a method for enhancing the sensitivity of liquid-state NMR or MRI experiments. In general, the method involves providing a frozen sample in a magnetic field, wherein the frozen sample includes a polarizing agent with at least one unpaired electron and an analyte with... Agent: Choate, Hall & Stewart LLP

20090311194 - Methods and compositions for the production and use of magnetosomes: Methods and compositions for using magnetosomes as cellular contrast agents and markers for magnetic resonance imaging are provided. Certain methods involve synthesizing magnetosomes in a cell as directed by a nucleotide construct comprising an exogenous polynucleotide sequence, wherein the magnetosome serves as a contrast agent or marker for magnetic resonance... Agent: Alston & Bird LLP

20090311192 - Core and core-shell nanoparticles containing iodine for x-ray imaging: Nanoparticles having an average particle size of less than 2000 nm, wherein said nanoparticles comprise a polymer having pendant cleavable iodine substituted groups are provided. Processes for preparing the nanoparticles and their use as a contrast agent for X-ray imaging are also described.... Agent: Nixon & Vanderhye, PC

20090311193 - Methods and reagents for in vivo imaging of cancer cell lines: Provided are reagents and methods for non-invasive in vivo imaging wherein the reagents comprise targeted carrier molecules conjugated to a NIR reporter molecule. In one aspect the targeted carrier molecule is an antibody, or fragment thereof that has specificity for an antigen in a living body, animal or human. In... Agent: Life Technologies Corporation C/o Intellevate

20090311195 - Compositions containing a solvated active agent suitable for dispensing as a compressed gas aerosol: A composition for solvating one or more active agents in an aqueous solution which is suitable for dispensing as a compressed gas aerosol composition is disclosed. The composition includes at least one surfactant, at least one active agent (such as a fragrance or an insecticide), and a compressed gas propellant.... Agent: S.c. Johnson & Son, Inc.

20090311196 - Pharmaceutical aerosol composition: Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090311197 - Method and compositions for oral hygiene: The present invention comprises novel compositions and methods for oral hygiene and for treating and preventing oral disease in humans and in animals. In one embodiment, the novel compositions of the present invention comprise a unique oral hygiene solution that can be added to drinking water. The invention provides compositions... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090311198 - Perhydrolase for tooth whitening: The present invention provides compositions and methods for the use of perhydrolase to whiten teeth.... Agent: Danisco US Inc. Attention: Legal Department

20090311199 - Use of hydrogen peroxide-producing bacteria for tooth whitening: The invention provides compositions and methods for whitening teeth of a subject comprising administering one or more isolated, non-pathogenic, hydrogen peroxide-producing bacterial strains to an oral cavity of a subject.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090311200 - Oral compositions and uses thereof: The present invention is directed to a dual phase mouth wash composition comprising a hydrophilic phase, a hydrophobic phase, and a hydrotrope, and methods of use thereof. The hydrophilic and hydrophobic phases remain separated and form a temporary emulsion when mixed. The emulsion spontaneously reverts back to the two original... Agent: Colgate-palmolive Company

20090311201 - Lipoxin analogs and methods for the treatment of periodontal disease: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms... Agent: Choate, Hall & Stewart LLP

20090311204 - Carotenoid compositions useful for whitening skin: The present invention relates to use of carotenoid preparations for promoting skin whitening. Particularly, the present invention discloses that a combination of phytoene and phytofluene is effective in whitening skin. The present invention further relates to carotenoid compositions comprising a combination of phytofluene and phytofluene effective in whitening skin and... Agent: Fennemore Craig

20090311205 - Co-polymers in hair styling applications: Hair is treated with a copolymer of an unsaturated ester and a styrene sulphonate monomer to reducing damage to hair caused by subsequent heat treatment. The styrene sulphonate monomer is desirably sodium styrene sulphonate and the unsaturated ester is desirably of an unsaturated monocarboxylic acid, such as (meth)acrylic acid, or... Agent: Jones Day

20090311206 - Cooling cosmetic or dermatological preparations comprising (1r,2s,5r)-2-isopropyl-5-methyl-n-(2-(pyridin-2-yl)ethyl)-cyclohexane carboxamide and/or (1r,2s,5r)-n-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide for reducing skin reddening: A topical cosmetic and dermatological preparation for reducing skin reddening which comprises (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)-cyclohexane carboxamide and/or (1R,2S,5R)—N-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide.... Agent: Greenblum & Bernstein, P.L.C

20090311202 - Cosmetic preparation for extension tanning: The invention relates to a cosmetic preparation for tan extension. The cosmetic includes as active ingredient a complex of 0.1 to 3.0 wt.-% caffeine, 0.2 to 2 wt.-% Phototan®, 0.01 to 1.0 wt.-% copper gluconate and further cosmetic auxiliaries, excipients, further active substances and mixtures thereof to make 100 wt.-%.... Agent: Millen, White, Zelano & Branigan, P.C.

20090311207 - Enhanced photoconductivity and spf of semiconductors: The present disclosure provides a way to enhance the photoconductivity and/or the SPF of a semiconductor. By dispersing the semiconductor with a compound having multiple phenyl groups in a polar carrier oil, the semiconductor exhibits greatly improved photoconductivity and/or SPF over dispersions comprising the semiconductor alone.... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20090311203 - Gem-difluoride c-glycopeptide compounds, their preparation and use particularly for preservation of biological materials: The invention relates to a gem-difluoride C-glycopeptide compound with formula I where n is an integer equal to 3 or 4, R represents a hydrogen atom, an alkyl, benzyl, acetyl, trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl group, R′ represents OR, NR′R″, N3, or a phthalimide, R′ and R″ represent a hydrogen atom or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090311208 - Oil in silicone emulsions and compositions containing same: The present invention provides an oil in silicone emulsion and an oil in silicone/water in silicone dual emulsion. These emulsions employ a silicone resin as the emulsifying agent, include an effective amount of one or more active ingredients, such as, a sunscreen and/or insect repellent and provide enhanced aesthetics and... Agent: Avon Products, Inc.

20090311209 - Interference pigments on the basis of glass flakes: The present invention relates to pigments, comprising a plate-like substrate of glass having an average thickness of <1 μm, especially of from 20 nm to 400 nm, and (a) a dielectric material, especially a metal oxide, having a high index of refraction; or (a) a metal layer, especially a thin... Agent: Joann Villamizar Ciba Corporation/patent Department

20090311210 - Conditioning agent and a method for making hair having a shape memory effect: A method of imparting a shape memory effect to hair may include administrating an effective amount of a hair-conditioning agent to hair. The hair-conditioning agent may include a shape memory polymer selected from the group consisting of a polyurethane, an acrylic acid copolymer, a pyridine-based copolymer, and a pyrrolidone copolymer.... Agent: Wilkinson & Grist

20090311211 - Aqueous dispersions of polyorganosiloxanes containing urea groups: Polyorganosiloxanes containing urea groups can be obtained in the form of aqueous dispersions by firstly dissolving them in an organic solvent, then dispersing this solution with water with co-use of auxiliaries, subjecting the mixture to homogenization and then at least partially removing the organic solvent. The aqueous dispersions prepared in... Agent: Huntsman Textile Effects Germany G Legal Department

20090311212 - Agent for forming double eyelid: l

20090311214 - Compositions and methods for the innate immune response pathway: Autoimmune diseases are the consequence of complex interactions between a mosaic of host genetic factors and etiologic elements. Celiac disease (CD) is an autoimmune disease prevalent in 1% of the general population, but is unique on two accounts; a) the majority (90%) of individuals with CD have the HLA class... Agent: Sughrue Mion, PLLC

20090311215 - Method for treating cervical cancer: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.... Agent: Darby/zymogenetics, Inc.

20090311213 - Methods and compositions for treatment of retinoid-responsive conditions: Methods and composition for treating a retinoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090311217 - 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses: t

20090311216 - Recombinant interferon-beta with enhanced biological activity: Human interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native human interferon-β, is recombinantly replaced with an aspartate residue exhibit a biological activity of human interferon-β (e.g. IFN-β 1b) at an increased level relative to IFN-β 1b. These analogs are obtained by introducing a... Agent: Novartis Corporate Intellectual Property

20090311218 - Mutant interferon alpha protein and use thereof: The present invention has objects to provide a mutant interferon-α protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-α protein as an effective ingredient; and solves the above objects by providing a mutant protein which has an amino... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090311219 - Oncolytic adenoviruses for cancer treatment: The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity.... Agent: Baker Botts, LLP

20090311226 - Composition and method for treating esophageal dysplasia: Enhancing the immune response to esophageal tumor cells reduces the incidence of esophageal cancer developing, recurring, or metastasizing. Esophageal cancer cells are modified to render them more immunogenic and proliferation compromised. They are used in an antigenic preparation to raise a T cell response in the recipient.... Agent: Banner & Witcoff, Ltd.

20090311225 - Compositions of and methods of using stabilized psma dimers: The invention includes cysteine-modified PSMA polypeptides and disulfide-bond-stabilized dimers thereof, compositions and kits containing the cysteine-modified PSMA polypeptides, including dimers thereof, as well as methods of producing and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, methods of producing antibodies... Agent: Wolf Greenfield & Sacks, P.C.

20090311224 - Therapeutic agent comprising lipocalin 2 against cancer metastasis, and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a... Agent: Jhk Law

20090311227 - Composition: The present invention relates to a composition comprising: i) at least one strain of a Lactobacillus sp and/or a metabolite thereof; and ii) a cannabinoid receptor agonist and/or a opioid receptor agonist. In addition, the present invention relates to methods using and uses of such a composition.... Agent: Steptoe & Johnson LLP

20090311221 - Biomaterials for regenerative medicine: It was examined whether a cartilage-like tissue is formed under various reaction conditions using cartilage matrix components: glycosaminoglycan, proteoglycan, and collagen. The present inventors have discovered that proteoglycan bound to glycosaminoglycan through self-organization form an aggregate when the glycosaminoglycan was reacted with proteoglycan under specific concentrations and pH, and that... Agent: Townsend And Townsend And Crew, LLP

20090311220 - Bone forming compound composed of a mixture of osteoblast and biomatrix and method for producing the same: A compound for bone forming and a method for producing the same are provided using a mixture of an osteoblast and a bio-matrix. The method comprises: isolating osteoblasts from bone tissue and culturing the isolated osteoblasts to prepare an osteoblast suspension; and mixing the resulting osteoblast suspension with a bio-matrix... Agent: Gwips Peter T. Kwon

20090311222 - Transplantation of neural cells: Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterised by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are... Agent: Bozicevic, Field & Francis LLP

20090311223 - Treatment of erectile dysfunction by stem cell therapy: Methods, cells and compositions of matter are provided for treatment of erectile dysfunction using stem cell therapy. In particular, various stem cells are modified or administered freshly isolated in order to induce smooth muscle regeneration, neural regeneration, and restoration of endothelial function. In some embodiments endogenous stem cells are mobilized... Agent: Knobbe Martens Olson & Bear LLP

20090311229 - Isolation and identification of cross-reactive t cells: Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues... Agent: Howrey LLP - East

20090311228 - Treatment of inflammatory bowel disease: A method of treating inflammatory bowel disease (IBD) comprises collecting regulatory T cells in an activated or non-activated state from a patient's sentinel lymph nodes draining bowel segments with or without IBD, optionally activating the cells by contacting them with a cytokine and an antigen extract obtained from an inflamed... Agent: Dickstein Shapiro LLP

20090311235 - Use of polymeric materials with other substances for improved performance: Methods of enabling or improving the ability of a hydrogel to swell in the stomach of an animal and/or increasing the amount of time said hydrogel remains swollen in the stomach are described herein. In one embodiment, a polymer is administered in combination with one or more pH modifying agents... Agent: Elmore Patent Law Group, PC

20090311231 - Product and process for liquefaction of mucus or sputum: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.... Agent: Sheridan Ross PC

20090311230 - Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease: The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide,... Agent: Bozicevic, Field & Francis LLP

20090311232 - Agent for use in the case of fructose intolerance: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of... Agent: Daniel Feigelson

20090311233 - Materials and methods directed to asparagine synthetase and asparaginase therapies: Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to... Agent: Leydig, Voit & Mayer, Ltd.

20090311234 - Use of beta-lactamase: Class A beta-lactamase may be used for reducing side-effects in the intestine associated with antibiotic therapy with a combination of beta-lactam antibiotic and beta-lactamase inhibitor.... Agent: Banner & Witcoff, Ltd.

20090311236 - Therapeutic peptide compositions and methods of making and using same: Therapeutic compositions include peptide formulations having a mixture of serum, albumin, casein, peptone, pacreatin, and sodium hydroxide. The peptide compositions do not include nucleic acid or any derivatives thereof. The peptide compositions have beneficial therapeutic properties to boost human immune system and to treat various ailments including malaria, allergy and... Agent: Carrier Blackman And Associates

20090311237 - Combination therapy using a soluble hyaluronidase and a bisphosphonate: Provided are combinations, compositions and kits containing a bisphosphonate composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating bisphosphonate-treatable diseases or conditions. Also provided are methods for subcutaneous administration of a bisphosphonate compound whereby the dosing regimen is substantially the... Agent: K&l Gates LLP

20090311238 - Topical composition and treatment method for cartilage damage: A method of treating cartilage damage by topically administering an effective amount of a pharmaceutical composition comprising (a) a substance P inhibitor and (b)a proteolytic enzyme with an suitable pharmaceutical carrier. The pharmaceutical composition is capable of promoting cartilage regeneration in animal and human subjects.... Agent: Wang & Ho

20090311239 - Recombinant or transgenic factor vii composition, each factor vii molecule having two n-glycosylation sites with defined glycan units: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3Gal glycan moieties is comprised between 0 and 4%. The invention is... Agent: Marsh, Fischmann & Breyfogle LLP

20090311240 - Vegf165 delivered by fibrin sealant to reduce tissue necrosis: The present application demonstrates the clinical potential of fibrin sealants to locally deliver growth factors to ischemic tissue. More particularly, it demonstrates that hydrogels such as Fibrin Sealants can be used to deliver VEGF165 to prevent tissue necrosis caused by hypoxia or ischemia. Specifically, a Fibrin Sealant (FS) was used... Agent: Mcandrews Held & Malloy, Ltd

20090311242 - Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a): The invention provides a human 5HT2a which is associated with the cardiovascular diseases, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular... Agent: Banner & Witcoff, Ltd.

20090311245 - Metalloproteinase 9 binding proteins: Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described.... Agent: Lando & Anastasi, LLP

20090311246 - Method of enhancing remyelination in demyelinating diseases of the central nervous system: The present invention provides methods for enhancing remyelination or decreasing or inhibiting demyelination in central nervous system (CNS) of a mammalian subject by administering to the subject an effective amount of a Semliki Forest Virus (SFV) epitope E2 137-151 peptide together with a pharmaceutically acceptable carrier, or an antibody to... Agent: Scully Scott Murphy & Presser, PC

20090311243 - Methods for identifying fzd8 modulators and the use of such modulators for treating osteoarthritis: Methods and kits for identifying agents that modulate the function of the Methods and kits for identifying agents that modulate the function of the receptor Fzd8 are provided. Accordingly, the present invention makes available methods for identifying agents useful as modulators of Wnt-Fzd8 signalling. Therapeutic uses of the identified agents... Agent: Fish & Richardson P.C.

20090311244 - Screening method: This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided.... Agent: Fenwick & West LLP

20090311241 - Human antibodies that bind human il-12 and methods for producing: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000

20090311252 - Anti-activin antibodies and uses for promoting bone growth: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.... Agent: Ropes & Gray LLP

20090311249 - Capecitabine combination therapy: The invention provides the use of a combination of an mTOR inhibitor and capecitabine in the treatment of cancer.... Agent: Ariad Pharmaceuticals, Inc. Ariad Gene Therapeutics, Inc.

20090311254 - Cd40 antibody formulation and methods: The present invention provides a method of treating tumor in a patient comprising administering to said patient a CD40 agonist antibody according to an intermittent dosing schedule. The present invention also provides a method of treating tumor in a patient comprising administering a combination of a CD40 agonist antibody and... Agent: Pfizer Inc

20090311253 - Dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbott Bioresearch

20090311248 - Hepatitis c virus neutralizing antibodies: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions,... Agent: Nixon & Vanderhye, PC

20090311250 - Methods and compositions for the diagnosis and treatment of cancer: Methods and compositions are provided for the diagnosis and treatment of colorectal cancers associated with amplification or overexpression of the FGFR2 gene.... Agent: Genentech, Inc.

20090311247 - Molecules and chimeric molecules thereof: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule such as EPO, Flt3-Ligand, Flt3, PDGF-B or VEGF-165 or chimeric molecules thereof comprising at least a portion of the protein molecule, wherein the protein or chimeric... Agent: Seed Intellectual Property Law Group PLLC

20090311255 - Preventing autoimmune disease: The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by administering a CD20 antibody to the subject in an amount to prevent the subject from experiencing one or more symptoms of... Agent: Genentech, Inc.

20090311251 - Scfv antibodies which pass epithelial and/or endothelial layers: scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said... Agent: Marshall, Gerstein & Borun LLP

20090311256 - 12 human secreted proteins: The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090311260 - Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders: The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP

20090311261 - Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders: The present invention is directed to compositions of matter useful for the diagnosis and treatment of inflammatory bowel diseases in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP

20090311259 - Compositions and methods for treatment of tumor of hematopoietic origin: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090311257 - Human antibodies specific for gastrin materials and methods: The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.... Agent: Marshall, Gerstein & Borun LLP

20090311263 - Human vascular ibp-like growth factor: A human Vascular IBP-Like Growth Factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090311258 - Medicament for lct poisoning: The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090311262 - Method for diagnosing cancers expressing the her2 receptor or its truncated variants: e

20090311264 - Use of disorazoles and their derivatives for the treatment of benign and malignant oncoses: The invention relates to disorazoles of the general formula I, which are employed as medicaments, preferably for the treatment of oncoses, in particular in the case of pharmaceutical resistance to other active compounds and in the case of metastasizing carcinoma. The possible uses are not restricted to oncoses.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090311265 - Human binding molecules capable or neutralizing influenze virus h5n1 and uses thereof: The present invention relates to binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. The disclosure provides nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies.... Agent: Traskbritt, P.C.

20090311266 - Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy: The invention relates to the use of an endothelin blocker in combination with an αvβ3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an αvβ3 integrin receptor antagonist, for the treatment or prevention of cardiovascular... Agent: Polsinelli Shughart PC

20090311267 - Inhibition of vwf - gpib/v/ix interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks: The invention relates generally to an anti-thrombotic treatment of occlusive syndromes in the cerebral vascular system causing cerebral infarct due to stroke or ischemic stroke, which is a major cause of death and permanent disability in industrialized countries. More particularly, the invention relates to a system and method of preventing... Agent: Traskbritt, P.C.

20090311268 - Cd40-binding activating antibodies: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing... Agent: Darby & Darby P.C.

20090311269 - Methods for collecting and detecting oligonucleotides: Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in... Agent: Searete LLC Clarence T. Tegreene

20090311270 - Methods, compositions, and kits for collecting and detecting oligonucleotides: Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in... Agent: Searete LLC Clarence T. Tegreene

20090311271 - Methods and compositions for selective inhibition of ligand binding to the lectin-like receptor for oxidized low density lipoprotein (lox-1): The present invention provides methods of selectively inhibiting the binding of one ligand for LOX-1, but not one other ligand for LOX-1. Moreover, the invention relates to the identification of binding partners that act in a selective manner to inhibit the binding of one ligand to LOX-1, but not one... Agent: Wyeth Patent Law Group

20090311272 - Methods and compositions for modulating angiogenesis and pericyte composition: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may... Agent: Wolf Greenfield & Sacks, P.C.

20090311273 - Treatment of multiple sclerosis and/or rheumatoid arthritis: The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the... Agent: Birch Stewart Kolasch & Birch

20090311274 - Nucleic acid and corresponding protein entitled 238p1b2 useful in treatment and detection of cancer: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene... Agent: Agensys C/o Morrison & Foerster LLP

20090311275 - Carrier for targeting nerve cells: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or... Agent: Foley & Lardner LLP

20090311276 - Nanolipoprotein particles and related compositions, methods and systems: Functionalized nanolipoprotein particle presenting an anchor substrate compound for binding with a corresponding anchor compound presented on a target molecule, and related compositions methods and systems.... Agent: Llnl/steinfl & Bruno John H. Lee, Assistant Laboratory Counsel

20090311277 - Nucleic acid compositions for stimulating immune responses: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.... Agent: Wolf Greenfield & Sacks, P.C.

20090311279 - Colorectal cancer antigen: A point mutation at position 399 in a commonly expressed gene, designated as COA-1 herein, is diagnostic of colorectal cancer and is capable of eliciting at all mediated immune response.... Agent: Greenlee Winner And Sullivan P C

20090311282 - Neutralizing gdf8 epitope-based growth enhancing vaccine: The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090311281 - Novel method for down-regulation of amyloid: Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing... Agent: Stroock & Stroock & Lavan LLP

20090311278 - Novel teleost derived antimicrobial polypeptides: The invention is directed to an isolated polypeptide which (a) is obtainable from a teleost; (b) has antimicrobial activity; (c) binds to oligoguanosine and/or CpG (SEQ ID NO:7); (d) comprises 58 strongly basic amino acids selected from the group consisting of K and R; (e) comprises 50 hydrophobic amino acids... Agent: Coleman Sudol Sapone, P.C.

20090311280 - Novel tnf receptor regulatory domain: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090311283 - Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090311284 - Recombinant viral proteins and particles: Disclosed are nucleic acids encoding fusion polypeptides containing the sequence of a Bamboo mosaic virus coat protein or a segment thereof; and an immunogenic heterologous fragment that is fused to the carrier fragment. Also disclosed are related chimeric bamboo mosaic virus particle, related expression vectors, related host cells, and related... Agent: Occhiuti Rohlicek & Tsao, LLP

20090311285 - Vaccine: The present invention relates to immunogenic compositions or vaccines comprising a Vi capsular saccharide-protein carrier conjugate, methods of making the immunogenic compositions or vaccines and uses thereof.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090311286 - Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders: The invention provides extracts of the microalga Aphanizomenon Flos Aquae Aquae Ralfs ex Born. & Flah. Var. flos aquae (AFA Klamath) and purified components thereof useful for the prevention or treatment of neurological, neurodegenerative and mood conditions or diseases.... Agent: Arent Fox LLP

20090311287 - Novel flavivirus antigens: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of... Agent: Maxygen, Inc. Intellectual Property Department

20090311288 - Imidazoquinoxaline compounds as immunomodulators: The invention proyides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other... Agent: Novartis Vaccines And Diagnostics Inc.

20090311289 - Vaccine: The present invention relates, in-general, to Human immunodeficiency virus (HIV), and in particular to a carbohydrate-based vaccine for HIV and to methods of making and using same.... Agent: Nixon & Vanderhye, PC

20090311290 - Urogenital or anorectal transmucosal vaccine delivery system: The invention is directed to a suppository based vaccine delivery system for immunizing against urogenital and anorectally transmitted infectious disease in humans and animals and a method for treating the same. More particularly, this invention is directed to a suppository based vaccine delivery system for the prophylaxis against or treatment... Agent: Davidson, Davidson & Kappel, LLC

20090311291 - Condoms with lubricant compositions and packaging providing enhanced functionality: The present disclosure provides improved packaged condoms that enable the use of a large quantity of a composition inside the condom. In addition, a sufficient quantity of certain spermicidal and/or microbicidal compositions is provided for efficient inactivation of sperm and pathogens. The present disclosure also provides condoms with reduced tendency... Agent: Kenyon & Kenyon LLP

20090311292 - Process for synthesis and incorporation of nitric oxide donors in macromolecular compositions: The present invention describes a process for the synthesis of S-nitrosothiols and the subsequent incorporation of these compounds in hydrophilic macromolecular compositions. By the process described herein, the S-nitrosothiols are synthesized in a device (FIG. 2) in a first step from the S-nitrosation reaction of their respective precursor thiols (A),... Agent: Birch Stewart Kolasch & Birch

20090311296 - Active agent delivery and/or odor retentive composition and methods of use thereof: An active agent delivery and/or odor retentive composition including a surfactant and wax spheres formed from at least one of beeswax and soy wax and methods of use thereof. The composition is particularly useful in the cosmetics and medical industry for delivering/carrying a particular ingredient to one's skin, scalp or... Agent: The Webb Law Firm, P.C.

20090311294 - Active delivery oral care implement: An oral care implement includes a head (12), a handle (10), a neck portion (11) connecting the head and the handle, and a reservoir (15) located in the neck portion which contains at least one active agent. The implement has an activator (22) for activating a delivery device which delivers... Agent: Colgate-palmolive Company

20090311293 - Method and composition for obtaining odor-suppressing textile products and textile products, namely garments, thus obtained: A method of obtaining a textile product having odor-suppressing properties. The product is treated with a composition which comprises, a polymeric binder, in addition to an active ingredient of aluminum chloride, for stably fixing the active ingredient to the product and releasing it gradually over the course of time. The... Agent: Pollack, P.C.

20090311295 - Particles with high uniform loading of nanoparticles and methods of preparation thereof: Methods to produce polymeric microparticles containing nanoparticles such, as pigments, dyes and other chromophores for cosmetic use, plastic surgery therapeutic use, and tattoos have been developed. The microparticles contain within the polymer a very uniform dispersion of dye particles. The methods by which the particles are made ensure a homogeneous... Agent: Fish & Richardson PC

20090311297 - Biocompatible transparent sheet, method for producing the same, and cultured cell sheet used the same sheet: The present invention provides a flexible, biocompatible transparent sheet (8) which has high biocompatibility and a high ability to adsorb a biologically relevant substance, which can be used as a novel biomaterial, and which can be used to observe the propagation, differentiation, and/or the like of living cells in real... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090311298 - Antimicrobial collagenous constructs: Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090311299 - Antithrombotic coating for drug eluting medical devices: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20090311301 - Coating construct containing poly(vinyl alcohol): A method of forming a surface layer that includes a hydroxyl polymer on a substrate coating on a medical device is provided.... Agent: Squire, Sanders & Dempsey LLP

20090311302 - Hydrophilized antimicrobial polymers: A bactericidal or antimicrobial polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal or antimicrobial in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal or antimicrobial polymers, methods for rendering... Agent: Brinks Hofer Gilson & Lione

20090311300 - Stent with a coating or a basic body containing a lithium salt and use of lithium salts for prevention of restenosis: The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive... Agent: Biotech Beach Law Group , PC

20090311303 - Biodegradable implants for bone fusion and compositions therefor: A biodegradable copolymer network, which is particularly suited for use in applications such as interbody implants for bone fusion, is provided. The biodegradable copolymer network of the present invention is biodegradable yet provides sufficient mechanical strength for use in procedures such as spinal fusion. Also provided are methods of producing... Agent: Alston & Bird LLP

20090311304 - Drug-loaded implant: The invention relates to a drug-loaded implant having a carrier body (10) and at least one drug for delivery into a delivery region. The drug is provided for chemotherapy and/or palliative treatment and can be released topically and/or regionally in a controlled manner at a predefinable rate and/or over a... Agent: Greer, Burns & Crain

20090311305 - Vaginal therapeutic device including copper metal and method of treating the vaginal using the vaginal therapeutic device: A vaginal therapeutic device made of copper metal has a shape to fit in the vagina and utilizes the copper metal as an antimicrobial agent to therapeutically treat abnormal biological conditions in the vagina.... Agent: Epstein & Gerken

20090311306 - Intrauterine contraceptive device: An intrauterine contraceptive device comprising a carrier body (1) and an active metallic alloy (4), characterized in that the active metallic alloy is of the formula ZnxCuyMnzAuk (I) or ZnxCuyMnzAgk (II), wherein x+y+z+k=100 weight %, x is in the range from approximately 18 to 30 weight %, z is in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090311307 - Hydractive recipe:

20090311308 - Skincare compositions comprising salicyclic acid: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises salicylic acid or a salt thereof and hydrolysed milk protein. The composition is useful in the treatment of acne.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090311309 - Novel tissue support: The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to... Agent: Tyco Healthcare Group Lp

20090311310 - Patch and patch preparation: The present invention provides a patch capable of suppressing adhesive residue on the skin surface upon peeling off from the skin in the presence of water due to perspiration and the like, as well as easy detachment from the skin in the presence of water due to perspiration and the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090311312 - Transdermal hormone delivery system: compositions and methods: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20090311311 - Transdermal local anesthetic patch with injection port: Described herein are transdermal delivery devices composed of at least one re-sealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the... Agent: Gardner Groff Greenwald & Villanueva. PC

20090311313 - Methods for treating tweak-related conditions: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that... Agent: Biogen Idec / Finnegan Henderson, LLP

20090311314 - Tiotropium containing powder formulation for inhalation: The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090311317 - Modified release tolterodine formulations: Modified or extended release formulations containing tolterodine and associated methods are disclosed and described. Methods for making and administering said modified release formulations are also disclosed.... Agent: Hunton & Williams LLP Intellectual Property Department

20090311315 - Multimicroparticulate oral pharmaceutical form with modified release of angiotensin ii receptor antagonists: Therefore, the invention is an oral pharmaceutical form with modified ARB release comprising a plurality of ARB microunits (mean diameter: 50-1000 μm) leading, after being taken, to a plasma profile wherein C18 h*≦C18 h, with C18 h=plasma ARB concentration, 18 h after being taken, C18 h*=plasma ARB concentration corresponding to... Agent: Patton Boggs LLP

20090311316 - Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and... Agent: Marshall, Gerstein & Borun LLP

20090311318 - Substituted (s)-benzoxazinones: The present invention provides enantiomerically pure substituted (S)-benzoxazinone compounds and an extended release formulation of the compounds. The compounds exhibit potent renin inhibition activities and improved bioavailability.... Agent: Townsend And Townsend And Crew, LLP

20090311319 - Oral preparation with controlled release: Abstract Oral preparation with controlled release A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may... Agent: Hedman & Costigan P.C.

20090311320 - Multilayer orally disintegrating tablet: This invention pertains to an orally disintegrating multilayer tablet wherein it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090311321 - Oral disintegrating tablet having masked bitter taste and method for production thereof: The present invention provides an orally disintegrating tablet containing mitiglinide calcium hydrate. The tablet has reduced bitterness and quickly disintegrates in the mouth, while exhibiting rapid dissolution in the digestive tract. The bitterness-masked orally disintegrating tablet comprises: (a) mitiglinide calcium hydrate; (b) microcrystalline cellulose; (c) at least one masking agent... Agent: Sughrue Mion, PLLC

20090311322 - Atorvastatin formulation: Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention.... Agent: Kenyon & Kenyon LLP

20090311323 - Autologous somatic cells from peripheral blood and uses thereof: The present invention is directed to developing treatment for spinal cord injury, traumatic brain injury and neural disease using autologous somatic stem cells isolated from peripheral blood. The method identified in the present invention will generate functional neural cells/tissues in order to replace the diseased or damaged neural cells/tissues. In... Agent: Benjamin Aaron Adler Adler & Associates

20090311324 - Polymer matrix, method for its production, and its use: The present invention relates to a polymer matrix for specifically tethering surface epitopes or receptors of cells, said polymer matrix having been pretreated by molecular imprinting. The invention also relates to a method of producing such a polymer matrix. The polymer matrices according to the present invention are used in... Agent: Leydig Voit & Mayer, Ltd

20090311325 - Enhancing solubility and dissolution rate of poorly soluble drugs: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution... Agent: Clark & Elbing LLP

20090311328 - Bulking of soft tissue: A soft tissue bulking material includes a plurality of particles. Each particle comprises a rounded polymeric shell defining an internal cavity and having a maximum outer dimension of 50 μm-250 μm. A port or opening is provided in the shell. The port or opening thus provides access to the cavity.... Agent: The Nath Law Group

20090311329 - Casein micelles for nanoencapsulation of hydrophobic compounds: The present invention relates to the field of food technology and delivery of hydrophobic biologically active compounds, particularly nutrients, via food products and beverages. In particular the present invention provides isolated casein micelles useful for the encapsulation of hydrophobic nutrients, therapeutic and cosmetic compounds, compositions thereof and methods of preparing... Agent: Winston & Strawn LLP Patent Department

20090311333 - Feed or food product composition: The present invention relates to a feed or food product composition which comprises a mixture of bovine colostrum, comprising bioactive components, and organic particulate matter having a size between 0.3 and 7 mm in diameter. The composition is especially adapted to deliver the mixture of bioactive bovine colostrum components to... Agent: Merchant & Gould PC

20090311330 - Liquid oral compositions: A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 μm in diameter. The present invention also includes uses of the suspension and methods of... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090311332 - Method for forming mesoporous silica nanoparticles, mesoporous silica nanopartices, and applications thereof: A method for synthesizing a mesoporous silica nanoparticle, a mesoporous silica nanoparticle, and applications thereof are provided. The method includes fractionating a mesoporous silica nanoparticle suspension to produce size-fractionated mesoporous silica nanoparticle. The method further includes etching the size-fractionated mesoporous silica nanoparticle to produce synthesized mesoporous silica nanoparticle having a... Agent: Squire, Sanders & Dempsey L.L.P.

20090311327 - Oral therapeutic compound delivery system: The present, invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is... Agent: Kenyon & Kenyon LLP

20090311331 - Pellet formulation comprising colloidal silicon dioxide: The present invention provides a pellet formulation comprising colloidal silicon dioxide (CSD) and one or both of a surfactant and a plasticiser. A process for the production of 5 said formulation is also provided.... Agent: Brinks, Hofer, Gilson & Lione

20090311326 - Pulmonary insulin crystals: The present invention provides methods and compositions for treating diabetes by administering insulin or an insulin analog via a pulmonary route, wherein the insulin or insulin analog is in crystalline form with a diameter below 10 microns when recovered from a solution having a pH between 7.0 and 9.5. The... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090311334 - Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyri-bocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic... Agent: Bozicevic, Field & Francis LLP

20090311335 - Combination of a triptan and an nsaid: A composition of a triptan and particles of a NSAID. The NSAID particles having an effective average particle size of less than 2000 nm and at least one surface stabilizer adsorbed on the surface thereof. The NSAID component of the composition, in a comparative pharmacokinetic testing with a non-particulate NSAID... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20090311336 - Particle containing ultraviolet absorber: A particle having an average diameter from 80 to 500 nm and having a core containing at least one compound having a λmax in the range from 250 to 400 nm and a cross-linked polymeric shell.... Agent: Rohm And Haas Company Patent Department

20090311337 - Biodegradable particle and method for producing the same: The present invention aims to provide a biodegradable particle capable of being molded without an aggregation or cohesion of the particles, capable of being carried or injected without clogging by an aggregation in a micro diameter tube such as of a catheter, needle or syringe mainly used in pharmaceutical and... Agent: Kubovcik & Kubovcik

20090311338 - Crosslinking methods and applications thereof: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.... Agent: Dardi & Associates, PLLC US Bank Plaza

20090311339 - Antiviral preparation: The aim of the invention is to extend a range of antiviral drugs by using entovirons in the form of components of an insect hemolymph exhibiting a direct antiviral action. The entovirons obtainable from Odonata, Coleoptera, Lepidoptera and Diptera representatives are most efficient in the form of drug prototypes.... Agent: Renner Otto Boisselle & Sklar, LLP

20090311341 - Method of applying a dispersion: e

20090311340 - Use of xenon as neuroprotectant in a neonatal subject: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to... Agent: Kenyon & Kenyon LLP

20090311342 - Method for activating and stabilizing dissolved hydrogen in water: A method for activating hydrogen molecules dissolved in water and stabilizing the concentration of the hydrogen molecules is provided. The method for activating and stabilizing hydrogen molecules dissolved in water is characterized by allowing hydrogen ions to coexist with the hydrogen molecules.... Agent: Kanesaka Berner And Partners LLP

20090311344 - Dosing regimen: The present invention provides a method for treating hematological disorders such as anemia and thrombocytopenia, whereby a TPO mimetic peptide compound is administered using a specified dosing regimen. The dosing regimen involves the administration of the TPO mimetic peptide compound within a specified time frame surrounding administration of a chemotherapeutic... Agent: Philip S. Johnson Johnson & Johnson

20090311345 - Natural oriental medicinal composition for the promotion of hair growth and method of preparing the same: A natural oriental medicinal composition for the promotion of hair growth is provided. The oriental medicinal composition includes a black bean extract, a tangerine extract, a potato extract, a pine needle extract and a quartzite powder. Since the oriental medicinal composition includes crude drugs extracted from natural substances that can... Agent: Lrk Patent Firm

20090311343 - Thiazole compounds, and compositions and methods using same: The present invention provides, in part, compounds and compositions including a thiazole moiety, that may be useful, for example, for treating cancers, for example kidney cancer.... Agent: Goodwin Procter LLP Patent Administrator

20090311346 - Method for treating acne: A novel method for treating acne in an affected area of skin where the method includes having application steps for preparing the affected area of skin, cleansing the affected area of skin and protecting the affected area of skin. The method includes determining a sensitivity level and an irritation level... Agent: The Law Offices Of Anthony L. Meola

20090311347 - Combination therapy for bipolar disorder: Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating... Agent: Morrison & Foerster LLP

20090311348 - Pharmeceutical and cosmetic use of silica: The invention provides the use of silica for cosmetic and/or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that silica exhibits a multi-faceted biological effect useful in the cosmetic and/or therapeutic treatment of skin for the... Agent: Quarles & Brady LLP

20090311350 - Compositions for alleviating inflammation and oxidative stress in a mammal: An antioxidant-promoting composition that increases antioxidant defense potential in a subject is disclosed comprising Bacopa monniera extract; milk thistle extract, ashwagandha powder, green tea extract, Gotu kola powder, Ginko biloba leaf extract; Aloe vera powder; turmeric extract; and N-acetyl cysteine. The antioxidant-promoting composition of the invention safely induces cellular antioxidant... Agent: Swanson & Bratschun, L.L.C.

20090311349 - Method of quantification of multiple bioactives from botanical compositions: A method of quantifying multiple bioactive compounds is disclosed.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090311351 - Composition containing a cereal milling product: The invention relates to a composition, in particular a bread, containing a cereal milling product, wherein the composition has a carbohydrate fraction of less than 15% by weight and an omega-3 fatty acid content of at least 2% by weight.... Agent: Morrison & Foerster LLP

20090311352 - Method for removing pets from harvested vegetables: A method for removing pests from harvested vegetables has steps of extracting a first portion of harvested vegetables to obtain a vegetable cleanser, and cleaning a second portion of harvested vegetables with the vegetable cleanser, such that pests residing on the second portion of harvested vegetables are removed from the... Agent: Andrews Kurth LLP

20090311353 - Equal-containing fermentation product of soybean embryonic axis, and method for production thereof: m

20090311354 - Composition comprising extracts or fractions of magnolia obovata thunb for treating and preventing inflammation disease: The present invention relates to a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata or fractions thereof as an active ingredient, more precisely, a composition for the prevention and treatment of inflammatory disease containing the extracts of Magnolia obovata fruits and floral buds... Agent: Lucas & Mercanti, LLP

20090304576 - Device for delivery of anti-cancer agents to tissue: A filament comprising a biocompatible material and a bioactive agent, adapted for implantation within the tissue of a patient wherein the bioactive agent is released over a period of time, is provided. An array of a plurality of the filaments implanted within the tissue of a patient, an array assembler,... Agent: Schwegman, Lundberg & Woessner, P.A.

20090304575 - In vitro method for identifying compounds for cancer therapy: The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect... Agent: Lariviere, Grubman & Payne, LLP

20090304580 - Anti-pancreatic cancer antibodies: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to... Agent: Immunomedics, Inc.

20090304578 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Fish & Richardson PC

20090304579 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Fish & Richardson PC

20090304577 - Peptides for treatment and diagnosis of autoimmune disease: There are provided peptides derived from antibodies with reactivity against a GPI linkage epitope and functionally equivalent ligands. These peptides can be used in the therapy and diagnosis of a variety of diseases, all of which are considered to be caused by the inappropriate presence in the body of autoantibodies... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090304581 - Single wall nanotube constructs and uses therefor: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other... Agent: Bejamin Aaron Adler Adler & Associates

20090304582 - Imaging protocols: e

20090304584 - Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders: Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090304583 - Pathological tissue detection and treatment employing targeted benzoindole optical agents: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090304586 - Chelating agent conjugated alpha-msh peptide derivatives, preparation method thereof and composition for diagnosis and treatment of melanoma comprising the same as an active ingredient: Disclosed are chelating agent-conjugated α-MSH peptide derivatives, preparation methods thereof, and compositions for use in a diagnosis or treatment of a melanoma tumor containing the same as an active ingredient. The novel α-MSH peptide derivatives conjugated with chelating agent according to the present invention are highly selective to the melanocortin-1... Agent: Greenlee Winner And Sullivan P C

20090304585 - Stabilized compositions and methods for radiolabeling pharmaceuticals with alpha-particle emitters: Oxidants (e.g., N-chlorosuccinimide) can be used to stabilize α-particle emitters (e.g., 211At) in solution, prior to their subsequent reaction to form α-particle emitter labeled compounds (e.g., a radiolabeled pharmaceutical or a radiolabeled pre-cursor used to prepare it). In particular, the use of an oxidant has been found to maintain the... Agent: Banner & Witcoff, Ltd.

20090304587 - Biodegradable composite for internal local radiotherapy: The present invention discloses composites which generally comprise a polymeric matrix and a hydrophobic organic compound which is associated with a radioisotope. The composites are biocompatible and biodegradable hydrogels suitable for use in internal local radiation therapy... Agent: Brooks Kushman P.C.

20090304588 - Biologically excitable cells: As an alternative strategy to electronic pacemaker devices, we explored the feasibility of converting normally-quiescent ventricular myocytes into pacemakers by somatic cell fusion. The idea is to create chemically-induced fusion between myocytes and syngeneic fibroblasts engineered to express HCN1 pacemaker ion channels (HCN1 fibroblasts), in normally-quiescent myocardium. HCN1-expressing fibroblasts formed... Agent: Banner & Witcoff, Ltd.

20090304593 - Detection of the detachment of immobilized contrast agent in medical imaging applications: An embodiment of a solution is proposed for imaging a body-part that is perfused with a contrast agent. A corresponding method includes the step of providing a sequence of input images (for example, acquired with an ultrasound scanner); the input images offer a digital representation over time of the body-part.... Agent: Graybeal Jackson LLP

20090304591 - Method and device for optical detection of the eye: A solution for optical detection of the eye. Molecular markers are used for high-contrast diagnosis of eye diseases, other diseases, and other vital parameters which can be diagnosed in the eye. For optical detection of the eye, a molecular marker with spectral characteristics of absorption and/or scattering in the visual... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20090304589 - Radiation sensitive liposomes: The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposome composition comprising a stable liposome-forming lipid and a polymerizable colipid, and a chain transfer agent. The present invention further contemplates methods... Agent: Townsend And Townsend And Crew LLP (varian)

20090304590 - Therapeutic compositions and methods: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.... Agent: Ropes & Gray LLP

20090304592 - Treatment of metastatic tumors: The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment,... Agent: Choate, Hall & Stewart LLP

20090304595 - Animal model and a method for producing an animal model: The present invention discloses a non-human animal model for a hereditary autosomal dominant disease. The non-human animal model expresses at least one phenotype associated with the disease and is obtained by a genetic determinant. The invention also relates to sperm cells and embryos comprising the genetic determinant for an autosomal... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090304596 - Methods for predicting psychotropic drugs which elicit weight gain: The atypical antipsychotic drugs (AAPDs) have markedly enhanced the treatment of schizophrenias but their use has been hindered by the major weight gain elicited by some AAPDs. We found that orexigenic AAPDs potently and selectively activate hypothalamic AMP kinase (AMPK), an action abolished in mice with deletion of histamine H1... Agent: Banner & Witcoff, Ltd.

20090304594 - Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers: The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness... Agent: Merck And Co., Inc

20090304599 - Protein nanoparticles and the use of the same: An object of the present invention is to provide nanoparticles that can easily be delivered to a small site such as a capillary and can be produced using highly biocompatible and safe material. The present invention provides a nanoparticle which contains at least one pharmaceutically active component, a magnetically responsive... Agent: Sughrue Mion, PLLC

20090304600 - Intradialytic administration of sodium thiosulfate: The invention provides a source of sodium thiosulfate via the dialysate used to cleanse the blood of toxic and metabolic waste in patients undergoing hemodialysis, peritoneal dialysis, or gastrointestinal dialysis for treatment of end-stage or near end-stage chronic renal disease. In the method of the invention, dialysis solution components contain... Agent: Kent Barta S.c.

20090304598 - Fluorescent membrane intercalating probes and methods for their use: The invention relates to a family of dyes which fluoresce in the UV-VIS, far red and near infrared wavelengths of the spectrum and possess asymmetric lipophilic alkyl chains. The dyes of the invention are soluble in commercially available membrane staining dyes, are useful as probes for rapidly staining lipophilic structures... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090304597 - Use of an active biological substance in abnormal cellular and viral membrane physiologies: An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides,... Agent: Kubotera & Associates, LLC

20090304601 - Method of marking a composition for use in oral administration: There is provided a marking method that is highly productive and enables production of easily-identifiable compositions for use in oral administration such as drugs and foods without damaging the quality of the oral composition. The marking method according to the present invention is a method for marking such a composition... Agent: Birch Stewart Kolasch & Birch

20090304602 - Nutritional supplement: A nutritional supplement useful for promoting good overall health and relieving minor aches and pains associated with inflammation and muscle soreness includes a plurality of active herbal ingredients (turmeric extract, white willow extract, passion flower extract, valerian root extract, and/or licorice root extract), a plurality of non-herbal active ingredients (magnesium... Agent: Cuenot, Forsythe & Kim, LLC

20090304603 - Topical steroid spray with botanic seed oils: A pharmaceutical topical spray composition including a topical corticosteroid, an alcohol, a propellant, isopropyl myristate, and a blend of botanic seed oils is described. The blend of botanic seed oils may include three or more botanic seed oils prepared using a cold press method. A method for treating an inflammatory... Agent: Briggs And Morgan P.A.

20090304604 - Pulmonary delivery of alpha-1 proteinase inhibitor: The present invention relates to a system that includes a pharmaceutical composition of a purified, stable, active alpha-1 proteinase inhibitor (API) in a form of a ready to use sterile solution and an inhalation nebulizer, and to methods of use thereof for treating pulmonary diseases.... Agent: Winston & Strawn LLP Patent Department

20090304605 - Substituted aminothiazole prodrugs of compounds with anti-hcv activity: and the variables X, Y, R, and R1 to R7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds... Agent: Cantor Colburn, LLP

20090304607 - Antibacterial flavor and fragance composition and halitosis-inhibition flavor and fragrance composition and oral care composition containing the same: A flavor and fragrance composition possessing an antibacterial activity effective against periodontal disease-causing bacteria and/or a halitosis-inhibition action capable of controlling production of volatile sulfides, which is safe for the human body, and containing at least one or more substances selected from food fragrance materials such as hexylaldehyde, caryophyllene alcohol,... Agent: Sughrue Mion, PLLC

20090304606 - Method for removing debris from tooth and bone surface using irrigation solution: Methods for removing debris and bacteria from tooth and orthopedic surfaces using irrigation solutions are provided. The solution includes disinfectant, surfactant, and organic acid components. Disinfectants such as tetracycline and doxycycline compounds can be used. Suitable surfactants include cocamidopropyl betaine compounds and polyoxypropylene-polyoxyethylene copolymers. The solution is particularly suitable for... Agent: Dentsply International Inc

20090304608 - Aqueous hydrogen peroxide solution for use as a disinfectant or anti-microbial personal care product: An aqueous hydrogen peroxide solution for use in disinfectants, soaps, shower gels, and mouth rinses is provided, with improved disinfectant and anti-microbial activity. The solutions contain at least one phosphorus based acid compound, e.g. phosphoric and/or a phosphonate and a cationic or non-ionic surfactant. Importantly, the solutions do not require... Agent: Clements Bernard PLLC

20090304609 - Freeze-dried makeup product, corresponding compositions and method for making same: A base composition for makeup capable of being freeze-dried to form a makeup product, the base composition comprising an emulsion of an oily phase and an aqueous phase; fillers which are mainly insoluble; dispersing agents in sufficient amount to ensure dispersion of the fillers in the emulsion and formation, after... Agent: Bryan Cave Powell Goldstein

20090304610 - Tannin polymers, processes of preparation and use thereof: The invention concerns synthetic polymers obtainable by oxidative polymerization of vegetal tannins, alone or in combination with eumelanin and/or pyrocatechic precursors, method of preparation and uses thereof in the cosmetic and dermato-logic fields; complexes of said polymers with metals and their use in dyeing processes are also disclosed.... Agent: Hess Patent Law Firm, P.C.

20090304611 - Artificial nail composition having excellent appearance: The present invention provides an artificial nail composition which can easily impart a special appearance to the tip of the finger, and which is an artificial nail material coated on a natural or artificial nail, and is used by coating on the surface of a natural or artificial nail followed... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090304612 - Artificial nail composition having excellent appearance: The present invention provides an artificial nail composition which can easily impart a special appearance to the tip of the finger, and which is an artificial nail material coated on a natural or artificial nail, and is used by coating on the surface of a natural or artificial nail followed... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090304613 - Use of a limnophila extract as a cosmetic agent, and cosmetic composition containing same: The invention relates to the use of a plant extract of a plant of the Limnophila genus, in particular an extract of the plant species Limnophila conferta, as a cosmetic agent or as an active agent in cosmetic compositions.... Agent: Woodcock Washburn LLP

20090304615 - Tricyclic compounds as melanogenesis modifiers and uses thereof: e

20090304614 - Use of polyunsaturated compounds as whitening agents: The invention concerns the cosmetic or dermatological use of at least one compound of formula (I), wherein: R1, R2, R3, R4, R5 and G are such as defined in the description as whitening and/or depigmenting agents for the skin and/or hairs and/or the hair. The invention also concerns a cosmetic... Agent: Birch Stewart Kolasch & Birch

20090304616 - Transparent antiperspirant gel: The present application relates to clear antiperspirant gels in the form of a water-in-oil emulsion.... Agent: Henkel Corporation

20090304617 - Low residue antiperspirant stick: The present invention relates to low residue, water-free antiperspirant sticks with enhanced properties.... Agent: Henkel Corporation

20090304618 - Acyl lactylate compositions for rinse-out and leave-on applications for skin and hair: The presently described technology relates to acyl lactylate containing compositions having improved stability and multifunctional performance characteristics (e.g., pH stability, phase stability, hydrolytic stability (e.g., aqueous stability), cleansing, foaming, skin softness and skin moisturization) that may be utilized in rinse-out and leave-on skin and hair applications. The acyl lactylate compositions... Agent: Mcandrews Held & Malloy, Ltd

20090304619 - Composition for hair care: A hair care composition that includes a combination of chemical mixture that includes a perfluororoalkylethyl acrylate/hema copolymer, butyl acetate, and an aliphatic isoparaffin; and further includes an added amount of an aliphatic isoparrafin. Most preferred is 15 wt % to 35 wt % of the chemical mixture that includes the... Agent: Mcdermott, Will & Emery LLP Attn:IPDepartment

20090304620 - Hair treatment products comprising polymers: The invention relates to hair treatment products, comprising at least one copolymer made of 0.1 to 50% (in relation to the total number of monomers in the copolymer) monomers of the formula (I), wherein the unknowns are defined as in claim 1, and A2) are monomers from the group of... Agent: Connolly Bove Lodge & Hutz LLP

20090304621 - Biofilm resistant polymer materials: The present invention relates to compounds and materials that reduce the accumulation of microorganisms on a surface by interfering with the attachment of the organisms to the surface. The compounds and materials of the present invention are thus useful in preventing the formation of biofilms. The compounds of the present... Agent: Megan Lyman

20090304622 - Method and means for infiltrating enamel lesions: The present invention refers to a method of infiltrating enamel for the prevention and/or treatment of carious lesions comprising (a) exposing an enamel area to a conditioner comprising hydrochloric acid; (b) exposing the conditioned enamel area to an infiltrant; and (c) curing the infiltrant. The present invention further refers to... Agent: Casimir Jones, S.c.

20090304623 - Once a day formulation for phosphate binders: A method for reducing serum phosphate in a subject in need thereof comprising administering once per day to said subject a phosphate binder, wherein the phosphate binder has a phosphate binding capacity of at least 52 mmole.... Agent: Genzyme Corporation Legal Department

20090304624 - Sugar-based bait: An ant bait which contains an active substance having insecticidal activity and a sugar syrup is described.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090304626 - Hepatitis c virus inhibitors:

20090304625 - Modulators of cardiac cell hypertrophy and hyperplasia: Provided are compositions and methods for modulating cardiac cell hypertrophy and hyperplasia using inhibitors of c-Kit activity.... Agent: Fish & Richardson P.C.

20090304627 - Smallpox dna vaccine and the antigens therein that elicit an immune response: The present invention relates to DNA vaccines that are capable of generating a protective immune response in mammals against a pox virus, and comprises at least one DNA plasmid capable of expressing a plurality of VACV MV antigens, and at least one DNA plasmid capable of expressing a plurality of... Agent: Pepper Hamilton LLP

20090304628 - Stabilized pharmaceutical formulations that contain the interferons gamma and alpha in synergistic proportions: The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign... Agent: Hoffmann & Baron, LLP

20090304629 - Macrocyclic hepatitis c serine protease inhibitors: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents.... Agent: Elmore Patent Law Group, PC

20090304633 - Chimeric vaccine antigens against classical swine fever virus: The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure... Agent: Hoffmann & Baron, LLP

20090304631 - Hepatitis c serine protease inhibitors and uses therefor: The invention provides compounds that inhibit a viral protease enzyme of the hepatitis C virus (HCV). The compounds are adapted for treatment of a HCV infection in a patient with the disease. The compounds include analogs of tripeptides and tetrapeptides that resemble the viral protease substrate. The invention also provides... Agent: Schwegman, Lundberg & Woessner, P.A.

20090304632 - Heterocyclic nf-kb inhibitors: e

20090304634 - Novel combinations: Invented is a method of treating viral diseases, particularly hepatitis C, in a human, in need thereof which comprises the administration of a combination of therapeutically active agents selected from a TPO receptor agonist and an antiviral therapy selected from: an alpha interferon, ribavirin, a ribavirin analog and an HCV... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090304630 - Treating severe and acute viral infections: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase... Agent: Nixon & Vanderhye, PC

20090304635 - Methods for generating new hair follicles, treating baldness, and hair removal: The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncorαmitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair... Agent: Pearl Cohen Zedek Latzer, LLP

20090304637 - Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy: The invention relates to a recombinant vector comprising a mycobacterial FAP protein coding sequence under the transcriptional control of a promoter active under hypoxia conditions and its use for the prevention and the treatment of epithelial tumors.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090304636 - Stem cell factor therapy for tissue injury: The present invention relates to the use of stem cell factor (SCF) for the treatment of ischemic injured tissue such as in cardiovascular disease. The method involves administration of a nucleic acid encoding SCF, wherein the nucleic acid is delivered to the site of the injury and is incorporated into... Agent: Foley & Lardner LLP

20090304652 - Identification and selection of stem cells being committed to differentiate to a specific type for obtaining a homogeneous population of stem cells: The artificially introduced DNA-molecule (6) comprises at least one binding site sequence (30) being apt to interact with the protein molecule (3), at least one DNA-sequence (40) coding an indicator molecule (5) and at least one minimal promoter sequence (50), allowing the gene expression of said indicator molecule (5), whereby... Agent: Rankin, Hill & Clark LLP

20090304651 - Insulin-like growth factor ii (igf-ii) binding factors: This invention relates to modified IGF-II binding domains of the Insulin-like Growth Factor 2 Receptor (IGF2R) which have enhanced binding affinity for IGF-II relative to the wild type IGF-II binding domain. Suitable IGF-II binding domains may be modified, for example, by substituting residue E1544 for a non-acidic residue. These modified... Agent: Wolf Greenfield & Sacks, P.C.

20090304654 - Methods for isolating adipose-derived stem cells and therapeutic use thereof: The application discloses adipose tissue-derived stem cells (ADSC) and related compositions and methods. ADSCs are useful for (i) production of insulin producing cells, (ii) treatment of diabetes, (iii) endothelial cell reconstitution, (iv) treatment of overactive bladder and urge incontinence, (v) prevention and treatment of bladder voiding dysfunction; (vi) treatment of... Agent: Townsend And Townsend And Crew, LLP

20090304653 - Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions: Disclosed are methods to identify an agent which may modulate resistance to HIV-1-mediated disease, comprising contacting at least one agent to be tested with a cell comprising human ICAM-1, and detecting the cell's resistance to HIV-1 viral replication, propagation, or function, wherein an agent is identified by its ability to... Agent: Swanson & Bratschun, L.L.C.

20090304650 - Repair of the bone marrow vasculature: Stem cells repair the marrow vascular niche following bone marrow transplantation. Donor-derived vasculogenesis occurred whether whole bone marrow cells, isolated stem cells, or single stem cells were transplanted. Damaged marrow sinusoids led to hypoxia, followed by upregulation of angiogenic factors hypoxia inducible factor-1 and stromal derived factor-1.... Agent: Akerman Senterfitt

20090304655 - Infant formula with probiotics: The invention relates to an infant formula comprising a source of protein in an amount of not more than 2.0 g/100 kcal, a source of lipids, a source of carbohydrate and a probiotic wherein the probiotic is present in an amount equivalent to between 102 and 105 cfu/g of dry... Agent: K&l Gates LLP

20090304656 - Controlled activation of the reuterin-production machinery of lactobacillus: Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri... Agent: Olive & Olive, P.A.

20090304638 - Composition for the treatment of ballast water containing bacteriophage as an effective component and biological method with the same for removing bacteria present in ballast water: The present invention relates to a composition for the treatment of ballast water containing bacteriophage capable of killing specific target bacteria as an active ingredient in order to eliminate or reduce bacteria including pathogenic bacteria present in ballast water, and a biological treatment method of ballast water.... Agent: Ballard Spahr LLP

20090304645 - In vitro engineered, regenerated urinary tract tissue compositions and methods for producing same: A method for providing a urinary tract tissue graft composition includes providing a tissue culture frame and a segment of small intestinal submucosa and positioning the segment of small intestinal submucosa in the tissue culture frame such that the segment of small intestinal submucosa is suspended and held in a... Agent: Dunlap Codding, P.C.

20090304648 - Mast cell stabilizers to prevent or treat laminitis: Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis.... Agent: Swanson & Bratschun, L.L.C.

20090304639 - Method for preparing an organ for transplantation: The present invention provides a means for achieving generation of a complex organ such as kidney and the like through the use of hMSCs to generate the human organ. The method for preparing a desired organ for transplantation to human by transplanting an isolated human mesenchymal stem cell to the... Agent: Kilyk & Bowersox, P.l.l.c.

20090304641 - Methods and compositions for regulating gene expression: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translational termination.... Agent: Wolf Greenfield & Sacks, P.C.

20090304643 - Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof: The invention provides compositions and methods for preparing and characterizing multipotential mesenchymal stem cell aggregates. The invention further provides methods for using stem cell aggregates of the invention.... Agent: University Of Virginia Patent Foundation

20090304642 - Methods of specifying mesodermal, endodermal and mesoendodermal cell fates: We disclose a method for producing a mesodermal or a endodermal cell from a pluripotent stem cell, the method comprising activating a Wnt signalling pathway in the pluripotent stem cell. In some embodiments, the pluripotent stem cell is in a substantially 2 dimensional configuration, such as a monolayer, for at... Agent: David S. Resnick

20090304646 - Multipotent/pluripotent cells and methods: Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090304647 - Production of neural stem cells from bone marrow tissue and use thereof: The invention provides reagents and methods for preparing mammalian mesenchymal-derived neural stem cells, especially autologous mesenchymal-derived neural stem cells, compositions thereof, and methods for using and administering the cells in a patient in need thereof.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090304644 - Systems and methods for manipulation of regenerative cells separated and concentrated from adipose tissue: The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects.... Agent: Knobbe Martens Olson & Bear LLP

20090304640 - Transfection of collagen-producing cells: A method is provided for introducing at least one polynucleotide of interest into an intervertebral disc cell, wherein the polynucleotide of interest is transfected with a lipid-based delivery agent. Also provided are methods for introducing polynucleotides encoding one or more telomerase catalytic subunits into collagen-producing cells and methods for increasing... Agent: Howson & Howson LLP

20090304659 - Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+ t cells: The present invention includes compositions and methods for inducing tolerance in a subject in need thereof comprising providing the subject with an effective amount of an anti-CD8 antibody sufficient in induce CD8+ T cell immune tolerance to allogeneic antigens.... Agent: Chalker Flores, LLP

20090304657 - Chimeric t cell receptors and related materials and methods of use: The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to... Agent: Leydig, Voit & Mayer, Ltd.

20090304660 - G-csf derivative for inducing immunological tolerance: The invention relates to a method for inducing immunological tolerance, in particular transplantation tolerance, by administering a G-CSF derivative or biologically active fragment, homolog, or variant thereof, in particular peg-G-CSF, to a donor cell or a transplantation donor. The invention also relates to expanding and stimulating selected donor cells by... Agent: Leydig Voit & Mayer, Ltd

20090304658 - Method of proliferating lak cell: A method of proliferating/activating cells of the present application comprises steps of, during the cell culture, supplementing a plant lectin (such as concanavalin A) and a growth factor having interleukin-2-like activity to the culture medium. Accordingly, the present method can proliferate/activate, on a preferential basis, aβ-type T cells associated with... Agent: Harness, Dickey & Pierce, P.L.C

20090304661 - Method and composition for proctecting neuronal tissue from damage induced by elevated glutamate levels: A method of reducing extracellular brain glutamate levels is provided. The method comprising administering to a subject in need thereof an agent capable of modulating stress hormone activity thereby reducing blood glutamate levels, thereby reducing extracellular brain glutamate levels.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090304662 - Methods for identifying and targeting tumor stem cells based on nuclear morphology: Described herein are methods for inhibiting tumor growth comprising targeting a tumor stem cell in the patient with an agent or treatment that chemically modifies a tumor stem cell-specific molecule, thereby preventing proliferation of tumor stem cells.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090304666 - Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof: A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes... Agent: Dunlap Codding, P.C.

20090304664 - Modulators of alpha-synuclein toxicity: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease.... Agent: Fish & Richardson P.C.

20090304665 - Super fast-acting insulin compositions: Provided are combinations, compositions and kits containing an fast-acting insulin composition and a hyaluronan degrading enzyme composition formulated for parenteral administration. Such products can be used in methods of treating insulin-treatable diseases or conditions. Also provided are methods for administration of a fast-acting insulin and a hyaluronan degrading enzyme.... Agent: K&l Gates LLP

20090304663 - Use of gsk-3 inhibitors for the treatment of prostate cancer: A method of combating prostate cancer in a mammalian individual, the method comprising administering an inhibitor of glycogen synthase kinase-3 (GSK-3), or a polynucleotide which encodes an inhibitor of GSK-3, to the individual. A further anti-cancer agent can also be administered. Use of an inhibitor of GSK-3, or a polynucleotide... Agent: Marshall, Gerstein & Borun LLP

20090304667 - Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase d and rheb: The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a... Agent: Marshall, Gerstein & Borun LLP

20090304668 - Larval polypeptides having a nuclease activity: This invention relates to a polypeptide obtainable from insect larvae, such as those from Lucilia sericata, and which have activity as a nuclease in that they are able to degrade, denature, digest, cut or cleave nucleic acids such as DNA.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090304670 - Food product comprising a proline specific protease, the preparation thereof and its use for degrading toxic or allergenic gluten peptides: The present invention relates to a pasteurized food product having a water activity of at least 0.80, preferably at least 0.85 and containing a proline specific protease.... Agent: Nixon & Vanderhye, PC

20090304671 - Method of treating endothelial dysfunction: Endothelial dysfunction (ED) is associated with a number of diseases and disorders. Agonists of the non-proteolytically activated thrombin receptor can be used in methods to treat ED or ED-related diseases and disorders.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090304669 - Preparative purification process for human furin: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on Capto-MMC™ resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after Capto-MMC™ chromatography... Agent: Baxter Healthcare Corporation

20090304672 - Adamts13 genes and proteins and variants, and therapeutic compositions and methods of utilizing the same: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments,... Agent: Casimir Jones, S.c.

20090304673 - Method of treatment of inflammatory diseases: The present invention relates to a method of treatment of an inflammatory disease, in particular sepsis, in particular sepsis caused by gram-positive bacteria, wherein the method comprises the step of administering to a subject in need thereof a sufficient amount of bacterial cell wall degrading enzymes. The present invention relates... Agent: Fulbright & Jaworski L.L.P.

20090304649 - Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells: Methods of inducing the expression of a proteoglycan such as aggrecan in a cell are described. A method is described which includes transfecting a cell with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. The LIM mineralization protein can be... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090304679 - Antibodies as t cell receptor mimics, methods of production and uses thereof: The presently disclosed and claimed invention relates to a methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies may be utilized in therapeutic methods of mediating cell lysis.... Agent: Dunlap Codding, P.C.

20090304676 - Compositions and methods for enhancing cognitive function: The present application provides methods and compositions for improving cognitive function and enhancing mental performance in subjects, including those suffering from memory deficiencies, by regulating the activity of beta amyloid (Aβ) in the brain of such subjects.... Agent: Global Patent Group - Edi

20090304680 - Diagnosis and treatment of kawasaki disease: A molecule for use in a method of treatment or diagnosis of Kawasaki Disease in an individual, the molecule comprising: (a) CACNA2D3; (b) CAMK2D; (c) KCNIP4; (d) ANGPT1; (e) NAALADL2; (f) ZFHX3; (g) MPHOSPH10; (h) a sequence having at least 90% sequence identity to any of (a) to (g); or... Agent: David S. Resnick

20090304677 - Extracorporeal removal of microvesicular particles: The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been... Agent: Knobbe Martens Olson & Bear LLP

20090304678 - Means for inhibiting the expression of protein kinase 3: The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090304675 - Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases: This invention relates to methods for modulating neuronal cell death or impairment, and methods for the treatment, prevention, and/or amelioration of symptoms of one or more conditions or diseases in a mammal caused by neuronal cell death or dysfunction.... Agent: Haynes And Boone, LLPIPSection

20090304674 - Methods for treating disease by regulating cll cell survival: The present teachings include methods for regulating apoptosis in a cell comprising contacting the cell with an agent capable of neutralizing BAFF or APRIL. In yet another teaching a method for treating leukemia is provided. In yet another embodiment, a method for detecting inhibitors of CLL is provided. These and... Agent: Dla Piper LLP (us)

20090304691 - Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of... Agent: Wolf Greenfield & Sacks, P.C.

20090304685 - Anti-factor xlla therapy: A method is disclosed for preventing arterial thrombosis in a subject comprising administering to said subject a therapeutically effective amount of an antibody or epitope-binding fragment or derivative thereof, wherein said antibody, fragment or derivative specifically binds to activated Factor XIIa and prevents the interaction of activated Factor XIIa with... Agent: Leon R Yankwich Yankwich & Associates

20090304693 - Dual variable domain immunoglobulins and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbott Bioresearch

20090304690 - Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090304686 - Interfering in activation of an immune cell by influencing interaction of lair and collagen: The invention provides a method for interfering in activation of an immune cell, comprising providing a substance which specifically interacts in the binding of leukocyte-associated immunoglobulin-like receptor (LAIR) and collagen. The invention in one aspect provides a method for down regulation of activation of an immune cell. In another aspect... Agent: Morrison & Foerster LLP

20090304688 - Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators: The present invention relates to methods and compositions for increasing the efficiency of therapeutic antibodies. More particularly, the invention relates to the use of a therapeutic antibody in combination with a γδ T cell activating compound or activated γδ T cells. thereby allowing a potentiation of γδ T cell cytotoxicity... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090304684 - Methods and compositions for needleless delivery of antibodies: The present invention relates, in part, to methods and compositions for needleless delivery of antibodies to a subject. The present invention also relates, in part, to methods for needleless delivery of fusion proteins comprising a bioactive molecule and an antibody fragment to subject. In one aspect, the methods and compositions... Agent: Jones Day

20090304689 - Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders: Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilize cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). The invention further... Agent: Goodwin Procter LLP

20090304681 - Methods for the treatment and prevention of infection using anti-selectin agents: Methods for the treatment and prevention of pulmonary infections are disclosed, in particular, methods comprising the administration of one or more anti-selectin agents to a patient diagnosed with a pulmonary infection. Anti-selectin agents that inhibit leukocyte recruitment to the lungs have been found to be beneficial for the treatment of... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090304687 - Methods of using cd40 binding agents: Provided are methods of using CD40 binding agents for treating a CD40-associated disease.... Agent: Seattle Genetics/fenwick

20090304682 - Multiple-variable dose regimen for treating tnfa-related disorders: Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor... Agent: Mccarter & English, LLP / Abbott Laboratories Ltd.

20090304683 - Soluble fragments of the sars-cov spike glycoprotein: The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins... Agent: Schwegman, Lundberg & Woessner/nih

20090304692 - Triazine compounds as pi3 kinase and mtor inhibitors: and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this... Agent: Wyeth Patent Law Group

20090304694 - Ang2 and vegf inhibitor combinations: The invention provides methods for using Ang2 inhibitors in combination with VEGF inhibitors to treat disease. The invention also provides compositions, kits, formulations, and specific disease treatments relating thereto.... Agent: Larry S. Millstein Holland & Knight LLP

20090304695 - Methods for treating cancer by inhibiting wnt signaling: This invention relates to methods of inhibiting the growth of cancer cells that overexpress a Wnt protein. The methods comprise contacting the cell with an agent that inhibits binding of the Wnt protein to a Frizzled receptor.... Agent: Bozicevic, Field & Francis LLP

20090304696 - Single chain fc polypeptides: The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090304697 - Identification and use of prognostic and predictive markers in cancer treatment: The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes... Agent: Vinson & Elkins L.L.P.

20090304701 - Antibodies binding il-1 related polypeptides: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous... Agent: Genentech, Inc.

20090304700 - Conformation specific antibodies that bind trefoil factors: The present invention relates to conformation specific antibodies to TFF and compositions thereof. The present invention also relates to methods of regulation of cellular proliferation, survival and/or oncogenicity, particularly methods for the treatment of cancers, tumors and proliferative disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090304702 - Gene expressed in prostate cancer and methods of use: A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies and immunoconjugates are disclosed that specifically... Agent: Klarquist Sparkman, LLP

20090304699 - Methods of treating fibrosis: Methods and compositions for treating fibrosis are disclosed.... Agent: Biogen Idec / Finnegan Henderson, LLP

20090304698 - Modulation of ovulation: The present invention is directed to the identification of a novel domain of functional significance on the GDF-9 and GDF-9B molecules and to peptides and antibodies which interact with the domain to modulate the biological activity of these molecules to alter mammalian ovarian function and ovulation rate.... Agent: Knobbe Martens Olson & Bear LLP

20090304703 - Compositions and methods for the diagnosis and treatment of immune disorders: In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e., disorders associated with a TH2 or TH2-like mediated immune response) such as atopic conditions (e.g., allergy and asthma).... Agent: Millennium Pharmaceuticals, Inc.

20090304704 - Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash): The invention provides a panel of genes useful for diagnosing non-alcoholic steatohepatitis (NASH). The invention also provides a method of diagnosing NASH in non-invasive assays based on the expression of particular genes in a panel of NASH-related genes. Methods of treatment for NASH and compositions for treating NASH are also... Agent: Blank Rome LLP

20090304706 - Antagonist anti-cd40 antibody pharmaceutical compositions: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and... Agent: Alston & Bird LLP

20090304705 - Biomarkers for chronic transplant dysfunction: The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection.... Agent: Novartis Corporate Intellectual Property

20090304707 - Monoclonal antibodies to basic fibroblast growth factor: The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Townsend And Townsend And Crew, LLP

20090304708 - Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin: The present invention concerns a preparation for preventing and/or treating a tissue change, wherein the tissue change involves tissue of mesenchymal origin or tissue changes derived therefrom and the preparation contains an antiviral agent.... Agent: Rockey, Milnamow & Katz, Ltd.

20090304709 - Modulators of p-selectin glycoprotein ligand 1: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to... Agent: Wolf Greenfield & Sacks, P.C.

20090304711 - Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies: Described are uses of an agent that reduces B7-H1 interaction with PD-1, and particularly monoclonal antibodies that bind to B7-H1 and interfere with B7-H1 interaction with PD-1 in combination with a vaccine to provide synergistic effects. The application provides methods of treatment and vaccination based on the combination of these... Agent: King & Spalding

20090304710 - Novel anti-cd38 antibodies for the treatment of cancer: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090304713 - Binding agents: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.... Agent: Marshall, Gerstein & Borun LLP

20090304714 - Ikki inhibitor therapies and screening methods, and related ikki diagnostics: The present invention provides diagnostics, screening methods, and treatment methods related to obesity, insulin resistance, diabetes, weight loss, and related disorders. In particular, the present invention provides methods of treating such conditions with IKKi inhibitors, methods of diagnosing such conditions based on IKKi status, and methods of screening candidate IKKi... Agent: Casimir Jones, S.c.

20090304712 - Neuronal cell death inhibitor and screening method: A neuronal cell death inhibitor comprising a compound having an inhibitory activity on the production and/or release of glutamic acid in a microglia; by inhibiting the production and/or release in a microglia, neurite bead-like degeneration or neuronal cell death can be inhibited.... Agent: Oliff & Berridge, PLC

20090304715 - Modified antibodies with enhanced biological activities: The present inventors generated modified antibodies in which several Fc domains are linked in tandem to the C terminus of the heavy chain, and modified antibodies in which Fc domains are linked in tandem via spacers, and measured the affinity for Fc receptors, CDC activity, and ADCC activity. A previous... Agent: Bozicevic, Field & Francis LLP

20090304716 - Treatment of metastatic breast cancer: The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.... Agent: Fulbright & Jaworski L.L.P.

20090304719 - Activatable binding polypeptides and methods of identification and use thereof: The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure... Agent: Bozicevic, Field & Francis LLP

20090304718 - Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them: Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090304717 - Immuno-rna-constructs: Subject of the invention is a compound, consisting of a targeting moiety which specifically binds to a disease related cell surface marker, a nucleic acid which specifically induces cell death and a linker, wherein the linker covalently links the targeting moiety to the nucleic acid. Subject of the invention are... Agent: Dardi & Associates, PLLC

20090304720 - Active agent-loaded nanoparticles based on hydrophilic proteins: Active agent-loaded nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins, and methods for producing the nanoparticles and the use thereof. Functional proteins or peptide fragments are bound to the nanoparticles via polyethylene glycol-α-maleimide-ω-NHS esters.... Agent: D. Peter Hochberg Co. L.p.a.

20090304721 - Toxin conjugated eph receptor antibodies: The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins.... Agent: Medimmune, LLC Patrick Scott Alban

20090304722 - Chlamydia trachomatis antigens for vaccine and diagnostic use: The present invention is related to antigens from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights... Agent: Knobbe Martens Olson & Bear LLP

20090304723 - Mono-and disaccharide derivatives: The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for,... Agent: Hoffmann & Baron, LLP

20090304724 - Compositions and methods for stimulating gastrointestinal motility: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.... Agent: Alan F Feeney Biomeasure Incorporated

20090304727 - Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies: The present invention relates to recombinant DNA molecules which encode chimeric polypeptides of differing allergens of Parietaria judaica which can be used for the prevention and treatment of allergies, in particular pollen allergies. Specifically, chimeric polypeptides composed of fragments of the allergens Par j 1 and Par j 2 having... Agent: Darby & Darby P.C.

20090304728 - Tem8 gene, expression forms and diagnostic and therapeutic uses thereof: The present invention relates to the modulation of a gene known as “tumor endothelial marker 8 (TEM8)” and refers to the differential levels with which the gene is expressed, in its variants, in cells exhibiting angiogenic and migratory properties such as dendritic cells and metastatic tumor cells. The present invention... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090304725 - Vaccine and antigen mimotopes against cancerous diseases associated with the carcinoembryonic antigen cea: The present invention relates to a vaccine against cancerous diseases associated with the carcinoembryonic antigen CEA.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20090304726 - Viral display vehicles for treating multiple sclerosis: Provided are viral display vehicles which display multiple sclerosis associated antigens on the surface thereof for induction of immune tolerance to autoantigens such as MOG. Also provided are methods and pharmaceutical compositions for treating multiple sclerosis using the viral display vehicles of the present invention.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090304729 - Cell-derived viral vaccines with low levels of residual cell dna: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing... Agent: Novartis Vaccines And Diagnostics Inc.

20090304730 - Influenza vaccine: The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus... Agent: Winston & Strawn LLP Patent Department

20090304731 - Recombinant antigens for diagnosis and prevention of spotted fever rickettsiae: The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group Rickettsia. The invention also relates to a method for the use of the recombinant proteins, either singly or in combination, in detection and diagnostic assays of spotted fever. The proteins can also be used to induce... Agent: Naval Medical Research Center Office Of Counsel (code 00l)

20090304732 - Cryptosporidium hominis genes and gene products for chemotherapeutic, immunoprophylactic and diagnostic applications: Cryptosporidium hominis genes and gene products are provided. The genes and gene products are useful for chemotherapeutic, immunotherapeutic, immunoprophylactic and diagnostic applications.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090304733 - Vaccine comprising recombinant ct or lt toxin: The present invention provides a recombinant toxin or the subunit B thereof selected from the group consisting of E. coli heat-labile enterotoxin (LT), its subunit B (LTB), cholera toxin (CT) and its subunit B (CTB), in immunogenic form, expressed in eukaryotic cells, a vaccine comprising said toxin or subunit B... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090304734 - Immunogens for meningitidis-a vaccines: An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit through a 1,6-linkage which connects C-6 of the first unit... Agent: Morrison & Foerster LLP

20090304735 - Immunogenic compositions: The present invention relates to an immunogenic composition for raising an immune response to an antigen, the composition comprising the antigen and a targeting moiety specific for lymph-resident dendritic cells. Use of the immunogenic composition in a vaccine and methods of boosting an immune response using the composition are also... Agent: Klauber & Jackson

20090304736 - Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera: The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3′untranslated region (3′UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090304737 - Vaccine against mycoplasma prrsv: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.... Agent: Intervet/schering-plough Animal Health

20090304738 - Methods for enhancing immune responses: The present invention is directed to methods for enhancing immune responses. Such methods serve to enhance dendritic cell activation, which, in turn, promotes a more robust immune response to foreign antigens. As such, the methods and compositions of the invention are for useful in the context of a variety of... Agent: Klauber & Jackson

20090304739 - Influenza vaccines including combinations of particulate adjuvants and immunopotentiators: Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen;... Agent: Novartis Vaccines And Diagnostics Inc.

20090304740 - Modified hiv env polypeptides: Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.... Agent: Novartis Vaccines And Diagnostics Inc.

20090304741 - Yeast-dendritic cell vaccines and uses thereof: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a... Agent: Sheridan Ross P.C.

20090304743 - Composition and methods for immunisation using cd1d ligands: The invention relates to immunogenic compositions containing CD1d ligands that induce long-term immunological memory in the absence of booster doses and/or in the absence of multiple priming doses. The invention further relates to immunogenic compositions containing CD1d ligands and antigens from influenza virus, group B streptococcus and serogroup B meningococcus.... Agent: Novartis Vaccines And Diagnostics Inc.

20090304742 - Influenza vaccines with reduced amount of emulsion adjuvant: Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of... Agent: Banner & Witcoff, Ltd.

20090304744 - Methods of enhancing immune response in the intradermal compartment and compounds useful thereof: The present invention relates to immunogenic compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more excipients. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one excipient which acts as an adjuvant, i.e., enhances the immune response... Agent: David W. Highet, Vp & ChiefIPCounsel Becton, Dickinson And Company

20090304745 - Chimeric alphavirus replicon particles: Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.... Agent: Novartis Vaccines And Diagnostics Inc.

20090304746 - Inducing cellar immune responses to hepatitis c virus using peptide and nucleic acid compositions: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HCV epitopes, and to develop epitope-based vaccines directed towards HCV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090304748 - Clostridial toxin pharmaceutical compositions: A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation.... Agent: Allergan, Inc.

20090304747 - Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders: This disclosure provides a method of treating urologic and related disorders, for example, urinary incontinence, in women through the administration of a composition comprising a neurotoxin and DMSO. Methods for making and using the described compositions are also provided.... Agent: Fish & Richardson P.C.

20090304749 - Method of producing rough strains of bacteria and uses thereof: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4′-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof.... Agent: Steptoe & Johnson LLP

20090304750 - Novel prime-boost combinations of attenuated mycobacterium: The present invention provides vaccine compositions for effective induction of both mucosal and systemic immunity to pathogenic Mycobacterium species. Vaccination protocols are provided in which both parenteral and mucosal vaccine formulations are administered to a host. The parenteral and mucosal formulations comprise live, attenuated Mycobacteria.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090304751 - Vault compositions for immunization against chlamydia genital infection: Methods and compositions are provided herein for immunizing a subject against Chlamydial genital infection by administering to the subject an effective amount of a Chlamydial immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. In some aspects, the vault-like-particles are administered to the nasal... Agent: Fenwick & West LLP

20090304752 - Hypoallergenic variants of the major allergen from betula verrucosa pollen: The invention provides hypoallergenic variants of Bet v 1 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.... Agent: Arent Fox LLP

20090304753 - Method and apparatus for forming delivery devices for oral intake of an agent: Methods, systems and apparatuses are provided for producing delivery devices, preferably for oral intake of an agent. In the broadest aspect, the method comprises assembling one or more layers comprising one or more materials with an agent or an agent-releasing formulation to form an intergraded, preferably laminated device; folding said... Agent: The Nath Law Group

20090304754 - Pegylated glutenase polypeptides: Glutenase proteins, such as prolyl endopeptidases, are stabilized by covalent PEG modification.... Agent: Bozicevic, Field & Francis LLP

20090304755 - Pharmaceutical formulation of losartan: A pharmaceutical composition comprising losartan and pharmaceutically acceptable salts thereof and a process of forming the same. The pharmaceutical composition of losartan comprises an active agent comprising an effective amount of losartan or its pharmaceutical salt thereof, and pharmaceutically acceptable additives, wherein d(0.9) of losartan is less than 50μ and/or... Agent: Merchant & Gould PC

20090304757 - Cosmetic compositions comprising a powdered thermoplastic: The present invention relates to cosmetic compositions used in particular in the care and makeup field. The invention relates to cosmetic compositions for making up and/or caring for keratin materials such as the skin, lips, nails, head hair, eyelashes, eyebrows or body hair of human beings. It relates more particularly... Agent: Hunton & Williams LLP Intellectual Property Department

20090304756 - Method for the encapsulation and controlled release of poorly water-soluble (hyprophobic) liquid and solid active ingredients: The invention relates to the filling of hydrophobic or hydrophobically modified porous microparticles with hydrophobic substances with subsequent encapsulation of the resulting hydrophobic particles using layer-by-layer (LbL) polyelectrolyte technology for the purpose of preparing homogeneous suspensions in water, and also for the controlled release of the encapsulated active ingredients. Through... Agent: Leon R. Yankwich Yankwich & Associates

20090304759 - Chitosan/sugar composite films and laminates made therefrom: Low-shrinkage chitosan films containing sugars and laminates made from the films are provided. The films and laminates can be used to make a variety of finished articles that can be used to provide protection from hazardous chemical and biological agents.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090304758 - Formulations of lipoic acid and hyaluroinc acid and/or the derivatives thereof in the pharmaceutical and cosmetic fields: The present invention relates to novel formulations comprising lipoic acid and hyaluronic acid and/or the derivatives thereof for use in the repair of chronic ulcers, the regeneration of damaged skin, the prevention of skin aging and, when administered by the systemic route, to treat peripheral neuropathies and intoxications by chemical... Agent: Ladas & Parry LLP

20090304760 - Biocidal film-forming composition and method for coating surfaces with it: A biocidal film-forming composition comprising, a nitrogen-containing biocide, a sulphur-containing biocide, an oleophilic carrier, and a film-forming agent. The invention also includes a method of coating an item with that composition. The present invention provides for the manufacture of solid items from plastics materials in which the biocidal composition has... Agent: Renner Kenner Greive Bobak Taylor & Weber

20090304761 - Functionally graded biocompatible coating and coated implant: The present invention provides a biocompatible coating comprising calcium phosphate that is functionally graded across the thickness of the coating. The coating, which preferably includes hydroxyapatite, is particularly useful for coating implants, such as dental or orthopedic implants. The functionally graded coating is generally crystalline near the interface with the... Agent: Alston & Bird LLP

20090304762 - Antimicrobial thermoplastic molding composition: A thermoplastic composition having antimicrobial and good impact properties is disclosed. The composition comprises (i) (co)polycarbonate, (ii) (co)polyester, (iii) grafted elastomeric (co)polymer and an amount of an antimicrobial agent. The antimicrobial agent that contains zeolite, metal oxide and hydrotalcite is present in an amount sufficient to impart to the composition... Agent: Bayer Material Science LLC

20090304763 - Insect attractant composition: This invention relates to a liquid insect attractant composition containing at least one C3-C12 ketone, an aqueous solution of lactic acid, and at least one C1-9 fatty acid. The composition may be used in apparatuses capable of releasing the insect attractant composition to lure flying insects into the apparatus.... Agent: Jacobson Holman PLLC

20090304767 - Bio-degradable block co-polymers for controlled release: A block or graft copolymer includes a first block, and a second block different from the first block, wherein the first block is a poly(lactide-glycolide) copolymer. The polymers may be formulated in compositions with drug components for use in coating medical devices such as stents. Different blocks of the block... Agent: Vidas, Arrett & Steinkraus, P.A.

20090304764 - Bone regeneration element for stabilising artificial tooth roots: A bone regeneration element for stabilizing artificial tooth roots (10) in a bone (12) comprises a ring-segment-shaped or full-ring-shaped annular body (20,22) which at least partially surrounds the artificial tooth root (10). The ring-segment-shaped or full-ring-shaped annular body (20,22) is produced at least partially from a porous material. A filling... Agent: Clements Bernard PLLC

20090304768 - Gastro-retentive system for the delivery of macromolecules: The present invention provides a gastro-retentive delivery assembly (GRDA) comprising a folded multi-layered device comprising a macromolecule-containing compartment bordered by enveloping layers and one or more enforcing strips, the device being adapted to unfold when in a subject's stomach, whereupon unfolding, the macromolecule is released from said device via at... Agent: The Nath Law Group

20090304772 - Implantable materials having engineered surfaces and method of making same: Implantable materials having engineered surfaces and method of making same comprising geometric features on at least one surface of the material having at least one of chemical, physiochemical and electrochemical activity different than regions of the at least one surface without the features.... Agent: Rosenbaum & Associates, P.C.

20090304771 - Local delivery system for the chemotherapeutic drug paclitaxel: The present invention provides methods for producing a semi-degradable polymeric composite drug delivery device for localized delivery of chemotherapeutic agents to be used in conjunction with total vertebral body replacement surgery that requires placement of a vertebral replacement cage for the treatment of a spinal neoplasm.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090304766 - Localized delivery of drug combinations: Implants comprising controlled delivery matrices, associated with, or including medical devices, having stably and releasably associated therewith predetermined non-antagonistic combinations of two or more therapeutic agents provide control of the ratio of these agents at a localized site. Methods of identifying such combinations are also disclosed.... Agent: Morrison & Foerster LLP

20090304769 - Methods for identifying agents and their use for the prevention of restenosis: Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.... Agent: Bozicevic, Field & Francis LLP

20090304770 - Polymer: A novel class of polymers obtainable by copolymerising a monomer mixture comprising (i) hydrophilic monomer of general formula (I) Y—B—X; (ii) styrene or a substituted styrene, a monomer or mixture of monomers which when polymerised form a polymer with a Tg lower than the Tg of a homopolymer of monomer... Agent: Sughrue Mion, PLLC

20090304765 - R-ras activity in vascular regulation: The invention provides means and methods for vascular regulation through enhancement or inhibition of R-Ras activity. The invention specifically provides means and methods for promoting a quiescent state of a vascular cell by providing additional R-Ras activity to the cell. The invention further provides means and methods for diagnosing a... Agent: Catalyst Law Group, Apc

20090304773 - Surgical adhesive and uses therefore: The present invention provides a liquid polymer composition which can be implanted into a living mammal and which forms a solid hydrogel by in situ polymerization upon contact with body fluid and tissue. The composition also can be used as a coating on a medical device, or for the formation... Agent: Rissman Hendricks & Oliverio, LLP

20090304775 - Drug-exuding orthopedic implant: An apparatus in accordance with the present invention may include an orthopedic implant having one or more voids integrated into a surface thereof. A beneficial agent may be deposited into each void, and a regulator element may substantially cover an open end of thereof. In this manner, the regulator element... Agent: Ceramatec, Inc.

20090304774 - Implantable devices having ceramic coating applied via an atomic layer deposition method: Substrates coated with films of a ceramic material such as aluminum oxides and titanium oxides are biocompatible, and can be used in a variety of applications in which they are implanted in a living body. The substrate is preferably a porous polymer, and may be biodegradable. An important application for... Agent: Gary C. Cohn, PLLC

20090304776 - Transmucosal delivery of therapeutic agents and methods of use thereof: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.... Agent: Gardner Groff Greenwald & Villanueva. PC

20090304777 - Agent administration: An intra-ruminal bolus and method of manufacture is described that releases a therapeutically effective amount of at least one beneficial agent to a ruminant animal over a time period of less than approximately 21 days. The bolus includes at least one beneficial agent, at least one densifier material, at least... Agent: Knobbe Martens Olson & Bear LLP

20090304778 - Diagnostics and methods for removal and detection of interferents: Described herein are substrates, methods, articles, and kits that are useful for removing interferents from samples for diagnostic purposes. The interferents are removed with phosphocellulose and cation exchange materials. These materials could also be used in vitro to improve the performance of a diagnostic assay or in vivo to remove... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20090304779 - Micro-membrane implant with cusped opening: Precut, user-shapeable, resorbable polymer micro-membranes having cusped orifices are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can... Agent: Stout, Uxa, Buyan & Mullins LLP

20090304780 - Wound dressings incorporating honey: An improved wound dressing using a honey composition is provided. Preferably, the honey composition includes buckwheat honey.... Agent: Spencer Fane Britt & Browne LLP

20090304783 - Compositions and methods for treating bacteria: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compositions (e.g., comprising a lantibiotic and mupirocin or... Agent: Casimir Jones, S.c.

20090304781 - Master gene of arteriogenesis: The present invention relates to a pharmaceutical composition comprising (a) a polynucleotide comprising or consisting of a nucleotide sequence encoding a polypeptide with the amino acid sequence as set forth in SEQ ID NO: 2; (b) a polynucleotide comprising or consisting of a nucleotide sequence which is a fragment of... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090304782 - Topical ibuprofen formulation: The present invention relates to a liposomal liquid pharmaceutical composition comprising ibuprofen, at least one phospholipid, at least one C2-C6 alkanol and water, characterized in that the liposomes comprise, in addition to at least part of the phospholipid and at least part of the ibuprofen, at least one bile acid... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090304785 - Escalating dosing regimen for effecting weight loss and treating obesity: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090304784 - Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component: A seamless capsule includes a core and a shell, wherein the core includes at least one polyunsaturated fatty acid, and at least one flavouring component, the process for manufacturing the capsule and products containing the capsule are also disclosed.... Agent: Young & Thompson

20090304787 - Drug delivery composition: A drug delivery composition that comprises extruded spheroids. The spheroids comprise at least one active pharmaceutical ingredient; at least one extrusion-spheronization aid; at least one superdisintegrant; and at least one glidant, at least one lubricant, and/or at least one oil. The spheroids may also be coated. In a further aspect,... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20090304786 - Stable dosage forms of an antidepressant: The present invention relates to stable solid dosage forms of an antidepressant. More particularly, the present invention relates to stable solid dosage forms of bupropion hydrochloride. The present invention also relates to a process for the preparation of stable solid dosage forms of bupropion hydrochloride.... Agent: Jay Akhave

20090304788 - Encapsulated materials and methods for encapsulating materials: A system that incorporates teachings of the present disclosure may include, for example, an apparatus having an outer nozzle operable to discharge an outer stream of a shell solution, and an inner nozzle operable to discharge an inner stream of a core solution intermixed with a plurality of materials. The... Agent: Akerman Senterfitt

20090304789 - Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders: The present invention is drawn to novel topiramate compositions as well as methods for treating obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention also features a pharmaceutical composition that includes, e.g., topiramate alone or in combination with a sympathomimetic agent and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090304790 - Controlled release pharmaceutical compositions comprising a fumaric acid ester: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that... Agent: Darby & Darby P.C.

20090304792 - Granule and orally disintegrating tablet comprising oxycodone: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090304791 - Solid oral forms of ebastine: The invention relates to compositions in the form of matrices consisting of solid ebastine dispersions in nonionic surfactants having a HLB of between 10 and 20 and a melting point of between 30° C. and 70° C. The invention also relates to solid oral pharmaceutical forms of ebastine containing said... Agent: Ratnerprestia

20090304793 - Sustained release opioid formulations and methods of use: The invention combines two different subunits with different release profiles in novel sustained-release oral dosage forms. In particular, the oral dosage forms include a subunit that comprises an opioid analgesic and a sustained-release material, wherein the dissolution rate in-vitro of the subunit, when measured by the standard USP Drug Release... Agent: Patrick J. Halloran, Ph.d., J.d

20090304794 - Controlled release formulations of pramipexole: A controlled release formulation of pramipexole for once-a-day administration to a mammalian subject, which formulation releases pramipexole along a pre-determined release profile, is provided.... Agent: Foley And Lardner LLP Suite 500

20090304795 - Tablets with improved drug substance dispersibility: c

20090304798 - Methods and compositions for therapeutic use of rna interference: The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an... Agent: Ropes & Gray LLP

20090304799 - Nanoemulsion influenza vaccine: The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.... Agent: Foley And Lardner LLP Suite 500

20090304796 - Nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle: A nano sized particle for in vitro or ex vivo biomolecule delivery to cell cultures through heat induced endosomal release comprising a superparamagnetic core coated in a heat sensitive coating, comprising membrane disruptive components and binding sites for attachment of biomolecules and markers to be delivered is provided. A method... Agent: Buchanan, Ingersoll & Rooney PC

20090304797 - Process for the preparation of micronized valsartan: The present invention relates to process for preparing micronized Valsartan with particle size distribution of d10 less than 5μ, d50 less than 10μ and d90 less than 20μ preferably d90<10μ.... Agent: Pharmaceutical Patent Attorneys, LLC

20090304800 - Dry coating using twin-screw kneader: An object of the present invention is to provide a dry coating process that can produce a dry-coated preparation in a large amount. A large amount of dry-coated preparation can be produced more efficiently, than by prior-art processes, by a process in which a material containing core particles and a... Agent: Kratz, Quintos & Hanson, LLP

20090304801 - Aerosol and injectable formulations of nanoparticulate benzodiazepine: Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam,... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090304802 - Nasal delivery: A sustained release nasal formulation for delivery to a nasal cavity of a subject, wherein the formulation provides for sustained release of a substance, in particular nitric oxide (NO), to nasal mucosa within the nasal cavity so as to provide one or both of a therapeutic effect and promote normal... Agent: Proskauer Rose LLP Patent Department

20090304803 - Compositions and methods relating to target-specific photodynamic therapy: The invention generally provides methods and compositions useful for providing photodynamic therapy to specific cells or tissues.... Agent: Ewards Angell Palmer & Dodge LLP

20090304804 - Biologic devices for hemostasis: A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in... Agent: Rozsa Law Group Lc

20090304805 - Combinations and modes of administration of therapeutic agents and combination therapy: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as... Agent: Morrison & Foerster LLP

20090304806 - Pharmaceutical compositions: A process for the production of a composition comprising a water-insoluble sartan which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble sartan, ii) a water soluble carrier, iii) a solvent for each of the sartan and the carrier, and b) spray-drying the mixture to remove the... Agent: Unilever Patent Group

20090304807 - Method for preparing a prion-free bond grafting substitute: The present invention relates to a method for preparing a bone graft substitute using bovine bone, and more particularly to a method for preparing a safe bone graft substitute which does not have the risk of infection with bovine spongiform encephalopathy, the method comprising treating bovine bone with sodium hypochlorite... Agent: Moore & Van Allen PLLC

20090304808 - Anti-cancer immune-modulating agent: The present invention discloses a method for the preparation of an anti-cancer composition from umbilical cord tissue and animal embryonic tissues, the latter preferably obtained from different animal classes. The composition obtainable by the method comprises different embryonic antigens and is used in therapy and prophylaxis of any type of... Agent: Westman Champlin & Kelly, P.A.

20090304809 - Dental fillers, methods, compositions including a caseinate: The present application provides dental fillers, and methods of making and using dental fillers that include a treated surface that includes a caseinate. Dental compositions including such dental fillers can be useful for delivering ions to the oral environment. Dental compositions, and methods of using dental compositions that include a... Agent: 3m Innovative Properties Company

20090304810 - Composition and method for enhanced sanitation and oxidation of aqueous systems: Compositions and methods for their use are presented that substantially increase the rate of inactivation of microbiological organisms, especially those resistant to inactivation from free halogen based sanitizers, and oxidation of oxidation resistant organic based compounds in aqueous solution. Aquatic facilities susceptible to accumulation of organic N-chloramines, cyanuric acid and... Agent: Roy W. Martin

20090304811 - Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide: A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises a polysaccharide, a source of hydrogen peroxide, and an anti-oxidant. The formulation can further comprise a chelating agent and/or an ophthalmically... Agent: Bausch & Lomb Incorporated

20090304812 - Topical pharmaceutical compositions: The present invention relates to compositions and applicator devices for providing accurate and localized administration of pharmaceutical compositions containing therapeutic agents to the skin. In particular, the invention relates to compositions which are solid at a temperature of about 250 C or less, and which soften upon continuous contact with... Agent: Davidson, Davidson & Kappel, LLC

20090304813 - Virucidal compositions and uses: A composition for use in treating or preventing a respiratory virus which comprises: (a) at least one water soluble zinc, copper, selenium and/or manganese compound able in aqueous solution to dissociate into zinc, copper selenium and/or manganese ions; (b) at least one water soluble ammonium agent able in aqueous solution... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090304814 - Fibrillation resistant proteins: Protection of proteins against fibrillation may be afforded by introduction of certain histidine substitutions into the protein, such that a pair of histidines are present with sufficient spacing as to allow the histidines to coordinate with zinc. In the case of insulin, introduction of histidine residue substitutions at residues A4... Agent: Hahn Loeser & Parks, LLP

20090304815 - Method of treatment for muscular dystrophy: The invention relates to a method of treatment for muscular dystrophies, including Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital muscular dystrophies and the like using a combination of nitric oxide-releasing and anti-inflammatory compounds.... Agent: Kenneth K Sharples Law Office Of Kenneth K Sharples

20090304816 - Method and composition for treating and diagnosing restless legs syndrome: A method of treating Restless Legs Syndrome (RLS) comprises the joint administration of an agent selected from dopamine turnover increasing agent and dopaminergic receptor exciting agent, in particular pramipexole, and iron in a biologically usable form, in pharmacologically effective combined amounts. Also disclosed is a corresponding use; a pharmaceutical composition... Agent: Dickstein Shapiro LLP

20090304817 - Glycosylation variants of ricin-like proteins: The present invention provides glycosylation variants of recombinant proteins and nucleic acids that encode such recombinant proteins, which are useful as therapeutics against cancer, and viral, parasitic and fungal infections. The proteins and nucleic acids have A and B chains of ricin-like toxin linked by a linker sequence that is... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20090304818 - Method of treatment: The present invention relates generally to a method of treatment and in particular a method of treating a subject exhibiting symptoms of kidney failure or are at risk of developing same. Even more particularly, the present invention provides a method of treating kidney failure or reducing the risk of developing... Agent: Morrison & Foerster LLP

20090304819 - Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance: Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic... Agent: Baker & Mckenzie LLP

20090304821 - Pharmaceutical combination: wherein the ring A represents a 5- to 7-membered ring which may be substituted; the ring B represents a 5- to 7-membered heterocyclic ring which may be substituted; X1 represents CR1 (wherein R1 represents a hydrogen, a hydrocarbon group which may be substituted, or the like) or the like; X2... Agent: Edwards Angell Palmer & Dodge LLP

20090304820 - Solubilized benzoyl peroxide topical drug formulation for the treatment of acne: The invention relates to a novel solubilized benzoyl peroxide topical formulation for the treatment of acne comprising: benzoyl peroxide, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the benzoyl peroxide is solubilized in the solvent. The invention further relates to the use of the... Agent: Heenan Blaikie LLP

20090304827 - Combinations of ingredients having synergistic anti-inflammatory effects: Nutritional supplement compositions comprising selected herbs and/or herbal constituents thereof that provide synergistic anti-inflammatory effects are disclosed.... Agent: Marshall, Gerstein & Borun LLP

20090304825 - Estrogenic extracts for use in treating vaginal and vulvar atrophy: Estrogenic extracts of Astragalus membranaceus, Astragalus mongholicus, Anemarrhenae asphodeloides and Achyranthes bidentata are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods... Agent: Wilson, Sonsini, Goodrich & Rosati

20090304822 - Extract of polygonum multiflorum thunb. ex murray var. hypoleucum and compositions for improving metabolic syndrome: An extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum (Ohwi) or of Polygonum hypoleucum (Ohwi) for improving metabolic syndrome is prepared by the following method: (a) providing fresh or dry Polygonum multiflorum Thunb. ex Murray var. hypoleucum (Ohwi) or Polygonum hypoleucum (Ohwi) in partial or whole plant ; (b)... Agent: Andrews & Kurth, L.L.P.

20090304826 - Method and composition for dermatoses: The invention provides a method and composition for treating dermatoses by topical application of a composition containing an antihistamine, an NSAID and optionally a botanical medicinal compound. The compositions are useful for skin conditions such as inflammatory skin conditions, including eczema, atopic dermatitis, non-allergic dermatitis, psoriasis and rosacea, or any... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090304823 - Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same: Compositions and methods for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting bone growth or for the maintenance of bone health and methods regarding same. In... Agent: K&l Gates LLP

20090304824 - Rapid-melt compositions, methods of making same and methods of using same: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.... Agent: Blank Rome LLP

20090304828 - Pharmaceutical composition and functional food for suppressing and relieving itching and inflammation: It is intended to provide a drug and a functional food by which any itching such as common itching and intractable itching can be safely controlled and relieved and, furthermore, inflammation can be controlled and relieved. A medicine capable of controlling and relieving itching and inflammation which contains a highly... Agent: Marshall & Melhorn, LLC

20090304829 - Use of a lepechinia caulescens extract as a cosmetic agent, and cosmetic composition containing same: he invention relates to the use of a plant extract of a plant belonging to the Lepechinia genus, in particular an extract of the plant species Lepechinia caulescens, as a cosmetic agent or as an active agent in cosmetic compositions.... Agent: Woodcock Washburn LLP

20090304830 - Composition comprising bamboo extract for androgen agonist: The present invention relates to a use of bamboo or bamboo extract to prevent or treat symptoms related to decrease of androgen; a composition for androgen agonist comprising bamboo or bamboo extract; a method for preventing or treating symptoms related to decrease of androgen by administering composition for androgen agonist;... Agent: Swanson & Bratschun, L.L.C.

20090304831 - Laxative composition and method: An improved laxative composition is provided having efficacy with reduced negative side-effects. The laxative composition is also provided with agents that promote healthy intestinal and liver function, reduce carbohydrate absorption and have antioxidant capacity. A method is also provided for reducing the negative side-effects associated with Anthranoid-based laxative compositions. A... Agent: Iovate Health Science Research Inc.

20090304832 - Treatment of parasitic infections in humans and animals: The invention provides a process for the production of a substance or composition for the treatment, by therapy or prophylaxis, of parasitic infections, in particular malarial infections such as Plasmodium falciparum infections, of the human or animal body. The process comprises extracting the substance or composition from roots of the... Agent: Crain, Caton & James